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As this is the era of transplantation it is inevitable that the field of allogeneic 
transplantation for the reconstruction of the upper extremity is explored also. 
This double-thesis deals with a number of aspects concerning allogeneic transplantation of 
the radial side of the hand in a rhesus monkey model. In the introduction the reasons for 
investigating the possibility of hand transplantation from one individual to another are 
clarified. In particular, the reasons why experiments in a nonhuman primate model were 
preferred, are explained. 
Should hand transplantation in man ever be performed, three major questions will always 
be foremost: is allogeneic transplantation of such a composite tissue allograft technically 
feasible, can allograft acceptance by the host be established, and if so will sensory and 
functional recovery occur? These questions inspired the authors to perform the experimental 
work presented. An attempt was made to integrate the major multi-disciplinary facets, 
clinically as well as preclinically. S.E.R. Hovius focussed on the technical and functional 
aspects of transplantation of this composite tissue allograft. H.P.J.D. Stevens examined the 
immunological aspects of this subject, and new ways to improve the immunosuppressive 
regimen for transplantation. 
Prior to the rationale of the experiments an introduction with regard to these aspects is 
presented. 
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There was an ape in the days that were earlier 
centuries passed and his hair became curlier 
cemuries more gave a thumb to his wrist; 
then he was man - and a positivist. 
[Mortimer Collins (1827-1876)] 
A .1 Hand reconstruction and replantation surgery 
A.l.l Hand reconstruction: a prospective view 
The ultimate goal of the subject of this double-thesis is to perform allogeneic human hand 
transplantation. We would like to illustrate the problems involved with the following 
scenario, which represents some speculations on the future of allogeneic hand 
transplantation. 
Scenario of the 21st century. 
"The 18-year old P.J. lost his right hand just proximal to the wrist whilst cleaning an 
automatic gripping device in a large factory. As the control switch accidently was touched, 
his right hand was caught in the machine and crushed. He was right handed. 
Following first aid at the factory, he was sent directly to a large upper extremity trauma 
unit. Unfortunately replantation proved to be impossible due to severe crushing of the hand 
with destruction of nearly all of the finger joints. Using a small dynamic Magnetic 
Resonance Imaging (MRI) machine, the exact extent of the non-vital tissues of his forearm 
could be assessed. At operation the non-vital tissues were removed. Debridement was found 
to be adequate following a quick peroperative assessment with the portable MRI machine. 
All clean tendons, nerves and vessel-ends were sealed off, with a biocompatible polymer 
containing an antifibrous tissue agent to prevent local fibrosis. As a cadaver transplant was 
planned in the near future, the forearm bones could be shortened and the wound adequatly 
covered with normal skin. 
Three months later Eurotransplant called to say that a donor right hand of a young man 
was available, and that it matched well with the Major Histocompatibility Complex (MHC) -
antigens of 18-year old P.J. Immediately a surgical team flew in to prepare the cadaver 
forearm for transplantation. Following transection of the transplant at the proximal forearm, 
the vessels were attached to a portable Fluosol-extracorporeal perfusor containing antibodies 
to desensitize the transplant. The transplant was placed in a continuously chilled ( 4'C) box, 
ready for transportation. 
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In the meantime P .J. was admitted to the upper extremity unit. In view of the pending 
hand transplantation infusions were administered with a new generation of highly specific, 
immunosuppressive agents. His right forearm stump was operated upon. Fibrosis was found 
to be minimal. Nerve, vessel and tendon ends were dissected and prepared for anastomosis. 
Following arrival of the transplant it was matched for length, of bones, tendons, nerves, 
vessels and skin, with the acceptor site. The bones were fixed with a biodegradable 
intramedullary memory device reacting to the external forces, while bone healing took place. 
Tendons and nerves were connected with fibrin glue. Proximal and distal to the nerve 
anastomoses special stimulating mini-electrodes were placed as well as a toroid registering 
magnetic fields to qualify and quantify nerve regeneration. Also small microcapsules 
releasing nerve growth factors were left near the nerve anastomosis to enhance initial axon 
ingrowth. The nerve ends could be meticulously matched with staining techniques to identify 
the fascicles for various motor and sensory qualities. A biodegradable microvascular coupler 
was used to anastomose the vessels. At different sites around small vessels and in the derma-
epidermal junction sensors were placed to assess the onset of infiltration specific for 
rejection and to permit early treatment. Following skin closure P.J. was taken care of in a 
special nursing unit equipped with continuous microvascular monitoring devices to detect 
vascular compromise or changes in blood viscosity and coagulation. With the aid of these 
monitoring systems, vascular complications were limited to a minimum. Early warning of 
initial rejection by the aforementioned sensors located in the dermo-epidermaljunction of the 
allograft, made it possible to cope with immunological complications by altering the 
administration of the immunosuppressive agents on demand. The drug dosage was regulated 
by a subcutaneous pump in the subclavicular space, installed at completion of the operation. 
Two weeks later P.J. was discharged. An intensive hand therapy programme, including 
dynamic splintage and nerve stimulation followed. Regular biopsies were taken to check the 
warning system of the sensors in the derma-epidermal junction for early rejection infiltrate. 
At three months a patchy epidermiolysis occurred, which could be adquatly treated with 
genetically engineered antibodies. At six months good sensory recovery was encountered as 
well as full flexion and extension. At twelve months postoperatively P.J. had already 
enrolled in a computer programming study. He was playing squash using his right hand." 
Writing this story, the author was inspired by an article ofW.W. Shaw'. 
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A.l. 2 Hand reconstruction: a retrospective view 
The reconstruction of the hand was recorded as early as the fourth century, when Saint 
Julius replanted a left thumb in a workers hand, which had just been amputated by an axe. 
This feat is represented in a fresco of the 15th century in the Saint Julius Basilica near 
Milan'. Apart from the aforementioned miracle little is known about hand reconstruction in 
those days. The Middle Ages and the Renaissance petiod were devoted to the development of 
prosthetic substitution. Ambroise Pare (1509-1590) in particular designed hand and arm 
prostheses whose principles are still valid today'. 
Until the mid-nineteenth century no known attempts at hand reconstruction are reported. 
In view of the scope of this thesis, attention will mainly be concentrated on the severe injured 
hand with emphasis on the reconstruction of one or more missing digits. A literature review 
reveals that most efforts in the past were devoted to thumb reconstruction as this element was 
long recognized as the master digit of the hand. For instance Huguier in France performed a 
successful phalangization of the first metacarpal in 1852'·'. After six weeks the patient was 
reported to have been discharged from hospital and able to spontaneously approximate the 
first metacarpal to the second, he could grasp a book forcefully. Guermonprez (1849- 1932), 
a French surgeon, was probably the first to write a book on Hand Surgery, which was 
published in 1895. He performed digital transposition, flfSt on cadavers and then on a 
macaque monkey. His first clinical transposition was carried out in 1885 when remnants of 
the middle finger were transposed to reconstruct a thumb in a 13-year-old boy whose thumb 
and index finger were missing6 • Twenty-five years following this operation the patient was 
carrying weights and driving his horse-cart while using his transferred finger remnant 
perfectly as a thumb. Guermonprez is considered to be the forefather ofpollicization. 
While the French used the remnants of the injured hand to reconstruct the thumb, 
Nicoladoni (1847 - 1902), an Austrian surgeon, conceived new and different methods. In 
1891 he reconstructed a degloving injury of the right thumb with a tubed pedicle flap from 
the pectoral region'. Nicoladoni also suggested the use of bonegrafts from the tibia to 
lengthen short stumps before coverage with a tubed pedicle flap. In 1898 he performed a 
pedicled transfer from the second toe to the amputated thumb of a 5-year old boy. Sixteen 
days later the skin pedicle was divided. Even though the distal phalanx became necrotic, the 
functional result was reported to be good'. Following the suggestions of Nicoladoni, the 
British surgeon Joyce described a digital transfer of the ring finger of the left hand to the 
stump of the amputated right thumb in 1918'. 
In the Netherlands Lameris published, in 1909", a successful replacement of the 
amputated left thumb with the second toe of the right foot in a 12-year old boy. The blue 
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discoloration which occurred postoperatively was relieved with leeches. This procedure is 
still used today to treat venous congestion in flaps. 
One of the pioneers of modern plastic surgery was the Dutchman J.F.S. Esser (1877-
1946). His influence on the development of plastic and reconstructive surgery is eloquently 
described in the thesis of B. Haeseker11 • Esser carried out fourteen toe-to-hand transfers. In 
1916 he even transplanted four toes with a part of their corresponding metatarsals to 
reconstruct four lost fingers including their metacarpophalangeal joints". A Hungarian 
soldier had lost his four fingers as the result of an exploding handgrenade, his thumb was 
scarred and immobile. Following excision of the scarred tissue of his right hand the right 
foot was brought to his hand, and incised dorsally. Tendons and bones were transected at 
different levels. The plantar side of the foot served as vascular pedicle. All structures were 
meticulously adapted, periosteum, fascia, tendons, tendon sheaths and nerves by suturing 
adjacent tissue. The first night he fell out of bed with his heavy uncomfortable cast. 
Fortunately only a slight wound dehiscence occurred, which healed well. The pedicle was 
stepwise divided in the fourth and fifth week postoperatively. The foot was closed primarily. 
Twenty years later the patient was reviewed. He was a farmer as he had been before the war. 
His thumb function was restored, the new fingers had some flexion and extension, and 
sensitivity to touch was present as well as response to temperature. Walking presented no 
problems" (figure la-e). 
Due to the uncomfortable position of the patient during the period of fixation of the hand 
to the foot as well as the lack of sensation and motion, this method did not gain wide 
acceptance. Nevertheless the aforementioned pioneers have led the way to the three basic 
methods of thumb reconstruction which are still valid today) i.e. osteoplastic reconstruction, 
digital transposition (pollicization) and toe-to-hand transfer. 
The patient with an amputated hand has been and still remains a challenge for a 
reconstructive surgeon who tries to recreate gripping ability. In 1917 Krukenberg described 
an imaginative procedure to convert a forearm stump into radial and ulnar rays 14 • The two 
opposing rays created by this procedure provide a pincerlike grasp that is motored by the 
pronator teres muscle. Candidates for this operation are the bilateral upper extremity 
amputee, especially if sight is also impaired. In 1920 Oehlecker transplanted the ipsilateral 
big toe to the distal end of the radius in a 1 0-year old boy with an amputated hand at wrist 
level". However, in the majority of cases either a prosthesis was prescribed or nothing at all. 
Although the principle of transposition of tissue on its vascular pedicle had already been 
described by Monks in 1898" and by Esser in 1917" (who called it the island flap), it took 
until after the second World War before it was widely applied in hand surgery. 
Figure ld 
~ Lt 
_4. r;. ~ .. 't/----) ~ )/ ~~-·--
Figure lb 
Figure le 
Figure la-e. The transfer of four toes from the right foot to the right hand by 
J.F.S. Esser in 1916. Preoperative condition (la,lb) and hand connected to foot 
(1 b, !d). Postoperative result of foot-to-hand transfer (!e). 
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Digital transpostuon on a neurovascular pedicle was then subsequently described by 
Bunnell in 1948", Gosset in 1949", Littler in 1953"' and Moberg in 1955". 
The horizon of reconstructive hand surgery was further extended enormously by the 
introduction of magnifying devices (microscope and Ioupe) together with the development of 
micro(neuro)vascular surgery in the sixties. 
A.1.3 Microsurgery and Replantation surgery: a retrospective view 
Around the tum of the century experiments had already been carried out involving 
reconnection of transected extremities. In 1897, Halsted" transplanted the hind leg from one 
side to the other leaving the principal artery intact. In 1903, Hopfner" replanted three hind 
limbs in dogs. Although survival rates were short (1, 6 and 11 days) it was clearly the 
beginning of replantation surgery. 
Anastomosing blood vessels in such a way that they would remain patent was obviously 
the key to further progress in this field of surgery. Von Horoch (1888)"', Mu!J>hy (1897)" 
and Dorfler(l899)" all performed end-to-end suturing of vessels. Mu!J>hy attributed his low 
patency rate in healthy vessels to infection. Dorfler applied continuous suturing of all layers 
of the vessel wall, a detail which proved to be very important. In 1906 Carrel and Guthrie"·" 
used a triangular vascular repair to perform successful auto-replantation and transplantation 
experiments of the dog leg, scalp and kidney. These surgeons created the basis for modem 
vascular surgery. Macrovascular surgery became more reliable through this technique, 
especially in larger vessels with a diameter of more than 4 mm. It is, therefore, surprising 
that so much time passed, before the first successful replantation of an arm in a human 
subject using macrovascular techniques was performed by Malt in Boston in 1962"'. Shortly 
thereafter, in 1963, Chen in China" reported the first successful reconnected forearm, while 
in Europe Vogt was the first to replant a completely amputated arm in 1966'~". 
In the beginning of the nineteenth century results of small vessel surgery were very poor. 
Still in 1948, Shumacker reported a 50% successrate in repairing abdominal vessels of about 
3 mm in dogs". 
To visualize the vessel lumen better and to allow correct placement of vascular sutures for 
anastomosis of small vessels the need for magnification was recognized. Microscopes had 
already been introduced for clinical use in middle ear operations in 1921 by the E.N.T.-
surgeon Nylen". Ophthalmologists were the second group to use the microscope". 
It was, however, not until 1960 that microvascular surgery was clinically applied to 
succesful repair of 2 mm intracranial vessels by Jacobson and Suarez37'3g'. These surgeons 
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worked with large sized instruments and thick sutures. The need for fine needles, sutures and 
instruments therefore emerged. Consequently, in the sixties laboratories were set up for 
experimental microsurgery. 
A number of microsurgeons have made a tremendous effort to design and develop 
instruments and techniques in order to solve the problems in suturing vessels with a diameter 
of up to 1 mm and less3!l-43 • 
Great pioneers in this field were: Sun Lee, who developed microsurgical techniques in 
experimental organ transplantation in the early sixties44 ; Buncke, who performed rabbit ear 
rep1antations, thumb and index replantations as well as toe-to-thumb transfers in the rhesus 
monkey from 1963 onwards45-47 ; Goldwyn, who transferred free groin flaps in dogs also in 
196348 ; Krizek49 and Strauch 50, who reported larger series with long term survival, using 
experimental groin flaps in 1965 and 1967, respectively and O'Brien", who had no failures 
with 7 groin flaps in the rabbit. It was only the beginning of numerous reports in this field. 
The first clinical free vascularized toe-to-thumb transfer was reported in 1966, and carried 
out by Yang in China. The first clinical free vascularized flap reported was performed by 
Antia and Buch" in 1967, who transferred a free vascularized abdominal dermo-fat graft to 
the face. Cobbett" followed in 1969 with the first free toe-to-thumb transfer in the Western 
world; McLean and Buncke55 in 1971 with the first free omental flap to the scalp; Daniel and 
Taylor" in 1973 with a free groin flap and many others followed carrying out free flaps in 
successive years. The groin flap proved to be the work-horse in the initial years of clinical 
free tissue transfer. The description of the vascularity of the groin flap and the concept of an 
axial vessel pattern to nourish the flap provided the essential stimulus for further 
development in free tissue transfer. 
As a result of microanatomic studies all over the world, a "new generation" of free flaps 
with a large sized, reliable axial vessel pattern has been designed, such as the skin/sub-
cutaneous flaps (for example the groin flap'"", the scapular flap"·"' and the parascapular 
flap"·"); the fascial and fasciocutaneous flaps (for instance the radial forearm flap.._.', the 
lateral arm flap68 '69 and the dorsalis pedis flap?0-73 ); the muscle and musculocutaneous flaps 
musculocutaneous flaps (such as the lattisimus dorsi flap7<~-76 , gracilis flap7v 8 and the rectus 
abdominis flap''"'); the osteocutaneous flaps (for example the radial forearm flap with 
bone67•&2,&3, SCapular flap With bOOesHS, groin flap With iliaC CfeSe6'87 and the fibula With Skill 
island"·"), and last but not least the toe-to-hand transfers with or without dorsalis pedis flap 
(such as the great toe-to-hand transfer54.90-92 , the second toe-to-hand transfer52 '!13,!M, the multiple 
toe-to-hand transfer95-97 , the wrap around procedure98 and also joint transferS 99' 100 ). 
A number of the aforementioned flaps not only provide adequate coverage, but can also be 
used as functional tissue. A few examples are the functional muscle flaps, in which the nerve 
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of the muscle is connected to a motor branch at the recipient siten,n; the radial forearm flap 
with vascularized tendon or nerve67' 101 and the toe-to-thumb transferi'0).-97 • 
With regard to replantation, experiments done at the tum of the century, were taken up 
again, but this time with the application of microsurgical techniques. Kleinert and Kasdan in 
the U.S.A. achieved the first revascularization of an ischemic thumb in 1963"". In 1965, 
Komatsu and Tarnai in Japan became the first in the world to replant an amputated thumb'03 • 
In the late sixties and early seventies numerous reports about successful replantations 
appeared all over the world104-110 • 
Survival without adequate reinnervation, however, is of little functional value. The repair 
of severed peripheral nerves should, therefore, receive special attention. The use of 
microsurgical techniques in nerve repair 111-m as well as the knowledge obtained clinically 
and experimentally considering internal neural anatomy, biology of nerve regeneration and 
factors influencing nerve repair116-120 has greatly contributed to the success of replantation 
surgery (see also A.3.3.1). 
A.1.4 Microsurgery and replantation surgery: a current view 
Free vascularized tissue transfers play an important role in reconstruction of the upper 
extremity. It should however only be used if tissue is not available near the recipient site. 
Especially in trauma, often resulting in large soft tissue defects in combination with exposed 
bone, nerve, vessel or tendon, free flaps can be very useful not only to cover the wound, but 
also to restore function121-124 (see A.l.3). 
Toe-to-thumb or toe-to-finger transfers either in post-traumatic or congenital cases have 
made it possible to reconstruct an amputated thumb or to substitute the loss of multiple 
fingers''"'"'. Toe-to-thumb transfers can provide a pinch grip and grip strength up to 70% of 
the normal side, with a two point discrimination ranging from 2 to 15 mm125•126• 130 • 
In large centres where routine microvascular surgery is performed overall survival rates 
from series of 194"' and 372"' free flaps are 94% and 91%, respectively (see A.l.5). All 
centres report a higher failure rate in the initial years of microvascular surgery. Traumatic or 
post-traumatic cases are less successful than non-traumatic cases (91% compared to 
97%)"'. 
In a modern, adequately served community replantation surgery is a must. It has become 
much more than an occasional spectacular surgical event, and is now routine work in most 
developed countries"'·"'. Replantations should be performed in specialized centres with a 
round-the-clock service. A team should be available consisting of surgeons, both senior and 
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junior, anaesthesists, nursing staff, and professionals of rehabilitation, including 
physiotherapists, occupational therapists and social workers 132' 134 • 
In the ideal situation an experimental microsurgical laboratory is in close relation to the 
hospital to provide facilities for training and experimental work'". Micro- (neuro)vascular 
surgical expertise is obtained by training and an adequate clinical workload. One clinical 
case every 3 months does not maintain this expertise and because of this there is little, if any 
place for the occasional microvascular surgeon. Consequently, to justify an expensive 
infrastructure of sufficient professional personnel and equipment a replantation centre should 
drain at least a population of 3 - 4 million people, depending on the degree of 
industrialization of the area132 • 
Replantation operations are long and tiring. They last from a few hours in the guillotine 
amputation of a digit in a child to 20 hours or more in multiple digit amputations or in hand 
amputations with extensive avulsion injury of the forearm. It is therefore only under the 
aforementioned conditions that a replantation centre can deliver a high quality of work over 
the years. 
The decision to replant or to amputate should be made by a surgeon experienced in these 
techniques after seeing the patient. Many factors are to be considered, such as level of 
amputation; type of injury - clean laceration, crush or avulsion - handedness, occupation and 
age; the presence of coexistent disease or trauma and last but not least the patient's wishes. 
The duration of cold or warm ischemia is extremely important in major amputations; in 
digits it is important but less critical. Transportation of the amputate in a dry plastic bag 
surrounded by iced water (about 4"Celsius) is essential. This subject is extensively discussed 
in paragraph A.2.2.2. The final decision may not be made until an initial exploration has 
been carried oue34 . 
The radial aspect of the hand is the site of the majority of the amputations, i.e. the thumb, 
index and middle finger. The most common level of injury is at the proximal phalangeal 
leveP08'13s..ns. The initial operation may be only the first in a planned treatment programme, 
although as much as possible should be restored right away. Rigid stabilization of the 
skeleton is usually accomplished by internal fixation. Damaged joints are either repaired, or 
arthrodesed or silastic prostheses are inserted at metacarpo-phalangeal level. Transected 
tendons are reapproximated. In replantation surgery normally for every repaired artery two 
veins are restored. In extensive injury reversed vein grafts at the arterial side and normal 
vein grafts at the venous side are mandatory. Nerves are usually repaired directly, but a 
nerve graft may be necessary. Vital skin cover is essential, especially if bone, nerves or 
vessels are exposed. Skin grafts, local or distant flaps, are required if the wound edges 
cannot be closed without tension. 
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In the early postoperative period close monitoring either clinically (colour, capillary refill 
and needle puncture bleeding) or by device (temperature, transcutaneous oxygen, 
photoplethysmography, ultra sound doppler or laser doppler flowmeter)'" can detect 
vascular compromise. This may require various measures such as positional adjustment, 
release of constrictive dressings or exploration with reanastomozing of thrombosed vessels 
or interpositioning of vein grafts. 
Following replantation or revascularization specifically trained personnel should be 
brought in, including physiotherapists, occupational therapists, and technicians with facilities 
for training and splint manufacture140-142 • 
Success rates of several large series range from 57%-93% 136'138'143'144 (see A.1.5). These 
numbers, however, only indicate survival and not functional recovery. Assessment of 
functional recovery should not be compared with a normal limb, but with the alternative, 
namely amputation. In digital replantation surgery, thumb replantation gives the best 
functional result and should be attempted at every opportunity"'·"'·"' . If all fingers are lost 
or severely injured, some or all of them should be replaced to provide a pinch grip. Single 
finger replantation is less indicated, especially if the level of amputation is proximal to the 
proximal interphalangeal joint'4ti. However, for instance in the young child or in a musician, 
single digit replantation, if feasible, is usually carried out. The more distal the replanted part 
the better the prognosis"'. A partly amputated finger should always be revascularized, 
although the indication can be discussed if only the index finger is involved"". Hand and arm 
replantation has proved its value"". Especially in a sharp injury just proximal to the wrist"'. 
In limb replantation most patients have accepted the aesthetic and functional result, and 
although usually shorter with diminished power and sensation, it is considered superior to 
what a prosthesis could offer. In the major replants, generally intrinsic muscle paralysis 
results, which necessitates multiple tendon transfers at a later stage. 
Chen et al published in 1978"' a follow-up of 214 patients for more than 1 year and 
assessed them in four ways: Grade 1: 73 patients (34.1 %) were able to resume their original 
work, had a range of joint motion that exceeded 60% of normal, had complete or nearly 
complete recovery of sensation and had muscular power of grades 4 - 5. Grade 2: 72 patients 
(33.6%) were able to resume some suitable work, had a range of joint motion that exceeded 
40% of normal, had nearly complete recovery of sensation of tissue supplied by the main 
sensory nerves and had muscular power of grades 3-4. Grade 3: 60 patients (28%) were 
able to carry on daily life, had a range of joint motion that exceeded 30% of normal, had 
partial recovery of sensation and had muscular power of grade 3. Grade 4: 9 patients (3.9%) 
had almost no functional recovery although the replanted limb survived. 
When compared with other centres with the same grading system these figures show only 
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slight alterations with a lower percentage in grade 3 and a higher percentage in grade 4""· "'· 
"' 
Late complications of replantation of digits include intolerance to cold, stiffness and 
anaesthesia. Cold intolerance almost always occurs, however, it does subside in the 
following years. Stiffness is related to level of injury, success of secondary tendon and joint 
surgery, and cooperation of the patient in the rehabilitation process. Sensory recovery can be 
very good if the replants were distal, the injury sharp, the patient young and sensory 
reeducation given. The sensory recovery is poor in crush or avulsion injuries, in the older 
patient and when sensory reeducation has not been prescribed 150 • In a reported series of74 
replanted digits the order of sensory recovery was pressure, touch, pain, cold, warmth, and 
perspiration with a mean time of first appearance varying from 10 to 27 weeks 151 • In 
summary the best result is achieved in the young patient, with a sharp or localized crush 
injury, who is entered early into the rehabilitation process and is motivated to cooperate. 
A cost-benefit analysis of replantation surgery is described in paragraph A.l.5. 
A.l.5 Microsurgery and replantation surgery in Rotterdam 
Experimental microsurgery and small vessel surgery started in Rotterdam in the 1970's, 
in the Laboratory for Experimental Surgery'". Stimulated by the department of general 
surgery and later also by the department of plastic and reconstructive surgery, W.J. Kart has 
developed a separate laboratory for experimental microsurgery. Apart from the many 
research projects which have been completed in this lab, also a microsurgical course is 
organized twice a year, since 1981. Furthermore all residents in plastic surgery receive their 
basic microsurgical training in this laboratory. 
In 1976, at our department the first clinical replantation of a guillotine amputated digit 
was performed by G.A.M. Malfeyt and J.M. Vaandrager. The first hand was replanted in 
Rotterdam by K.E. Bos in 1977. K.E. Bas can be seen as the founder of clinical 
microvascular surgery in Rotterdam130'153 • The first free vascularized flap in the Netherlands 
was a groin flap performed by him in 1976 in Rotterdam, together with W. Boeckx from 
Leuven, Belgium. His successor A.R. Smith performed microsurgery on a more regular 
basis. He organized a replantation team in 1980154 • Experimental work was also initiated in 
this period, concerning preservation of ischemic tissues 155 as a preliminary to composite 
tissue transplants as well as clinical postoperative monitoring of microvascular surgery 156 
(see A.2.2.2). 
The author and co-workers have been performing microvascular surgery since November 
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Table 1 (left) In the last 15 years a total number of 339 parts were replanted or revascularized in 272 
patients. In the last five years 54% of the total amount was operated. The survival rate of the last 
group was 93%. Attempts to replant were not included. (right) In the last 15 years a total number of 
197 free vascularized flaps were performed. In the last five years 63% of the total amount was 
operated. The survival rate in this period was 91% . 
1985 on a routine basis. 63 % of the flaps and 54% of the replantations and 
revascularizations listed in table I were operated in the last five years. Survival rates during 
this period were 91% and 93% respectively (figure 2a-d). The laser doppler flowmeter was 
introduced in 1985 for postoperative monitoring of microvascular surgery and in October 
1990 4 instruments were installed in a specific nursing unit in our department. The data from 
this monitoring system are collated by an especially designed computer programme. The 
laser doppler flowmeter has facilitated greatly the decision to reexplore following vascular 
compromise, resulting in better survival figures (table 1)157•158 • 
This thesis is an example of our experimental work in the last five years. 
Replant surgery is costly for health insurance organizations. The expenses, however, are 
much higher if replantation is not carried out and the patient does not have a change to return 
to work. A retrospective analysis in 1983 of 34 patients in whom replantation was carried 
out, 21 were successful, saving 6.5 million guilders, provided all patients reach the age of 65 
years. From a macro-economic view, therefore, the benefit for the total community is 
clearts9. 
Microsurgery is here to stay! 
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Figure 2 a) Hand amputation with moderate crush: replantable; b) Hand amputation with severe 
crush: non-replantable; c) Following replantation (same patient as ~a)'), full extension is possible; 
d) Following replantation (same patient as 'a)'), full flexion is possible. 
A.l. 6 Hand injuries 
Research has been carried out in our department to calculate the number and incidence of 
hand injuries in 1982 in the Netherlands (15 million inhabitants). In that particular year the 
number of hand injuries was 70,000, of which 30,000 were industrial injuries. About 10% of 
these injuries (generally without replantation), resulted in permanent invalidity. The average 
absenteeism from work was 33 days. The majority of patients were 20 to 35 years old. In 
1982 it has been calculated that direct costs for medical care of hand injuries were about 120 
:rpillion guilders, while indirect costs such as benefits were about 363 million guilders160 • 
The Dutch "Prive Ongevallen Registratie Systeem PORS, Stichting Consument en 
Veiligheid", registers injuries, with exclusions of traffic and industrial injuries. They report 
the number of injuries to the upper extremity as 280.000 per year. The percentage of injuries 
of hand and fingers in this report in relation to the rest of the upper extremity averages 58% 
(figures of 1986- 1989)'". 
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In the U.S.A. (250 million inhabitants), the National Safety Council's Accident facts"', 
reported that the number of disabling work injuries in 1986 was I ,800,000. Of this total, 
160,000 were arm injuries, 90,000 hand injuries and 250,000 finger injuries. The National 
Institute for Occupational Safety and Health in collaboration with the Consumer Product 
Safety Commission reported that in 1982 a total number of 1,129,392 occupational hand and 
finger injuries were treated in hospital emergency rooms (35% of total injuries)'". Total 
arm, hand and finger injuries constituted 20% of the compensation costs of all injuries. Costs 
of work accidents in 1980 were 30 bi!lion dollars, all costs of accidents were calculated at 83 
billion dollars, again 20% of these costs involved the upper extremity. In their extensive 
survey of the frequency and costs of upper extremity disorders in the U.S.A., Kelsey eta!'" 
postulated that indirect costs of lost earnings and compensation was more than double the 
costs of actually treating these injuries. 
Burke's study in Great Britain suggests that 475 new hand trauma cases requiring hand 
surgery expertise occur in every 100.000 population each year. The mean age of patients was 
30 years, most were males. Nearly 18% of all injuries involved the hand and wrist. He 
states that the enormous indirect costs of hand disorders, due to loss of employment and 
compensation, could be greatly reduced if co-ordinated services for care of the hand could be 
developed throughout the country"'. 
In the U.S .A. about 20.000 amputations occur each year'". Nylander et al, from Sweden 
reported in 1984 an incidence of 110 serious amputation injuries per year (8 million 
inhabitants). Criteria for serious amputations were amputation of the thumb proximal to the 
IP joint, two or more fingers amputated through or proximal to the PIP joint and hand or arm 
amputations. In their study in 70% of the cases, replantation would have been technically 
possible but has been only carried out in 10%'". 
All these numbers are difficult to obtain and interpret. For instance the number of 
amputations of the hand in the Netherlands in the years 1987- 1989 were supposed to be 22, 
of which 13 were replanted 168 , these figures do not agree with our own figures. A more 
extensive coding system is necessary to provide exact numbers and percentages. 
A.2 The hand amputee 
The patient without a hand (the hand amputee) is the ultimate challenge for the 
reconstructive hand surgeon who has to recreate gripping ability. Historical remarks on 
conventional methods of reconstruction of hand amputations are described in A.l.2. 
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A.2.1 Reconstruction of the hand amputee 
The first microvascular reconstruction of the antebrachial stump by transplantation of two 
separate toes in order to create a grip, occurred in China in 1979169 • The stump was 
lengthened on this occassion with a metallic implant. The toes were positioned on the 
implant opposing each other. Following many complications, they changed their method 
using two separate toes with long metatarsals, which were placed at the end of the stump 
opposite each other'"'. These procedures are very demanding and have gained little 
popularity. 
In 1985, Vilkki"' published a method of reconstructing gripping ability in hand amputees. 
He accepts the length of the stump and uses it as a counteiJJoint or post for the grip. The 
transplant consisted of a second toe with its metatarsal bone and a hemipulp flap from the 
lateral side of the big toe. The main indications were victims of hand amputation who are 
also blind. Bilaterally injured patients and in some unilateral hand amputees this method can 
also be used. Pinching power in six patients were 5.5 - 11 kg with an opening range of 3 to 
4.5 em. The limitations of the new grip and the subnormal sensibility can be a disadvantage, 
although patient acceptance is better than with a Krukenberg procedure"·"' (see A.l.2). The 
aforementioned methods do not preclude the use of functional or aesthetic prostheses. 
A.2.2 Alternatives to reconstruction 
Alternatives to current surgical reconstruction of the amputated hand can either be nothing 
at all, a prosthesis or the prospect of allogeneic hand transplantation. 
A. 2. 2.1 Hand prostheses 
"Though engineers and prosthetists have made 
substantial contributions, they need perspective and 
humility to inspire and guide the very long, sustained 
efforts required to replace even a few of the roles of 
the hand." [E. F. Mu!Jlhy, 1970"'] 
The acquired or congenital absence of any portion of the hand and arm results in a visible 
and functional disability. The patient or parents of the affected child have to accept the loss 
or absence of the upper extremity or a part of it, otherwise it is unlikely that a successful 
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Figure 3 a) Following non-replantatble forearm 
amputation, the elbowjoint was saved using a 
free vascularized m. latissimus dorsi flap with 
split skin coverage. b) The same patient with 
a myoelectical prosthesis manufactured by 0. Bock, 
Son en Breugel, The Netherlands. 
rehabilitation and functional use of a prosthesis will be achieved, if a prosthesis is 
considered. The acceptance must become the primary focus in the total rehabilitation 
process 174 • 
The human hand is an extremely complex device with very delicate sensory and motor 
function capabilities. Even the most advanced hand and hook prosthetic devices, cannot 
provide the functional restoration to individuals with complete hand deficiencies"'. 
In traumatic upper limb amputations it is essential to understand the needs and expected 
capabilities of the patient before application of a functional prosthesis. An immediate or early 
fitting of a prosthesis can be beneficial, however, if not properly managed the results can be 
detrimental176"177 • In congenital limb deficiencies a passive hand prosthesis can already be 
introduced at the age of 3 months. The passive hand will provide gross opposition during the 
early stages of eye-hand coordination as well as the development of the child"s tolerance to a 
prosthesis. 
As gross palmar prehension and hand dominance develop at approximately 8 months of 
age178 , the introduction of a functional prosthesis should be consistent with this. Upper limb 
prosthetic terminal devices are designed as mechanical or electromechanical systems and are 
either biomechanically or electrically powered or a combination of various systems. 
Before the clinical use of electric hands in the sixties. first developed in 1948"', 
considerable controversy existed with respect to the use of mechanical hands or hooks. The 
hand being more aesthetic, but heavy and awkward as compared to the more functional hook. 
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Figure 4 a) A patient with a congenital hand malformation. b) The same patient with an aesthetic 
prosthesis manufactured by J. Pillet, Centre de Prosthese Plastique, Paris, France. 
Conventional mechanical prostheses, however, are reported to be lying in the cupboard in 
more than 50% of the individuals provided with them"". The introduction of the prosthetic 
hook early in the rehabilitation process is possibly the major factor in rejecting a 
prosthesis, because it interferes with the psychological needs of the particular individual at 
that time181 • 
Biomechanically powered devices function through body movement'"'·m, electrical 
devices from a battery. They are the source of power for various control systems of the 
device, such as cable control, myoelectric control and switch control. The prosthetic hand 
serves as an assistent to the sound hand, just as the non-dominant normal hand is related to 
the dominant normal hand. The device is important for gross grasp, such as holding and 
stabilizing objects, while the normal hand performs the fine motor prehension activities. 
The electric powered prosthetic hand device, which is controlled using electromyographic 
(EMG) potentials from opposing muscle groups within the residual limb, will best serve the 
need to perform most functional tasks during daily life. This is especially valid for the 
patient with unilateral upper limb involvement (figure 3a +b)'"'"'"'. 
The aesthetic prosthesis fulfills the need of the person with an upper limb deficiency, i.e. 
the wish to go unnoticed and have two hands like everybody else. An example of an aesthetic 
prosthesis with an additive passive function in a congenital amputee is demonstrated in figure 
4a+b!s7. 
A prosthesis, however, can never replace any functional restoration of hand function 
which can be achieved following a traumatic or congenital limb deficiency. 
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A.2.2.2 Allogeneic transplantation of the human hand 
There is no place for the "bullseye" psychology, "Let's put 
it in, give the drug, and hope we hit the mark." 
[J.E. Murray, Editorial P.R.S. 1964"'] 
In 1944, Hall'" published a detailed protocol for an operative procedure for human 
homologous upper extremity transplantation. He presented a human cadaver transplantation 
of the arm, performed at mid-humeral level. Hall also described the problem of infection, 
vessel anastomosis and thrombosisl osteosynthesis, preservation and the necessity of the 
experienced surgical team working in a well equipped hospital. He did not mention however, 
the role of nerve regeneration nor the role of rejection. 
An allogeneic human hand transplantation was carried out in 1964. It was transplanted 
from a fresh cadaver and remained viable about 14 days. The patient had received cortisone 
and azathioprine as immunosuppressive agents. Local irradiation was also applied to the 
graft100 • 
If an allogeneic human hand transplantation could be performed today the following 
factors should be considered, i.e. technique, preservation, immunology (rejection), 
functional recovery, rehabilitation and logistics concerning transplantation. 
The technique of the actual transplantation can be compared to a replantation procedure at 
the same level routinely used in large replantation centres (see A.1.4). 
With respect to preservation of the larger donor graft a few remarks on the effect of tissue 
anoxia of the transplant should be made. In an ischaemic situation tissue reacts with the 
formation of oedema, increasing potassium levels and metabolic acidosis due to a rise in 
lactate. These factors increase with prolonged ischemia and are inhibited by cooling. The 
cooling effect is best in iced water (4" Celsius). 
U sui et al'" demonstrated in an experimental study on canine limb replants that eight out of 
ten dogs could tolerate 12 hours of ischaemia before revascularization following cooling by 
iced water as opposed by only eight out of 15 survivals when the amputated limb was kept at 
room temperature for six hours. Cooling had no effect on the lactate level which actually 
increased. The change in lactate and pH were found to cause marked differences between the 
dead and surviving animals. 
Muscle tissue is particularly sensitive to ischemia, histologic changes can be detected 
following two hours of ischemia, whilst rapidly increasing irreversible damage will occur 
following six hours of ischemia at room temperature. Recovery of nerve tissue conduction 
following ischemia takes a couple of minutes after two hours) and about 30 minutes after six 
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hours. Following eight hours, however, intra fascicular oedema occurs and nerve function 
does not recover192.m. 
Fingers can tolerate anoxia up to 8-10 hours at these temperatures as they do not contain 
muscle tissue. Fingers cooled in iced water have been reported to be successfully replanted 
following 39 hours of ischemia194' 1 !}~. 
The maximum hypothermic ischemia in replants containing muscular tissue has been 
investigated by van Alphen et al"'. He replanted the latissimus dorsi muscle following 5, 8, 
16 and 24 hours of cold ischemia. In the first three groups slight to severe degenerative 
changes, with a severe reactive proliferation of fibroblasts were seen. Degenerative changes 
were seen more often as ischemia time lasted longer. In all sections of the 24-hour group 
total or nearly total necrosis was found. Cold ischemia alone therefore, will not be sufficient 
enough to prevent muscle damage if a planned hand transplant has to be carried out with a 
donor graft, when there has been a long interval between disconnection at the donor site and 
revascularization at the recipient site. 
Organ preservation has concentrated since the late sixties on cold storage in special 
solutions, as described by Collins197 as well as machine perfusion, as described by 
Belzer"'. These methods have remained essentially unchanged for the past 20 years. They 
were effective for kidneys but not so effective for livers, pancreas and hearts. Until 1987, 
therefore, these organs were transplanted as emergency procedures with safe preservation 
times of about six to ten hours. The mechanisms of preservation-induced organ damage are 
not yet fully understood199'2C(). Preliminary clinical results at the University of Wisconsin 
(UW) have shown successful transplantation of pancreas and liver after about 20-24 hours of 
cold storage preservation using their UW-solution. This is in accordance with other reports 201 
achieving extended preservation with UW solution as compared to Euro-Collins solution. 
The need for emergency procedures in these organs has therefore been eliminated202 • 
Machine perfusion with special solutions is still experimentally investigated. For instance 
Ploeg et al"" obtained 63% survival following five day perfusion preservation of the dog 
kidney. 
Another solution is Fluosol DA-20%"'"' (an isotonic 20%-solution of Fluorocarbons), 
which has a high affinity for oxygen and hence can act as a tissue oxygenator. In a study at 
our Institution in five patients with traumatic amputations, the amputated part was perfused, 
with a pulsatile pump at a mean arterial pressure of about 90mm Hg, using Fluosol DA-20% 
for between 16 and 46 hours. Following eight hours of perfusion a 10% increase in weight 
occurred, which gives an idea of the degree of interstitial oedema. Parameters such as 
oxygen tension, potassium, lactate, glucose and adenosine-triphosphate suggested that the 
tissue was sufficiently provided with oxygen and viable after many hours of perfusion. One 
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perfused digit was even successfully replanted following 17 hours of perfusion and 24 hours 
of ischemia''". Unfortunately the American Food and Drug administration did not approve 
the solution, therefore, further research with Fluosol has stopped. It is beyond the scope of 
this thesis to discuss all different kinds of storage or perfusion methods and solutions for 
preservation, although the need for good preservation in case of hand transplantation is clear. 
The importance of immunology and rejection are obvious and are described in chapter I, 
section B. 
With regard to functional recovery the results of reinnervation should be compared with 
the results of replantation following guillotine amputation at the same level (see A.l.4). 
Questions which have to be resolved concerning this subject are the influence of 
immunosuppressive agents and the influence of rejection on nerve regeneration and 
ultimately functional recovery. 
Cyclosporine A (CyA) is currently the most used immunosuppressive drug in 
transplantation surgery. Amongst other adverse effects it can also be neurotoxic""·"". Most 
presentations of neurotoxicity in humans involve the central nervous system with seizures, 
cerebellar disorders, neuropathies and other problerns208 • Tremor and minor sensory loss, 
particularly of the extremities, are stated to be the most common symptoms of neurotoxicity 
and often disappear with continued treatment. On the other hand, prolonged high levels of 
Cy A are known to increase side effects in general209 • 
It has been noted that CyA can significantly improve functional testing in the early 
postoperative period in syngeneic nerve grafts in rats as compared to nerve grafts without 
Cy A treatmene'o. Cy A may promote nerve regeneration across the nerve anastomosis, by 
inhibiting wound healing and fibroblast migration, and it may also promote revascularization 
of the nerve graft"'. Methylprednisolone, being the other suppressive drug in our protocol is 
not known to cause neurotoxic effects, unless it is administered intrafascicularly in the 
nervez'z. 
Samulack et af13 reported that under immunosuppressive therapy in nonnal glabrous skin 
in baboons latency times of single axons are prolonged. These data suggest a neurotoxic 
effect. In allogeneic non-rejected skin of composite tissue transplantation under high levels 
of CyA, in the same study, latency times of single axons were also prolonged compared to 
normal glabrous skin. The most significant differences in latency times of single axons, 
however, were encountered in rejected allogeneic glabrous skin. 
With respect to the role of rejection on nerve regeneration, there is a definate negative 
influence213 • 
Rehabilitation following hand transplantation is essential, but will be technically the same 
as in a replanted hand (see A.l.4). 
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Logistic problems concerning the acquisition of a donor hand should be solved by public 
information, changing of the existing general donor codicif14'215 and linkage with the 
Eurotransplant organization216 • 
This thesis aims to make a contribution in the long struggle before actual human hand 
transplantation can be performed safely. 
A.3 The research model for experimental allogeneic transplantation of the hand 
The history of experimental allogeneic limb transplantation, including two hand 
transplantation studies in baboons, is described in Chapter I.B.l. From an anatomical, 
immunological and functional point of view, studies in the higher developed non-human 
primate can be better extrapolated to the human being than studies in rodents and dogs. In 
the major part of the introductory studies and in the main project, therefore, the rhesus 
monkey was chosen as the experimental animal (see Chapter I. C). 
A.J.l The rhesus monkey 
The hands of the various primates, including man, are very similar, their minor variations 
are adaptations to their special activities. Only the primates have opposable thumbs. 
Opposition is a compound movement of abduction, flexion and medial rotation occurring at 
the carpo-metacarpal joint of the thumb. The thumb is either absent, rudimentary, or is like 
the other digits in other mammals. In the later developed monkeys and apes, the thumb is 
smallest and least opposable in arboreal forms. Monkeys that dwell on the ground have much 
better developed thumbs. In man, the thumb shows the greatest specialization and 
development in strength, opposition and size. Next in order come the great apes, the gorilla, 
baboon and chimpanzee'". The rhesus monkey lives in the trees as well as on the ground. 
The thumb is reasonably well developed. The pollical index, or percentage of length of the 
thumb to that of the long finger, is comparable to that of the gorilla and chimpanzee"'. The 
rhesus monkey belongs to the Old World monkeys. They possess a saddle joint at carpo-
metacarpal level which makes opposition possible219 • The flexor pollicis longus muscle, 
however, is less developed in the rhesus monkey than in man, the extensor pollicis brevis 
muscle is absent and the thenar muscles although present are less developed. These factors 
make opposition less refined. The arm and hand nerves throughout primates are practically 
the same. Detailed descriptions on anatomy and function with regard to our research model 
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are provided in Chapter II. B. 
A.3.2 The set-up for operation 
All experimental studies on rhesus monkeys were performed at the "Primate Center" in 
Rijswijk, The Netherlands. 
At this centre four monkey cages in an isolated temperature controlled room were at our 
disposal. A veterinary surgeon and two veterinary assistents helped us to take care of the 
animals before, during and after operation. The operating room consisted of two operating 
tables with all necessary equipment for modem surgery, including two artificial ventilators. 
An operating microscope (Contraves-Fioorstand OPMI-MDM) was provided by Zeiss. We 
used basic fine surgical instruments, with addition of a microsurgical set. At the day of 
operation two anesthesists with an assistant, an operating nurse, a veterinary assistant (with 
operating experience) and both authors were present (see figure 5). 
The operative procedure is extensively described in Chapter III.B.2.2.2and III.A.2.4. 
A.3.3 The set-up for jUnctional testing 
As has been stated before, functional recovery is essential following hand transplantation. 
Consequently, the design of the research model had to be a complete functional unit, with 
separate recovery of sensory and motor function. Therefore, our research model, included 
amongst other nerves, the median nerve with the motor branch to the thenar muscles, as well 
as the sensory branch with the radial and the ulnar digital nerve to the thumb (Chapter II.B, 
liLA and C). First some general remarks on nerve injury and repair will be made. 
Subsequently the set-up for functional testing will be described with a justification of the 
selected tests in our research model in the rhesus monkey. 
,~ 
II 
/ 
4' 
I 
I 
·u 
r~~; v i-_j~li~- .:_ ,~-· i \ -"'"/ 
r- ;··r:' ~~ / - \ 
i ~ I m'' \. ;--- Q'::'' ___,---- /1 - "-") __,-~ l '\/I~ ---:7-
c} /l V ... 11-l$-~A, 
L
l __ -~-_-_I (._~~~-~--__ /r:/ ___ 1 
.0 \00~- ·- t/·]· c:_--;. 1 
///1 • ;'-" .,,,-~~-w .- s, -
/". . . ,. _I!' \ '\ - -)\1-0/ /!'-/• ./! -_-
; /::/ ; ' \ J-~ ,, .. j -
I 
'7 • ' . . "'"; 1
1 
,.- I f \ _ _-- - '"7 I 
/ 
.j ' -- -/;'/I I;'. I / I ' 
-Ur- )/ ;; 
' ;, 
t!' ~Jl]'L;/ 1 
(~) 
~
Figure 5. Operating room setup at the Primate Center, TNO, Rijswijk, The Netherlands; D: Donor monkey; R: Recipient monkey; LDF: Laser Doppler 
Flowmeter; N: Nurse; V: Veterinary assistant; Al: Anaesthesist; A2: Anaesthesist; Sl: Surgeon; S2: Research fellow; M: Microscope. 
------------------------------- Technical and functional aspects ------------------------------------ 37 
A.3.3.1 Nerve injury and repair 
"if the central cell body were the height of an average 
man, its axon would be one or two inches in width and 
would extend more than two miles. " 
[T.B. Ducker, 1980""] 
The division of a peripheral nerve causes a variety of changes in the nerve cell body, in 
the proximal segment of the nerve, at the site of the nerve injury, in the distal segment of the 
nerve, and in the distal endings of both sensory receptors as well as the motor end-plates119 • 
The nerve cell will respond with metabolic activity to restore the cytoskeleton of the 
damaged axon within a few hours of the injury. There is an increase in ribonucleic acid, 
protein metabolism and lipid synthesis and a decrease in neurotransmitter production. The 
proximal nerve end degenerates. Depending on the severity of the injury degeneration will 
occur over a longer distance along the axon. This process can involve one or more nodes of 
Ranvier (the non-myelinated part of the axon) and even result in death of the cell body"'·"'. 
At the site of the lesion multiple axons will sprout into regenerating units during the first 24 
hours following injury. While first unmyelinated, these units become myelinated in time. At 
the end of each axon a growth cone with filopodia"'·"' tries to make contact with the distal 
segment. Probably dependent on the success of this contact the large number of fibres 
decreases, over a period of months to return to normal119 • The sprouts which do not make a 
connection atrophy and disappear or become surrounded by fibrous tissue forming a 
neuroma. 
The distal nerve segment also degenerates following transection (Wallerian degenera-
tion"') a process which lasts several weeks and occurs concurrently with axonal sprouting. 
Schwann cells (cells wrapped around the axon to form a multilaminated myelin sheath) 
proliferate, the myelin breaks down and is phagocytosed by these cells. Phagocytosis of all 
cellular debris may take one to three months. Endoneuria] tubes (basal lamina of the 
Schwann cell) of the distal segment collapse, due to the phagocytosis of myelin and axonal 
components, to form the "bands of Biingner". These bands represent the non-reinnervated 
endoneural tubes. The proliferating Schwann cells organize themselves into columns. The 
axon sprouts from the proximal nerve segment are associated with these columns and 
regenerate between the basal lamina of the Schwann cells, which form new endoneural tubes. 
After a few months there is a change in the organisation of firstly the proximal stump and 
later the gap between the stumps as the axons advance. This process is called 
compartmentation. There is a reorganisation of the nerve trunk into many small 
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compartments, each surrounded by a new perineurium. 
Compartmentation is more prominent when the nerves are exposed to foreign 
environment, i.e. in the periphery of a nerve, where the perineurium is damaged. This is 
probably an effort to reorganise the abnormal endoneural environment, restoring the 
perineural barrier. After a year there are few or no signs of it left. The clinical implication 
may be that it results in a change of fascicular pattern, thus making matching of the cut ends 
more difficult if the repair is done late118 • 
The final functional result will depend on the number of axon sprouts associating with 
Schwann cell columns and reinnervating matching end organs. 
Muscle fibres usually atrophy several weeks following transection of their motor nerve. 
The atrophic muscle fibres appear histologically as round structures with a nucleus, which 
has migrated to a central position. In normal muscle a random mixture of type I and II fibres 
can be seen. In muscle which becomes reinnervated clear groupings of one type of muscle 
fibres can be detected, instead of a random mixed pattern. 
The synaptic folds are present for more than 1 year following denervation. Acetylcholine 
receptors change their position from central to peripheral along the entire muscle, creating a 
supersensitivity to acetylcholine226 • As reinnervation occurs, sprouting axons reach the 
original motor end plates to reform the neuromuscular junctions. These axons also sprout 
collaterally to reinnervate several muscle fibres, thus creating groupings of muscle fibers of 
one type, instead of the normal mixed pattern. Sprouting and synapse formation are followed 
by a process of synapse regression in which redundant reinnervation may be modified in 
favour of a predominant endplate connection. Furthermore, trophic factors are released by 
the muscle to influence nerve regeneration. This can be illustrated by the fact that the axon of 
a sensory nerve placed in a muscle will sprout into the denervated muscle and not into the 
innervated muscle227'228 . 
Sensory receptors (see A.3.3.2) progressively change following denervation. The non-
nervous components, however, survive for a long period of time. Recovery of protective 
sensibility is possible even years after nerve injury. Although the critical time period with 
regard to the possibility of reinnervation of sensory receptors has not been determined, 
functional sensation appears to decrease with a delay in repair longer than 6 months 
following injury"'·"'. The great plasticity of sensory reinnervation is demonstrated by the 
return of some degrees of pain, touch and temperature sensation in distant non-innervated 
skin grafts and skin flaps231-234 .In a reinnervated vascularized tissue transfer, such as a toe-to-
thumb transfer, sensory reinnervation assessed by moving two point discrimination can even 
be better than it was when the toe was still on the foot"". The quality and quantity of 
recovery following the same kind of nerve repair varies between individuals. 
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Nerve injury causes a breakdown of the blood nerve barrier (in the internal perineurial 
layers and in the endothelial cells of the endoneuria! microvessels)"' at the site of injury 
resulting in loss of the normal homeostasis. Following breakdown an immunologic response 
occurs at the nerve ends inhibiting nerve repair. Cy A has been demonstrated to be beneficial 
in nerve regeneration probably due to modification of the immune response (see A.2.2.2"f". 
Furthermore in the normal nerve there is fast and slow axoplasmatic transport236 • Material 
necessary for the structural skeleton moves at a slow rate to the periphery (1-6 mm/day), 
while material that plays a functional role, for example neurotransmitters move rapidly (-410 
mm/day)"'. Recycled neurotransmitter vesicles are also transported in a retrograde direction 
serving as a mechanism in controlling the nerve cell body"' .Following nerve injury the 
composition of the transported material alters in favour of material necessary to rebuild the 
axonal cytoskeleton239 • 
It is most likely that axonal transport is essential for the trophic effects of the nerve on the 
target end organs. 
Peripheral nerves will regenerate across small gaps with target specificity"". For instance 
discrimination between tendon and nerve119'241 , as well as differentiation between sensory and 
motor segments242 • This mechanism of target specificity is called neurotropism and is 
demonstrated across a gap of 5 mm243'244 • Along a longitudinal fibrin matrix within a nerve 
conduit axons elongate much more effectively than through a randomly oriented fibrin matrix 
or an empty chamber, suggesting the existence of contact guidance119 • 
The role of ion shifts near the nerve ends, growth factors, hormones and many other 
regulators still need to be established"'""". 
The ideal nerve repair should integrate all the aforementioned factors"'. Clinically 
established factors in nerve repair which influence nerve regeneration are type of trauma2S1 , 
length of the gap'"·'", presence of blood clots and debris in the environment enhancing 
fibrous scarringm·119 • Malalignment and stress or tension at the suture line(s) as well as type 
of nerve repair also play a role. Examples of nerve repair are epineural suturing, perineural 
suturing, nerve grafting and fibrin glue approximation of nerve ends or tubilisation by 
various methodsw;,154-261 • In our model epineural suturing was performed to approximate the 
median nerve ends without tension using the microscope. As the nerve is small, epineural 
sutures were considered to be less harmful than group fascicular suturing. Size was not the 
only factor to use epineural repair, as there is still controversy regarding the best 
microsurgical repair method260 • Extensive research has been and still is performed regarding 
peripheral nerve regeneration. 
Much less, however, is known regarding changes in the cerebral cortex following 
peripheral nerve injury. In the cerebral cortex, two specialized areas are present, i.e. the 
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primary motor area (M!) and the primary somatosensory area (SI). These areas are 
somatotopically organized: each part of the body is represented in the cortex such that 
adjacent body parts have adjacent representations in any one of the functional areas. 
Denervation of such specialized cortical areas due to peripheral nerve trauma leaves these 
parts, though itself anatomically intact, without its functional substrate. In recent years the 
functional plasticity of these cortical areas has been investigated both immediately after 
peripheral nerve transection and after subsequent functional recovery of the nerve. 
Merzenich et a!"' and Dykes"' showed that neurons in monkey SI hand area fell silent 
immediately after deafferentation by median nerve transection. Within hours however 
neurons in this area could be activated by stimulation of adjacent, non-denervated skin. 
Within a few months the previously denervated area was almost totally reorganized and filled 
with response areas from other parts of the hand. When the median nerve was repaired, 
sensory function in the hand recovered only partly. Neurons in the previously deafferented 
section of SI could again be driven by sensory input from the matching part of the hand. 
However, some abnormality in the organization of spatial information persisted. 
These comparatively quick changes in cortical representation patterns following 
peripheral nerve transection suggest that synaptic relations between cortical areas and 
peripheral sense organs or somatic musculature can be continually reshaped in adult 
mammals. The persisting abnormalities in cortical somatotopy and the poor sensory spatial 
resolution that remain after recovery of function following peripheral nerve repair can 
possibly be due to imperfect matching of fiber bundles between the proximal and distal 
stump. 
A.3.3.2 Functional testing 
In rhesus monkeys evident limitations exist with regard to functional testing. In our 
experimental set-up we selected methods, which were not too complicated to perform, 
allowing frequent testing of function recovery and preferably in conscious monkeys. 
Information on longitudinally assessed recovery of sensory and motor function was our 
main interest. Specific tests for evaluation of sensory receptors (mechano-receptors, thermo-
receptors and polymodal nociceptors)264--266 were not considered as these tests can be 
performed only as terminal experiments, under general anaesthesia, with exposed nerves 
combined with single unit electrophysiological measurements"'. Consequently, for sensory 
recovery evaluation a small electric current was used in the conscious monkey that 
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stimulated sensory nerve ends and provoked a withdrawal reflex in case of reinnervation 
(chapter Il.B and III. C). 
To evaluate motor function, two basic methods were used. The first method is 
electromyography"' and the second method is observation of functional tasks monitored by 
video recording. Applying the same philosophy as mentioned with regard to sensory 
evaluation, transcutaneous assessment of compound motor action potentials of the thenar 
muscles was used to determine muscle reinnervation. 
Functional assessment in terms of range of motion of the grafted thumb is hardly possible 
and very variable in non-operated thumbs219 • Therefore, video recordings were used to 
demonstrate functional use of the thumb. If the rhesus monkey repeatedly picked up food 
morsels with thumb and index finger of the operated side, while the other hand was 
bandaged, the functional task was scored as positive (see chapter II.B and III. C). 
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Rl Historical notes on the role of plastic surgeons in the field of transplantation 
innnnnology 
In their search for ways to reconstruct tissue defects in patients, plastic surgeons helped to 
launch the field of transplantation surgery. The first description of a skin transplantation, 
performed to repair a nose, is found in the Indian medical handbook 'Sushrutta Samheta' 
dated A.D. 600'. In the 16th century Gaspare Tagliacozzi, the "Father of Plastic Surgery", 
was one of the first Europeans to thoroughly describe his efforts with regard to nasal 
reconstruction2 • His work also generated some fanciful reports of allografting by innovative 
writers of his day. In exchange for his freedom, a 'sympathetic' slave was reported to have 
donated a parabiotic flap from his arm to a gentleman who had lost his nose in a sword-play. 
The reconstructed nose was a success for three years, but then the allogeneic flap was 
suddenly rejected, leaving the patient with his original defect. Strikingly, the slave had died 
of a common disease at exactly the same time. According to Tommaso Campanella, a 
philosopher, the slave's soul had remained as a whole, hosted in the slave's body as well as 
in his donated part; At death, the soul left both residences, resulting in rejection of the 
transplant'. Thereafter, successful allografts were reported from time to time through 
history, but none were substantiated'. In 1804, Baronio reported successful auto- and 
allotransplantation of skin of a sheep (fig. I)'. He described the reconstruction of a nose with 
a skin graft taken from the thigh of a patient. However, transplantation of organs other than 
skin was not possible before it was known how to make anastomoses of vessels. 
Genuine surgical technique in macrovascular surgery was only developed during the 
beginning of this century, mainly by Carrel and Guthrie. Like Hopjner' they were able to 
perform an autoreplantation of a dog leg'·". They also transplanted the kidney unilaterally and 
bilaterally and, uniquely, the entire side of a dog's head including the scalp and the ear on 
the external carotid system. In 1922, Guthrie even transplanted an entire dog's head into the 
neck of another dog at the University of Pittsburgh and was able to demonstrate eye lid 
function and salivation in the transplanted head. Padgett and Brown both established that 
skin grafts exchanged between identical twins would survive indefinitely9•10 • At that time 
allogeneic skin grafts were only found to be effective to close wounds temporarily, for 
example for patients with life-threatening loss of skin due to massive bums 10 • Research into 
the immunological nature of the 'take' or 'rejection' of skin grafts became more substantial 
with the work of Medawar, who in initial experiments collaborated with plastic surgeon 
Gibson at the Glasgow Royal Infirmary" during World War II. It was demonstrated that 
rejection characteristics such as latency, memory (second-set phenomenon), and specificity 
of graft rejection proved the existence of an active immune response. 
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Fig. 1. The first transplantation of allogeneic skin in history, performed in a sheep (Baronio, 1804). 
In the following decade, Converse, who also worked in the field of skin grafting"·", 
started the biannual International Conferences on Transplantation in New York which 
developed in to the International Transplantation Society". Interestingly, the organizational 
efforts of another plastic surgeon named Conway who investigated skin allografts in rats with 
an in vivo transparent chamber15 , led to the onset of the Transplantation Bulletin as part of 
the journal, Plastic and Reconstructive Surgery. It was this Transplantation Bulletin that 
finally evolved into the journal Transplantation. 
In the mid 1950's, Murray a plastic surgeon who had worked with Brown and Conway, 
sought a more flexible model than skin grafts for the study of allograft phenomena and 
eventually succeeded in obtaining functioning kidney transplants in dogs". It was he who led 
the team which obtained the first clinical success with kidney transplantation between 
identical twins" and then with kidney allografts, using azathioprine for immuno-
suppression'"''. Recently Murray received the Nobel prize 1990 for his achievements in 
medicine. His successes led to a dramatic surge for clinical accomplishments in organ 
transplants, and stimulated others to reinspect the work of Hopfner and Carrel. 
In the 1960s, immunosuppression for prolongation of composite tissue allografts (CTAs) 
was achieved with methods impractible in man. Schwind used parabiosis before 2 weeks of 
age in rats to successfully transfer a limb for a 14-day period". Lapchinsky achieved 
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immunological tolerance in a dog through complete exchange transfusion from the donor 
when the recipient was 9 days old. Nine months later, a limb was transplanted and reported 
to have survived at least 2 months21 •22 • 
Once 6-mercaptopurine, azathioprine and prednisone had proven their beneficial effect in 
kidney transplantations" these immunosuppressive agents were also used in CTA 
transplantation. Goldwyn et al could only slightly prolong dog limb allograft survival with 6-
mercaptopurine and azathioprine24 • Rejection could not be prevented and in some cases fatal 
systemic drug-induced side effects occurred. Most interestingly, in this paper a cadaver 
human hand transplantation is reported to have taken place in 1964'". Complete allograft 
rejection occurred after 14 days already, despite cortisone and azathioprine therapy and local 
irradiation to the graft. At the time of their removal, the transplanted parts were too necrotic 
for microscopic assessment of the rejection process26 • Doi encountered similar results in rats 
with a maximum of 24 days of CTA survival, suppressing the immune response by means of 
azathioprine and prednisone". The only study showing prolonged survival before the 
introduction of Cyclosporine A (CyA) was that by Lance et aF who transplanted hind limbs 
between unrelated beagles using combinations of various potent ways to obtain immuno-
suppression. The most successful results were obtained in three animals receiving a short-
term course of massive immunosuppressive drug therapy, with or without splenectomy or 
thymectomy, followed by induction of immune tolerance from donor splenic cells or 
exchange transfusion. Despite a somewhat unstable course, long-term graft survival was 
achieved; one limb was rejected on day 200, and the other two survived beyond 60 and 300 
days respectively. 
The first data on survival of allogeneic limb transplants with CyA immunosuppression 
were published in the early 1980s by the group of Furnas, Black and Hewitt"·". Lewis rats 
that received limbs from hybrid Brown Norway/Lewis rats treated with a 20 day course of 
25 mg/kg CyA showed a dramatically increased transplant survival, with at that time at least 
one animal keeping its allogeneic limb beyond 225 days. Fritz et al could repeat these results 
and obtained indefinite CTA survival provided that the treatment with moderate doses of 
CyA was continuous". Tolerance to limb allografts in rats could probably, partly or totally 
be attributed to the development of donor-host chimeras"·". 
Recently orthopedic surgeon Arai demonstrated that the newly developed immunosup-
pressive drug FK506 that is reported to be more potent than CyA (Chapter I, Section 
B.3.1.6), also significantly prolonged limb allograft survival in rats". A 14-day FK506 
treatment of 1 mg/kg yielded a mean graft survival time (MST) of 149.5 (SD=64) days and 
a single dose of 50 mg/kg even prolonged limb MST to 104.4 (SD = 17) days. 
However, for study into the feasibility of allogeneic hand transplantation in man, research 
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in rodents and dogs only yields limited information and results can not be extrapolated 
directly to the situation in evolutionary higher developed species. For immunological and 
phylogenetic reasons the nonhuman primate is obviously a more representative experimental 
animal, this was substantiated many years ago". So far only two hand transplantation studies 
in the nonhuman primate (baboon) have been reported, respectively by the groups of Daniel 
et af" in 1986 and Stark et aT!' in 1987. In these two studies long term hand transplant 
survival occurred in two out of four (188 and 304 days) and one out of eight monkeys (296 
days), respectively. In both studies high dosis ofCyA and prednisone were used. 
B.2 Aspects of allograft rejection 
The labyrinthine interrelationship between the complex immunological cascade of cells 
and antibodies leading to rejection of a 'foreign' allograft is still not fully understood. 
An immune response will be provoked when the major histo-compatibility complex 
(MHC) antigens between donor and recipient differ. As a result the allograft will be rejected 
unless the host immune response is modified by immunosuppression. The MHC in man, also 
known as the human leukocyte antigen (HLA) system, is an extremely complex genetic 
system. It includes the 'classical' gene loci which control the expression of MHC class I 
antigens: HLA-A, -B, -C, and MHC class IT antigens: HLA-DR, -DQ, -DP. Each of these 
gene loci have multiple alleles resulting in an extensive polymorphism of the MHC"'". Also 
a number of 'nonclassical' gene loci have been described for class I (HLA-E, -F, and -G) as 
well as for class II (HLA-DZa and -DOfi). Not all protein products of these nonclassical 
genes have been found or their physiological functions have yet to be established. In 
addition, there are several minor histocompatibility antigens which may also cause an early 
and irreversible rejection even in the presence of identical MHC43 , however in the rest of this 
section only the relevance of the 'classical' MHC antigens will be discussed. 
Traditionally, MHC antigens from the donor organ are processed by antigen presenting 
cells (APC) in the recipient and are presented by these specialized cells (probably dendritic 
cells) to T-helper/inducer (Th/i) lymphocytes of the CD4+ phenotype", to initiate the 
immune response (Fig. 2). The CD4+ Th/i-cells recognize the foreign antigen in association 
with recipient MHC class II antigen on the presenting cell (this is known as MHC class II 
'CD = Cluster of Differentiation, as defined during the Leucocyte Typing Conferences in 
Paris, 1982; Boston, 1984; Oxford, 1986; and Vienna, 1989. 
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• • donor Ag 
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Humoral response: 
1. CDC 
2. ADCC 
Figure 2. A simplified representation of the immune reponse against foreign tissue. 
Abbreviations used: Ag=antigen; hDc::::host dendritic cell; hM¢=host macrophage; dDc=donor 
dendritic cell; dMcj>=donor macrophage; IL-l=interleukine 1; TNF-o:=tumor necrosis factor-
alpha; MHC I,II=major histocompatibility complex class I-, U-antigens; Ts=suppressor T-cell; 
Th/i=helper-inducer T-cell; IL-2=interleukine 2; B-cell-GF=B-cell growth factor; JFN-')'= 
interferon-gamma; p-Tc/s=precursor-cytotoxic-suppressor T -cell; Tc/s= cytotoxic-suppressor T-
cell; CDC= complement dependent cytotoxicity; ADCC=antibody dependent cellular cytotoxicity; 
DTH =delayed type hypersensitivity; CMC =cell mediated cytotoxicty. 
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restriction). However, in the case of a vascularized graft, the APC will be of donor origin. It 
seems possible that recipient Th/i-lymphocytes entering the graft can recognize incompatible 
MHC class U antigen as presented by these specialized dendritic cells of the donor directly, 
without the need for processing by host presenting cells. Moreover, it is also possible that 
these donor dendritic cells leave the allograft and interact with recipient Th/i-cells at a more 
central site such as the spleen44 • 
Once the recipient Th/i-cell has recognized the foreign antigen it produces a whole series 
of lymphokines resulting in a true amplification of the rejection response. Interleukine 2 (IL-
2) is produced, and in concert with IL-l, a cytokine produced by antigen activated 
macrophages"·", also expression of!L-2 receptors (IL-2R) is increased"·". IL-2R is not only 
expressed on Th/i-lymphocytes but also on some B-cells, macrophages, dendritic cells, and 
MHC class I restricted CD8+ T-cells or the T cytotoxic/suppressor lymphocyte subset 
(Tc/s)". IL-2 reacting with these receptors will drive I'~-2R-expressing antigen-activated 
cells to clonal expansion and will ensure viability. Also indirectly via stimulation of the 
release of B-cell growth factor, inter!eukines stimulate the proliferation of antigen activated 
B-cells to produce donor specific antibodies"'. At the same time, the release of lymphokines 
such as interferon--y (IFN--y) and tumor necrosis factor-a (TNF-a) offer another way of 
amplifying the immune response. IFN--y mediates the chemotactic migration and activation 
of T cells" and macrophages" and enhances the cytotoxic activity of natural killer cells, 
monocytes, cytotoxic T cells and polymorphonuclear leucocytes"·". Like IFN--y, TNF-a 
increases the expression of membrane glycoproteins such as intercellular adhesion molecule-
! (ICAM-1), relevant for the adhesion of circulating granulocytes, monocytes and 
lymphocytes to endothelial cells"·". TNF-a also exerts direct cytotoxic effects towards 
endothelial cells". Moreover, !FN--y as well as TNF-a both enhance the expression of MHC 
class I and II antigens on almost every cell type"". Increased expression ofMHC antigens of 
donor as well as host origin will initiate a vicious circle as the antigenicity of the allograft 
will be increased'>", MHC class II restricted activation ofTh/i-cells will be increased"·" and 
subsequent induction of cell-mediated cytotoxicity will be enlarged". 
The cellular reactions aimed at destroying an allograft, can be divided into a delayed-type 
hypersensitivity (DTH) and cell mediated cytotoxicity (CMC)""". In the effector phase, the 
DTH process is a non-specific reaction resulting in tissue destruction by monocytes, 
macrophages and polymononuclear leucocytes. During CMC, however, CD8+ Tc/s-
lymphocytes will induce allogeneic cell lysis in a MHC class I restricted way. Both cellular 
reactions seem to take part in the rejection response of the host, CMC activity during the 
beginning of the effector phase of rejection, later phases of rejection may involve non-T 
killer activity as significant numbers of B lymphocytes, mononuclear cells, histiocytes and 
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natural killer (NK) cells invade the allograft also. 
Humoral immunological reactions can damage a graft via complement dependent 
cytotoxicity (CDC) and via antibody dependent cellular cytotoxicity (ADCC)"·"·". CDC 
implicates activation of the cascade of complement factors resulting in lysis of the cell to 
which these complement factors are bound via an immune complex, e.g. antibodies bound to 
the surface of an allografted cell. In ADCC, antibody-binding between a target cell 
specifically bound on one side to an effector cell and non-specifically bound on the other side 
of the antibody, results in lysis of the target cell by the effector cell also. 
To produce and maintain an immunologic homeostasis in the host after 'successful' 
rejection or acceptance of an allograft, suppressor T (Ts) cells of the CD4+ as well as 
CD8 + phenotype play a pivotal role"·". It has been demonstrated that in the induction phase 
of host unresponsiveness, Ts-cells in lymphoid tissue were antigen specific; however, those 
at the graft site gave a nonspecific suppressor effect". CD4+ Ts-lymphocytes alone were 
responsible for induction of unresponsiveness but both CD4+ and CD8+ Ts-cells were 
operative in the maintenance phase76'77 • However, it should be stressed that the relationship 
between phenotype and function is not absolute; the same cell may express different 
phenotypes under varying conditions of stimulation. There even is a vivid discussion about 
the true nature of suppressor cells and their suppressor function. 
It is almost needless to emphasize that the immune response to an allograft is a very 
complex set of cellular and humoral interactions and that this section remains an incomplete 
synthesis of what is known about this subject, today. 
B.3 Modification of the hmmune response 
As clarified in the previous sections, allografts (except one from an identical twin) will be 
rejected by the host unless intervention can prevent rejection. Many non-specific and more 
specific methods of immunosuppression have been developed and tested as more organs are 
being transplanted. In this chapter, however, only the effect of matching for MHC antigens 
and those immunosuppressants that have been used in this research project will be discussed 
in detail (sections B.3.1.1-3.1.6). In this respect, a number of different immunosuppressive 
treatment schedules will be discussed (section B.3.2). Other ways to suppress the host 
immune response against foreign tissue will be reviewed briefly in section B.3.3. 
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B.3.1 Modification of the innnune response relevant to this thesis 
B.3.1.1 Matching for major histocompatibility antigens 
Nowadays, there seems to be a fair consensus that matching for MHC class I and II 
antigens has a beneficial effect on organ allograft prognosis and patient survival rates'". 
However, there seems to be an organ related influence as to whether matching for MHC 
class I antigens is of more importance than matching for MHC class II-DR antigens. The 
effect of matching for MHC-DR antigens, is thought to outweigh matching for MHC class I 
antigens in kidney transplantation. In a prospective study in the rhesus monkey it was clearly 
demonstrated that mixed lymphocyte culture (MLC) nonresponsiveness ( = MHC class II 
compatibility), had a profound effect on kidney graft prognosis, while matching for MHC 
class I antigens had no discriminating influence79'80 • This could be confirmed in clinical 
kidney transplantation trials 81-83 • In skin transplantation studies in man, however, MLC 
reactive host/donor combinations matching for MHC class I-A and -B antigens correlated 
with improved graft survival times". In the rhesus monkey it also led to a modest but distinct 
prolongation of skin graft survival times85 , whereas MLC nonresponsiveness between donor 
and host only had a minor beneficial effect, if any at all". 
With the advent of cyclosporine A (CyA) there has been some question as to whether 
matching is still relevant. With regard to kidney transplants both the UCLA registry and the 
European Collaborative study with large numbers of patients still show a significant 
influence of matching for HLA-DR in patients treated with CyA"·'". Also a correlation 
between matching for MHC-DR and cardiac allograft survival under CyA treatment has been 
demonstrated89 . 
B.3.1.2 Prednisolone 
Since the early sixties prednisolone, the active compound of the glucocorticosteroid 
prednisone, has been successfully used as a conventional post-transplant immuno-
suppressant". Very few other drugs, with the exception of azathioprine and the alkylating 
agent cyclophosphamide, have been used as widely in clinical transplantation. The clinical 
effect of prednisolone may be due to a combination of its anti-inflammatory activities and its 
immunosuppressive properties91"93 • The anti-inflammatory activities result in reduced 
migration of neutrophils in response to chemotactic stimuli as well as in reduced 
inflammation by inhibiting lysosomal enzyme release by neutrophils. The influence of 
prednisolone on the suppression of the immune response is complex and might result from a 
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combination of different immunosuppressive effects. Intra-nuclear activities, at the level of 
transcription have been demonstrated to result in modifications of enzyme synthesis (either 
induction or repression)""'. Moreover, inhibition of the production of the cytokines IL-l, 
IL-2 and IFN-i'"' will clearly have a immunosuppressive effect by hindering the cascade of 
the cellular and humoral immune response (section B.2). Furthermore, steroids are reported 
to interfere in the process of antigen presentation and recognition by their effect on MHC 
class II expression on antigen presenting cells95·n. 
B.3.1.3 Blood transfUsions 
Oplez et al were the first to demonstrate, in a retrospective analysis of clinical data, that 
nonspecific transfused kidney allograft recipients had superior graft survival as compared 
with nontransfused patients". This finding was confirmed in experimental studies in 
rodents99•100 , dogs101 and the rhesus monkey102 as well as in clinical studies103 . Since these 
reports in the early seventies many controversial results have been published with regard to 
the number of transfusions, the composition and preparation of the transfusate, the timing of 
the transfusions and the number of (mis)matched for MHC class I and/or II antigens that 
would yield best graft survival rates, it is still widely accepted that pretransplant blood 
transfusion to the recipient produces a favorable effect on graft survival. Even under CyA 
therapy third party blood transfusions have been demonstrated to have a beneficial effect on 
allograft survival times"". 
Theories dealing with the possible mechanism of the transfusion effect concern non-
specific mechanisms (recipient selection105 , clonal deletion106 , iron overload and macrophage 
blocking'") humoral mechanisms (MLR-blocking antibodies"', anti-idiotypic antibodies"") 
and cellular mechanisms (suppressor cell induction110' 111 ). 
B.3.1.4 Cyclosporine A 
In 1972, Borel was the first to demonstrate the immunosuppressive actlVlty of 
cyclosporine A (CyA), a fungal metabolite extracted from a fungus- Tolypoc/adium injlatum 
Gams - which was originally isolated from soil samples collected from the Hardanger Vidda 
in Norway"'. CyA is a neutral, highly lipophilic, cyclic peptide containing II amino acids 
(Fig. 3). Though the exact mechanism of action of CyA is not known, its 
immunosuppressive activity is thought to be due to at least two properties: I) its ability to 
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inhibit the production of lymphokines 
such as IL-2, IFN-')', B cell differen-
tiation factor. and cytotoxic differen-
tiation factor and 2) inhibition of the 
response to IL-2 of precursor cytoto-
xic effector lymphocytes23 '9" 113 • At the 
same time, T -suppressor cell expres-
sion is not extensively disturbed 114'115 • 
On the molecular level CyA penetra-
tes the nucleus of its target cell and 
interacts with sites on the chromo-
some, specifically disordering the 
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Fig. 3. Structure of Cyclosporine A 
transcription of messenger RNA coding for lymphokines. As a result, the synthesis and 
release of the above mentioned lymphokines is inhibited"' and thus a more or less selective 
immunosuppression impairs the T-helper/inducer lymphocyte function. As can be seen from 
Figure 2 (section B.2}, this will have enormous influence on the cascade of the rejection 
response. Importantly, Cy A does not appear to directly affect granulocyte or macrophage 
function"', and has hardly any myelosuppressive effect. Thus, CyA inflicts general host 
resistance less than more widely acting immunosuppressants such as azathioprine and 
prednisolone. 
CyA which came into generalized use in 1983, has proven to be the most successful 
primary drug in preventing rejection. It improved the !-year graft survival from a previous 
50-55% to over 80% in recipients of renal grafts from unmatched cadaveric donors"'. With 
or without steroids 3-year kidney allograft survival could be prolonged to 70% to 80%, 
clearly better than could be obtained with azathioprine and steroids treatment"·'". 
Despite these positive properties, literature also mentions a number of major side effects 
of CyA. Most frequently reported are; moderate to severe nephrotoxicity, hepatotoxicity, 
tremors, hirsutism, gingival hypertrophy, central nervous system toxicity, and 
gastrointestinal intolerance. All side effects have shown to be dose-related and reversible on 
stopping the drug"·"""'. Soon after the introduction of CyA substantial concern arose that 
lymphomas might be more frequently observed after CyA treatment than with conventional 
immunosuppression 118 • Subsequent clinical studies could not confirm this 123 and neither could 
a recent study with data from over 4500 patients from 76 centers in 17 countries with patient 
follow-up over a 2- or 5-year period'"'. Initially CyA doses were much higher than currently 
recommended, which may, in part, explain the differences. 
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B.3.1.5 Monaclonal antibodies 
Heterologous anti-lymphocyte serum (ALS) or anti-thymocyte globulins (ATG) have been 
used for years to treat or prevent rejection with considerable success 125 • But such 
heterologous sera (usually made in horses or rabbits) are very broad in their reactivity not 
only to leucocytes but often to other targets, such as platelets. Inevitably there is also a 
substantial batch-to-batch variability in efficacy and toxicity. Therefore, monoclonal 
antibodies (MAbs), which are by definition homologous in composition and monospecific, 
seem to be a more promising tool for the modulation of the immune response. Using the 
hybridoma technique of Kohler and Milstein''", it became possible to develop reactive 
monospecific immunoglobulins (Fig. 4) with target structures that can vary from cell-
surface-markers to free molecules (like cytokines). 
antigen 
binding 
sites 
The basic structure of Immunoglobulin G 
disulphide 
bond 
L heavy chain F C • complement J fixing region 
Figure 4. Structure of an immunoglobulin. Four polypeptide chains make up the immunoglobulin 
molecule. Sequence variability (V) occurs in the shaded areas in both the heavy (H) and light (!..) 
chains, which are referred to as the V H and V L regions respectively. The rest of the molecule has a 
relative constant (C) structure. The constant portion of the light chain is termed the CL region. The 
constant portion of the heavy chain is further divided into three structurally discrete regions: CHI, Cm 
and Cm. These globular regions, which are stabilized by disulfide bonds, are referred to as domains. 
The sites at which the antibody binds antigen are located in the variable domains. Fe indicates the 
complement fixing region. 
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With such MAbs i.e. selective T cell populations relevant for rejection can be manipulated, 
without impairing the host's immune competence. Moreover, because of these properties, 
MAbs are most useful in several diagnostic tests (Chapter II, Section C). 
Several mechanisms of action have been proposed to explain the immunosuppressive 
effect of MAbs: 1) MAbs can bind directly to antigen, thereby preventing a potential 
antigenic stimulus127 , 2) MAbs may inhibit adhesion processes involved in the immune 
response'", 3) MAbs binding to cell-surface antigens may inhibit immune function, which is 
known as coating"', 4) MAbs bound to a functional lymphocyte subset marker may induce 
cell clearance, possibly by complement dependent cell lysis or by destruction through the 
mononuclear phagocytic system, also in the presence of complemenf", 5) and finally the 
MAbs-target-complex may also be removed from the cell a phenomenon which is called 
surface antigenic modulation131 • The kinetics of the latter three cell-related mechanisms is 
likely to depend on (any combination of) the affinity of the MAb with its target, the isotype 
of the MAb, and the nature and density of the target antigen (see also Chapter III, section D). 
Clinical results with MAbs for the treatment of rejection episodes are mainly limited to 
the CD3 antigen. The first patient trial was performed by Cosimi et a!, who used OKT3, 
which is CD3 specific, for the treatment of established kidney graft rejection episodes 
without other treatment and with concomitant lowering of steroid treatment. Within two to 
seven days in eight out of eight patients allograft rejection could be reversed 132 • Subsequent 
larger kidney transplant studies confirmed the beneficial effect of OKT3 and demonstrated 
that the efficacy of OKT3 (reversal rate 94%) was significantly better than that with 
conventional steroid treatment (reversal rate 75%)"'- OKT3 has also been reported to be 
effective for the reversal of kidney and liver allograft rejection episodes that were 
nonreversible by high-dose steroids and/or ATG"'·"'. Clinical trials with other MAbs such 
as anti-Tl2 (CD6-specific"'), RFT2 (CD7-specific"'), WT32 (CD3-specific''"), and CELl 
(blast-cell specific"') also showed reversal of acute renal allograft rejection, in 43%, 60%, 
88%, and 89% ofthecases, respectively. 
Numerous experimental studies have been performed and still are being performed to test 
newly developed MAbs. Noteworthy are efforts to increase the specificity of the immunosup-
pressive effect by trying to impair the function of subsets ofT-cells. In this respect, MAbs 
specific for CD4+ T-cells have been tested and found to possess immunosuppressive 
potencies in transplant studies of different organs in the rodent'40' 141 and non human 
primate142' 143 • Also some MAbs specific for CDS+ T-cel1s143•145 and IL-2-receptor expressed 
by activated T -cells146 appeared to suppress the immune response. Furthermore, new 
approaches in using MAbs for immunosuppression are being developed. Strom et a!. 
replaced the DNA sequences of Diphteria toxin that code for the receptor-binding protein 
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domain with human IL-2 DNA sequences. In this way a recombinant IL-2 toxin hybrid 
molecule could be produced that showed immunosuppressive potencies"'. 
Clearly, the potential for the use of MAbs in transplantation is enormous. Nevertheless, 
several side effects have been reported related to MAbs therapy. CD3- and CD8-specific 
MAbs may cause adverse reactions shortly after the first injection148'149 • Fever, chills, 
bronchospasms and shock-like symptoms are most frequently observed and are explained by 
a massive release of lymphokines133'148'149 • This problem might be circumvented by changing 
the Fe portion of the immunoglobulin from an IgG2a to an IgA variant, as the Fe portion of 
the CD3 MAb (IgG2a-isotype) determines the activation and subsequent lymphokine release 
of the target cell'"'. The major drawback of murine MAb therapy is the induction of an anti-
mouse antibody (AMA) response, generally consisting of anti-isotype and anti-idiotype 
antibodies133'14j'148 • Obviously, such an AMA-response is unwanted because especially the 
anti-idiotype antibodies are found to abrogate therapeutical effectiveness of those injected 
MAbs they are specific for. Moreover, anti-isotype antibodies can cause an anaphylactic 
reaction when a second or third MAb treatment is given. To prevent sensitization against the 
murine immunoglobulin, 'idiotype switching' has been reported to be successfuP-~\ though 
repeated courses of different MAbs may lead to the formation of crossreactive anti-idiotype 
antibodies causing unresponsiveness to a large number of MAbs1~2 . High doses of 
concomitant immunosuppression at the time of MAb therapy will prevent an AMA-
response152'153, however this implies a possible intoxication of the MAb recipient. 
Theoretically, a human or humanized MAb would offer the best chances to prevent the 
occurrence of an anti-isotype response as their Fe tail is expected to be less immuno-geneic 
than the Fe tail of a murine MAb. Theoretically, this approach would also minimize the 
formation of neutralizing anti-idiotype antibodies. The first clinical trials with humanized 
MAbs do not permit any conclusions yee54'155 • However, in a preclinical study in the 
chimpanzee, humanized anti-CD4 did not elicit a significant anti-anti-CD4 repsonse (M. 
Jonker, personal communications). 
B.3.1.6 FK506 
In 1987, a powerful new anti-T cell agent, designated FK-506, was first described'"·"'. 
The drug was extracted from the fermentation broth of the soil fungus Streptomyces 
Tsukubaensis. Although it is structurally distinct from CyA (Fig. 5) it possesses similar if 
not identical immunosuppressive properties and at the same time is approximately 100 times 
more potent than CyA in in vitro studies. Currently it is thought that the primary target of 
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FK-506, like that of CyA, may be a transcription 
activator(s) (or factors controlling its synthesis) 
required for lymphokine gene expression'". In 
this way, in vitro 'early' phase CD4+ T 
(helper/inducer) cell gene expression and 
secretion was blocked for IL-2, IL-3, IL-4, IFN-')' 
and TNF-"· Constitutively expressed genes 
(encoding i.e. MHC class I) and 'late' phase 
activation genes (encoding i.e. IL-2R, transferrin 
receptor or TNF-n) were not affected by FK-506. 
In vivo experiments revealed that at consider-
ably lower doses than those of CyA (!0-100 times 
less), allograft survival of rat hearts'" as well as Fig. 5. Structure of FK-506 
kidneys in beagle dogs could be prolonged'"'. Although in dogs major complications such as 
anorexia and vascular changes were observed 1oo.-162 , in other animals no such severe side 
effects occurred'". Subsequently in a clinical trial oral administration of FK-506 in low 
doses was demonstrated to be an effective and safe immunosuppressant for liver, kidney and 
pancreas transplantation'". FK-506 was less nephrotoxic than CyA and did not cause 
hypertension. However, many questions about its mode of action still need to be solved and 
longer experience of FK-506 in clinical trials is required before a fuller assessment of its 
relative merits, compared with CyA, can be made. 
B.3.2 Treatment schedules 
As most of the side effects of CyA therapy proved to be dose-dependent (Section 
B.3.1.4), attempts were made to devise protocols which used lower doses of CyA with or 
without the concomitant use of other drugs. In this respect, and to further increase graft and 
patient survival rates, a number of different approaches have been tested. 
Steroids with CyA did not significantly improve kidney graft survival compared to CyA 
alone164'165 , though in comparison to conventional immunosuppressive therapy three-year 
graft and patient survival was better"'. In one trial, data were presented, suggesting that the 
degree of nephrotoxicity was reduced with the addition of steroids'". 
Conversion some months after transplantation from CyA to azathioprine (AZA) and 
steroids lead to a dramatic improvement of renal function on cessation ofCyA166-- 169 • Provided 
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that there is an overlap of immunosuppressive therapies around the time of conversion, it 
would seem that high incidences of graft rejection within the first month of conversion could 
be prevented. 
Double therapy with CyA and AZA did not improve graft survival rates, but showed less 
graft rejection compared to CyA monotherapy"". 
A controlled trial comparing triole theraoy consisting of low doses of CyA, AZA and 
steroids with high-dose CyA and steroids showed no difference in graft survival times"'. 
However, there were more rejection episodes in the triple therapy group and more 
nephrotoxicity and infection in the high-dose CyA group. 
Quadruple therapy, consisting of addition of ALG for the first 14 days (later reduced to 7 
days) to a triple therapy regimen also showed excellent graft survival times both for re-grafts 
as well as first grafts m. 
Sequential theraoy by giving CyA after cessation of initial ALG therapy together with 
AZA and steroids, provided that renal function is adequate is also practiced by many 
transplantation centers'"·"'. The use of OKT3 instead of ALG in the same set-up would be 
accompanied with an unacceptable mortality and infection rate despite the occurrence of less 
rejection episodes174 • Experience with prophylactic use ofMAbs is still limited. Several other 
studies confirmed the lower incidence of rejection episodes during the first few weeks 
following transplantation175•176 • Eventually however, graft survival rates and kidney function 
are often comparable to controls and hence at this moment the major therapeutic advances of 
MAb treatment appears to be at the time of allograft rejection. 
The majority of the data presented in this section concern protocols for kidney 
transplantation. There are insufficient data concerning the use of these protocols in 
transplantation of other organs to be sure that the same conclusions apply, though it does 
seem likely177 • 
B.3.3 Other ways of modifying the immune response 
Many other ways of suppressing the host immune reponse against an allograft have been 
described and tested. In this section only a brief selection is presented. 
Azathioprine (AZA), an agent which blocks DNA replication after it is metabolized in 
vivo to 6-mercaptopurine, has been mentioned earlier in this section. AZA was the first 
proven immunosuppressive reagent to be used clinically". Originally it was thought to be a 
rather weak immunosuppressant, however, in combination with CyA and/or steroids (section 
B.3.2) it has clearly proven to be useful. 
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Total lymohoid imdiation (TLI) or ALG with 
or without subsequent bone marrow transplan-
tation or low-dose immunosuppressants to induce 
long term donor specific unresponsiveness, is 
causing renewed interest17u 79 • 
Obviously, pharmaceutical industries try hard 
to develop completely new drugs to improve cur-
rent immunosuppressive regimes for commercial 
reasons. In this respect FK506 which has been 
described in section B.3.1.6, can be mentioned. 
Structural similarities between FK506 and rapa-
mycin (Fig. 6) has stimulated researchers to 
reinvestigate the immunosuppressive properties 
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Fig. 6. Structure of Rapamycin 
of rapamycin in a transplantation model'"". Renal allograft survival in dogs and pigs could be 
prolonged. RS-61443, a morpholinoethyl ester of mycophenolic acid, is a completely new 
drug which also suppresses the immune response against a heart allograft in mice181 • 
Allogeneic skin, heart, islet cells and kidney survival could be prolonged by 15-Deoxysper-
gualin"' in rats. Furthermore, A 85 4777, a homopiperazine derivate could prolong skin 
allograft survival in rats alsd!r.l. 
Many more drugs could be mentioned and more will be developed in the coming years. 
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C.l Rationale of the experiments 
C.l.l Objectives & experimental animals 
Interest in the use of allogeneic composite tissue to reconstruct congenital or acquired 
deformities of extremities is centuries old (Chapter I, Section B). In the Netherlands, there is 
clinical demand from patients (and/or their parents) for reconstruction of large extremity 
defects that can not be solved by autogenous tissue transfer (Chapter I, Section A). 
Especially with the advent of Cyclosporine A (CyA), monoclonal antibodies (MAbs) and the 
possibility of microsurgical operations, a new stimulus has been given to this field of 
composite tissue transplantation. 
Several authors have provided data on the feasibility of composite tissue allograft (CTA) 
transplantation under various kinds of immunosuppression, but mainly in a rat hind limb 
transplantation model'~. Rodent models for tissue transplantation give leads as to what 
technical, functional and immunological aspects are of importance. In this respect, our 
group performed a limb transplantation study in the rat to monitor the onset of rejection. 
However, the limitations of studies in less developed animals are clear with regard to the 
preclinical testing of the afore mentioned aspects of eTA-transplantation. Only in a higher 
developed species such as the nonhuman primate, can more substantial extrapolations to the 
situation in man be made with regard to the technical feasibility of CTA-transplantation. 
Only then can it be tested optimally whether or not functional recovery can be expected and 
what immunological events occur during the immune response of the host and therapeutic 
intervention to suppress this response. The rhesus monkey was chosen as an experimental 
animal. Research was performed at the Primate Center TNO as in this institute ample 
experience existed with transplantation studies in these animals. Conventional immunosup-
pressants and polyclonal anti-lymphocyte sera were tested in vivo in the late sixties10·11 and 
seventies" already. Also anti-human MAb have been successfully applied in vivo to modify 
the immune response 13'14 • Non-human primates are more likely to fulfill the requirements for 
testing the efficacy and safety of immunosuppressive drugs and MAbs in particular"·". 
Furthermore, the (immunological) status of the rhesus monkeys is well defined. All 
monkeys are serologically typed for a large number of MHC antigens, which show close 
resemblance with the MHC antigens of man'"". Recently, identification of new MHC alleles 
is being established by restriction fragment length polymorphisms (RFLP) analysis also". 
Some of the topics of interest have been elucidated in two hand transplantation studies in 
the baboon""'. However, even high doses of CyA in combination with prednisolone could 
not prevent rejection of the allogeneic hand transplant in the majority of the cases, nor could 
an increase in steroid treatment reverse all rejection episodes effectively. Moreover, 
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functional recovery testing was not performed longitudinally. 
It was therefore our objective to evaluate the technical feasibility of an allogeneic 
transplantation model of the radial side of the hand in the rhesus monkey with special 
emphasis on improving the necessary immunosuppressive regime. Longitudinal monitoring 
was performed with respect to allograft survival, sensory and motor function recovery, and 
several immunological parameters both in the peripheral blood of the host as well as in the 
allograft itself. Also, the immunosuppressive effect was tested of several monoclonal 
antibodies and a new immunosuppressive drug 'FK-506' in a skin transplantation model in 
rhesus monkey and rat, respectively. 
C.l. 2 Ethical aspects 
Initially it was the intention to transplant the complete hand in a rhesus monkey model, 
for the ultimate goal was to explore the possibility of allogeneic transplantation of the 
complete hand in patients who lack one or both hands due to congenital deformity or trauma. 
However, during discussions with members of the ethical committee of the Primate Center 
TNO, Rijswijk it was agreed to transplant the radial side of the hand only. In this way, both 
allograft donors and recipients would still maintain fairly good function of the hand if the 
first ray of the hand had to be amputated. Loss of the radial side of the hand (the thumb) 
does interfere with pinch and key grip but not with grasp and support function of the 
affected hand. From a research point of view, such a complete functional unit as a transplant 
of the radial side of the hand would still allow for all possible technical, functional and 
immunological investigations. 
Indeed, post-experiment evaluation revealed that 13 out of 14 allograft donors could use 
their operated hands for almost normal grasp and support functions. Also all allograft 
recipients that survived the research project had good grasp and support function of the 
operated hand after amputation of a completely rejected allograft. 
All experiments were performed in consultation with the veterinary physician of the 
Primate Center and the Article 14 Officer of the Government, who makes sure that all 
regulations regarding animal research are followed. 
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C. I. 3 Studies peifonned 
In section A of chapter I, the historical background of hand reconstruction and the 
development of microsurgery is reviewed. The inability to reconstruct a patient with an 
amputated hand has been the objective for our reserach model. The set-up for this model 
from a technical and functional point of view is described. In section B, historical and 
immunobiological aspects of composite tissue allografting are presented. More detailed 
information is given with regard to the immunosuppressive drugs that have been used in this 
thesis. In section C, the rationale of this research project are given together with some 
ethical considerations. 
In chapter II, five introductory studies are described dealing with A) the value of different 
factors for the monitoring of the rejection of an allogeneic hind limb in the rat; B) the 
anatomy of the upper extremity of the rhesus monkey and the partial hand we transplanted in 
particular; C) the experiences that were encountered using a thermoplastic splint for the 
fixation of the upper extremity in the rhesus monkey; D) the value of several anti-
lymphocyte MAbs for the suppression of the immune response and the effect of combining 
seven of these MAbs; and E) the crossreactivity of a panel of anti-human MAbs with rhesus 
surface markers in immunohistochemical analysis on frozen sections. 
With the koowledge gained from the studies described in chapter II, 12 consecutive 
allogeneic transplantations of the radial side of the hand were performed successfully in the 
rhesus monkey. In chapter III, study A) deals with the technical aspects of these operations; 
study B) describes the results from longitudinal tests into the recovery of sensory and motor 
functional recovery of the transplant; and study C) deals with the lymphocyte subset 
fluctuations that were observed in the peripheral blood as well as in the allograft itself. 
Furthermore, in study D) the encountered complications were investigated with regard to 
correlation with historic and therapeutic factors. The occurrence of four post-operative 
lymphoprolifertave disorders under immunosuppression and their association with Simian 
T-Leukemia retrovirus infections of the graft recipients is described in study E. 
Finally, in chapter IV two new approaches to improve immunosuppressive therapy were 
investigated in skin transplantation studies. Study A deals with the synergistic effect of the 
combination of two MAbs specific for two potent cytokines in the rhesus monkey. Study B 
describes the beneficial effect of the new drug FK-506 in combination with Cy A, in the rat. 
In chapter V and hoofdstuk VI an overall discussion and summary is presented in English 
and Dutch, respectively. 
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A.l Introduction 
Allogeneic limb transplantations have been performed in rats before3'4'7 • Without 
immunosuppressive drugs the life expectancy of a transplanted limb in general does not 
exceed three weeks. With the well-known, strong immunosuppressive drug cyclosporine A 
transplanted limbs remained vital for as long as this drug has been given. Due to the side-
effects of immunosuppressive drugs it is important to keep the dosage as low as possible 
without losing the allogeneic transplant. Information about the initial onset of rejection is 
therefore essential. The earlier the onset of rejection is detected the earlier a change in the 
immunosuppressive drug scheme can be initiated and thereby prevent possible severe damage 
to vital tissues in the transplant'. The purpose of this study is to find parameters which 
indicate the initial onset of rejection. 
Clinical examination is not always easy to interpret and when skin changes are evident 
rejection is already advanced. Frequent histologic examination is in practice difficult. In the 
clinical patient we have gained experience with postoperative monitoring after microvascular 
surgery, especially temperature, transcutaneous oxygen and laser doppler flowmetry'. In the 
allogeneic limb transplantation model in the rat, temperature and transcutaneous oxygen 
measurements were not used by us, because temperature measurements are unreliable and 
easily influenced1'6 and the transcutaneous oxygen probe is to large to measure on a rat limb 
transplant. Therefore we decided to use peripheral blood gases instead. In rejection, a 
decline in glucose and increase of lactate peripheral blood levels could be expected due to the 
hypoxic state of the transplant'·". These were also included in the study. 
Laser doppler flowmetry (LDF) was used to assess flux in the microcirculation of the skin. 
LDF has proven to be valuable as described by others'·". 
Since we were not able to obtain blood samples and histology from the transplanted limb 
repeatedly, all measurements were done in every rat only once on the random day of 
sacrifice. A pilot study had been performed to obtain technical experience with the model. In 
this pilot study none of the allogeneic limb transplantations survived two weeks, therefore 
we did all our experiments between days 2 and 14 after transplantation. 
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A.2 Materials and methods 
A.2.1 Experimental design 
Allogeneic limb transplantations were performed on 20 rats. Inbred specific pathogen-free 
BN/Bi rats were used as donors and Wag/Rij rats were used as acceptors. This combination 
represents a very strong mismatch. In the control group 6 limb transplantations were done on 
Wag/Rij rats. Weights of the rats ranged between 315-400 grams. They were not used for 
other experiments. 
The planned day of post mortem study was determined for each rat in a random fashion, 
with the restriction of an even distribution of the rats over the relevant period. In the 
allogeneic group all experiments were done between days 2 and 14 and in the control group 
between days 7 and 304. On the day of obduction all animals were subsequently subjected to: 
clinical examination, laser doppler flowmetry (LDF), bloodgases, glucose, lactate and 
biopsies for histological examination in the transplanted limb as well as in the contralateral 
limb. 
In clinical examination the transplant was always compared to the normal contralateral 
limb. The following parameters were scored: edema, colour, hairless, epidermolysis, crust 
formation and exsudation. LDF measurements (Perimed PF 2) were taken in all animals 
during 5 minutes on the same three locations, i.e. distal and proximal volar aspect as well as 
the dorsum of the foot. The obtained graphic representation was divided into 5 blocks of I 
minute. The median of each block was assessed from the values taken at 6, 18, 30, 42 and 54 
seconds. The medians of each block were combined to achieve a mean value for every 
location. We used the mean value of the three locations to obtain an overall mean value as a 
representative LDF measurement for every limb. 
Duplicate peripheral bloodgases, glucose and lactate were taken from the toes of the 
transplant and the contralateral limb after intravenous injection of I ml heparine solution (50 
IU/ml). Bloodgases were measured with the A VL 945 automatic blood gas system. Glucose 
was tested with the glucoquant (Boehringer), lactate with the lactate UV-test (Boehringer). 
The mean of the obtained duplicate values was considered as representative. 
Histological examination was done from the skin, the subcutaneous soft tissue and the 
bone at the height of the proximal foot. Histological grading consisted of none; epidermal 
changes and inflammatory infiltration; mononuclear infiltration; obstructive vascular 
changes and diffuse mononuclear infiltration; hemorrhage and necrosis. Bone marrow 
rejection was scored as present or not. All gradings were done by the same pathologist in one 
session. 
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A.2.2 Surgical technique 
We used the same procedure as described by Fritz et a!. in 1984'. After induction and 
maintenance of anaesthesia with an ether gauze the vessels of the donor limb were mobilized 
through an inguinal approach. The femoral vessels were dissected inferiorly in continuity 
with the saphenous vessels which run superficially along the medial aspect of the leg. 
All other branches, including the profunda femoris and the popliteal vessels were ligated 
with bipolar coagulation. The saphenous vessels were dissected free to the level of the 
midcalf, where amputation was performed leaving the leg attached to the long vascular 
pedicle. I ml Heparine solution (50 !U/ml) was given intravenously. At this point the 
recipient rat was prepared by mobilizing the femoral vessels to the level of the superf1cal 
epigastric vessels. A subcutaneous tunnel was formed by blunt dissection from the inguinal 
region to the mid dorsum. A 2 em dorsal midline incision was made at the end of the 
subcutaneous tunnel. The donor and recipient femoral vessels were then clamped and 
divided. The limb was pulled through the subcutaneous tunnel with the toes first. Care was 
taken not to twist the long vascular pedicle. The limb was sutured to the dorsum of the 
recipient rat. After anastomosis of the femoral veins and arteries with 10-0 nylon, under the 
operating microscope, the clamps were released and blood flow observed. 
A few drops ofxylocain 2% were applied on the anastomoses. The operation was completed 
by the closure of the inguinal incision. 
At the end of the operation the recipient rat was given 2 ml 0,9% NaCI intravenously as 
infusion and recovered under heatlamps at 37'C. Time of ischemia was 45-60 minutes. Total 
operation time was 2-3 hours. 
A.2.3 Statistical analysis 
For all parameters their measured values were related to time elapse. The degree of 
histologic rejection was compared to LDF values. The ratio of values measured 
simultaneously in transplanted and contralateral limb was taken as outcome in order to 
minimize surrounding influences (for example room temperature, depth of anesthesia etc.). 
For statistical analysis the rank correlation test according to Spearman was used. This test is 
known to be hardly influenced by extreme values. We used the one sided test because the 
direction of the correlation under the alternative hypothesis was known a priori. 
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A.3 Results 
A. 3.1 General results 
In the study vascularised transplants were performed in 34 animals. 8 Animals were 
excluded from the experiment,i.e. 2 rats were lost during anaesthesia, 5 transplants were lost 
within 48 hours due to vascular thrombosis, 1 rat in the allogeneic group was excluded on 
day 12 following severe rejection and loss of the transplant. 
In the control group (6 animals) limbs were transplanted from one Wag/Rij rat to another 
inbred Wag/Rij rat (Fig. 1). The transplanted limbs showed moderate edema, which resolved 
within a week. The limbs appeared healthy for as long as 10 months after operation, except 
for the toes which were nibbled of the denervated limb after two to three months 
postoperatively. In the allogeneic group (20 animals) limbs were transplanted from BN/Bi 
rats to Wag/Rij rats. The transplanted limbs showed progressive edema. Colour changes 
were difficult to assess due to brown donor limbs. Hairloss was seen in 5 rats after the lOth 
postoperative day. Epidermolysis, crust formation, exudation and leathery skin were 
progressively seen from the seventh postoperative day onwards. 
'Figure l. Allogeneic limb trans-
plantation postoperatively: (A) = day 2; 
(B) = day 7; and (C) = day 12. 
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Peripheral blood gases from the toes of 
the transplanted limb and the contralateral 
limb taken on the planned day of obduction 
were valid in 13 rats. In 4 rats bloodgases 
were excluded due to a different sampling 
technique. Peripheral glucose and lactate 
were measured in respectively 10 and 8 
rats, because after completion of blood gas 
sampling it was difficult to get enough 
blood for further examination (Table I). 
Peripheral blood gases, glucose and lactate 
were statistically not significant in relation 
to time elapse. 
In 16 rats of the allogeneic group a 
reliable graphic representation was 
obtained. This was also achieved in all rats 
of the control group (6 rats). In the 
allogeneic group the LDF measurements 
were not statistically significant for the 
contralateral own limb in relation to time 
elapse (p > 0, 05). This of course is as 
expected, the variation in absolute values 
however are substantial. The LDF 
measurements for the transplanted limb and 
the ratio of transplanted and contralateral 
limb were statistically significant in relation 
to time (p<O.OOl and p<O.OOOl respecti-
vely) (Fig 2). 
A.3.2 Histology 
The earliest morphological changes in 
the allotransplanted limbs become manifest 
on day 4 after surgery (Fig 3a). 
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Figure 2. Laser Doppler flowmetry (LDF) in 
the allogeneic group related to time. (Ratio 
TIC= ratio of transplanted limb and 
contralateral limb). 
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Table 1. Measured factors in allogeneic limb transplantations in rats related to time. 
Contralateral limb Transplant Ratio T/C 
Parameter n carr. coEHf. p n carr. coett. p n carr. coeff. p 
p02 13 -0,05 >0,05 13 0,15 >0,05 13 0,26 >0,05 
pC02 13 0,24 >0,05 13 0,17 >0,05 13 -0,07 >0,05 
pH 13 -0,02 >0,05 13 -0,19 >0,05 13 -0,33 >0,05 
Lactate 8 -0,51 >0,05 8 -0,64 >0,05 8 -0,16 >0,05 
Glucose 10 -0,13 >0,05 10 -0,31 >0,05 10 0,01 >0,05 
Laser 16 -0,06 >0,05 16 -0,74 <0,001 16 -0,86 <0,0001 
Doppler 
Flowmetry 
According to Spearman's Rank Correlation Test 
Correlation coefficient and one-sided p-value corrected for ties 
The same Parameters in lsologeous Rats were not significant (p>O,OS) 
Figure 3a. Day 4. The epidermis shows a 
slight damage with spongiosis, nuclear 
pycnosis and lymphocytic infiltration. In the 
upper parts of the reticular dermis there is a 
mild mononuclear inflammatory infiltration. 
(H&E, original magnification x 180). 
Figure 3b. Day 8. A dense diffusely distribu-
ted inflammatory infiltration in the dermis. 
(H&E, original magnification x 180) _ 
Figure 3c. Day 12. Severe epidermal changes 
consisting of spongiosis, cell vacuolation and 
nuclear pycnosis. The papillary dermis shows severe diffuse edema, inflammatory infiltration and 
occlusion of the capillary blood vessels (H&E, original magnification x240). 
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The changes consisted of focal areas of moderate epidermal spongiosis and dyskeratosis, 
they were accompanied by a polymorphous leucocytic inflammatory infiltration of the 
papillary and the reticular dermis. The capillary blood vessels were strikingly dilated and 
filled with red blood cells. At the fifth and the seventh day a mononuclear inflammatory 
infiltration was distinctly observed in the dermal layers and in the subcutis. The infiltration 
had a patchy distribution mostly arround the capillaries and the small venules. The cell 
population was mostly lymphocytic, but some large mononuclear cells with vesicular nuclei 
and eosinophylic cytoplasma were seen. 
The infiltration becomes more dense and was diffusely distributed on day 8 (Fig. 3b). 
Occlusive lesions of the dermal capillaries and small sized vessels, accompanied by 
endothelial damage and followed by desintegration of the vessel wall were the most 
prominent vascular alterations at that time. Frequent invasion of the periostium and the bone 
marrow was apparent. 
The progressive obliterations of the dermal vessels resulted in ischemic necrosis of the 
transplants. It was evident by days 12 to 14 (Fig. 3c). The rejection of the transplanted limb 
for soft tissue and bone marrow in relation to time was significant (p=0.02). This was not 
the case for periosteal rejection (p=O.lO). In relation to the LDF measurements soft tissue 
rejection was significant for the transplanted limb (p<0.05) as well as for the ratio 
transplanted and contralateral limb (p<O.Ol; Fig. 4). 
A.4 Discussion 
Clinical examination of the allogeneic transplanted limb correlated well with histologic 
signs of rejection as has been often described3'4'7 • After crust formation clinical examination 
is difficult, however if severe skin changes were seen in the presence of edema the 
underlying tissue was still viable. This was proven by blood loss after extraction of a toe 
nail. When this edema disappeared it meant loss of viability of the limb. Epidermolysis as a 
strong clinical evidence of rejection was seen from the 7th postoperative day onwards. 
Daniel and his group could reverse severe skin changes together with edema by changing the 
immunosuppressive treatmene. 
Peripheral blood gases as well as glucose and lactate were not useful as a parameter of 
rejection in our model. 
LDF measurements showed a continuous decline after operation. 
From the 7th postoperative day the values were consistently low (at most 55% of the 
contralateral limb). Before the 6th postoperative day all values were above 55% of the 
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contralateral limb. According to these 
values there is a significant correlation with 
clinical and histological rejection, as such 
the LDF is a good parameter. Early 
detection of transplant rejection is of great 
importance because a change of immuno-
suppressive drugs dosage and/ or scheme 
can still be administered to save the 
transplant. 
In our model however LDF measure-
ments could not be used as a predictor for 
the initial onset of rejection, because a clear 
turning point before the 7th postoperative 
day could not be detected. 
In search for this turning point 7 rats were 
followed nearly daily with LDF measure-
ments. Due to a great variety of values 
before the 7th postoperative day this point 
could not be produced. To reduce the great 
variety of values and to produce a turning 
point continuous measurements are 
preferred, as we are accustomed to do in the 
clinical patient. In the rat model this is not 
possible. 
In conclusion, in the allogeneic limb 
transplantation model in the rat clinical and 
histologic examination as well as laser 
doppler flow measurements (LDF, 
p < 0.0001) are good parameters for rejec-
l.D.F. 
(T/C) 
2. 5 
2.0 
1 '5 
o. 5 
• 
• 
• 
• 
n = 11 
carr. coeff. =- 0,70 
p -;0,01 
• 
• • 
• • • 
• 
Grading of soft tissue rejection 
Figure 4. Rejection correlated to laser 
Doppler flow (LDF) in the transplanted limb. 
(Grading of soft tissue rejection: O=no 
rejection; 1 =epidermal changes and 
inflammatory infiltration; 2=mononuclear 
infiltration; 3=obstructive vascular changes 
and diffuse mononuclear infiltration; 
4 =hemorrhage and necrosis. T /C =ratio of 
transplanted limb and contralateral limb). 
tion. In contrast peripheral bloodgases, glucose and lactate were not useful as parameters for 
rejection. In this model however LDF values cannot predict an initial onset of the rejection 
before clinical signs are evident, presumably due to the impossibility of continuous 
measurements. 
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B.l Introduction 
Clinical organ transplantation is successful'· ", it is therefore logical to extend this field 
with experimental composite tissue allografts, as a preliminary to human hand 
transplantation. Experimental limb transplantations in the rat have been performed by many 
different groups'· '· '· 7 • Prolonged survival of these limb allografts treated with the 
immunosuppressive agent Cyclosporine A was established. If however human hand 
transplantation is considered, functional studies should be performed on higher species, as 
for instance the non-human primate. The possibility of extrapolation to the human situation 
can thus be improved. Research was performed on the hand of the rhesus monkey in the 
early sixties. Replantations of thumb and index were caried out in those days to develop 
microvascular surgery'. In the baboon, hand transplantation has been performed by Daniel et 
al in 1986 and Stark et al in 1987'· ". Long term allograft survival was established in two out 
of four and one out of eight monkeys, respectively. In these studies evidence of sensory and 
motor function recovery has been demonstrated. 
The hand of the non-human primate is closely related to the human hand, regarding 
anatomy and functional use. For ethical and functional reasons transplantation of the whole 
hand was not performed in our studies. Instead the first ray enlarged with the radial forearm 
flap, was used as a model, still enabling research on sensory and motor function recovery. 
Basic handfunction in the remaining wrist and four fingers of the donor monkey in case of 
transplantation, could thus be maintained. 
This paper is comprised of three parts. Firstly an anatomical study was done to define the 
radial unit, secondly four replantations of the radial side of the hand of rhesus monkeys were 
performed to establish the feasibility of the model and finally functional recovery was tested. 
B.2 Materials and methods 
B.2.1 Anatomical dissection 
In fifteen fresh cadaver upper extremities of the rhesus monkey (Maccaca mulatta) the 
thumb and radial forearm flap were dissected to evaluate the muscles in the forearm and 
hand. In eight arms special attention was directed to the distal radial artery and cephalic vein, 
to the distal median, ulnar and superficial radial nerve as well as to the thenar musculature 
and distal part of the tendons around the first ray. The size of the radial forearm flap was set 
at about 20-25 em'. 
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B.2.2 Replantations of the radial side of the hand 
To prove the technical feasibility of the research model, four replantations of the first ray 
of the hand with the radial forearm flap were performed, with a maximum follow-up period 
of three years. 
B.2 2.1 Animals 
Rhesus monkeys were born and raised in the TNO Primate Center, Rijswijk, The 
Netherlands, employing a "harem type" breeding system. Average weight was 7.5 kg, age 
varied from nine to 24 years and male to female ratio was two to one. The animals were 
selected on normal kidney and liver functions and non-injured, relatively large hands. If 
possible left or right handedness was assessed. 
Animal care complied with the "Principles of Laboratory Animal Care" and "the Guide 
for the care and use oflaboratory animals" (NIH-publication no. 80-23, revised 1978). 
B.2.2.2 Pre-. per- and postoperative care 
Under routine general anaesthesia a continuous axillary plexus block was applied 
(mepivacaine and adrenaline, 20m! I% and 0,1 mg respectively per eight hours). Dextran 40 
(Rheomacrodex 1,5 gr/kg) was administered as an intravenous drip during and direct after 
operation for hemodilution. Prophylactic antibiotics were injected intramuscularly during 
five days. Acetylsalicylic acid 100 mg was also injected on the day of operation. 
Following shaving of the arm, the rhesus monkey was placed in a lateral position with the 
arm abducted. Under sterile conditions and tourniquet control the radial forearm flap was 
dissected"· " (figure 1). All the important transsected structures were marked during the 
operation. The flexor, extensor and abductor pollicis longus muscles were cut at the wirst, 
the adductor was freed from its origin. The following nerves were dissected and cut: the 
palmar cutaneous branch of the median nerve proximal to the wrist, the median nerve just 
before the junction of the motor and sensory branches, the motor branch of the ulnar nerve 
beneath the adductor muscle and the superficial radial nerve branch to the thumb just distal 
to the site where it pierces the brachioradialis tendon. The branches of the median and 
superficial radial nerve to the other fingers were left intact. The lateral antebrachial 
cutaneous nerve was transected proximal to the flap. 
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Disarticulation was performed at the 
first carpometacarpal joint. The 
thumb and radial forearm flap were 
then developed from distal to 
proximal, after which the tourniquet 
was released and careful hemostasis 
ensured. 
Following clamping and transection 
of the proximal vascular pedicle the 
amputated part was replanted again 
by starting with an arthrodesis of the 
first carpometacarpal joint with a 
transosseus cerclage wire. The 
adductor pollicis muscle was 
reinserted and the tendons of the 
flexor pollicis longus, the extensor 
pollicis longus and abductor pollicis 
longus muscle were reconnected. 
Subsequently the nerve ends of the 
motor branch of the ulnar nerve, the 
common trunk of the median nerve, 
the palmar cutaneous nerve and the 
superficial radial nerve were 
anastomosed with lOxO nylon sutures 
(BV 6, R/Ethilon) under the 
microscope. The radial digital nerve 
of the second digit was not restored. 
As well, the radial artery and the 
cephalic vein were microsurgically 
Dorsal 
Figure 1. The replant model. The dotted line marks 
the radial side of the hand with radial forearm flap. 
Nerves: U.n. =ulnar nerve; M.n. = median nerve; 
S.R.n. = superfical radial nerve. Muscles: f.p.l. = 
m. flexor pollicis longus; a.p.l. = m. abductor 
pollicis longus; e.p.l. = rn. extensor poHicis longus. 
A. = m. adductor pollicis; T. = thenar muscles. 
Vessels: R.a. =radial artery; C.v. =cephalic vein. 
anastomozed end-to-end, with the same suture. The skin was loosely approximated, small 
drains were placed and the clamps were released (figure 2a +b). The microcirculation of the 
skin of the replant was monitored after release of the clamps. This was performed with a pin 
prick test for bleeding as well as continuous Laser Doppler Flowmetry (R/Perimed, PF2, 
Sweden) recorded, on a marked spot on the forearm flap and the pulp of the thumb. 
The monkeys were kept sedated, for general and microcirculatory monitoring. 
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Figure 2a,2b. The radial side of the hand with radial forearm flap following complete transection (a) 
and after replantation (b). 
Consequently a few hours later the arm was dressed and a custom made thermoplast splint 
was applied, as described previously". 
Wound inspection was performed two to three times a week under light sedation. Also 
laser doppler flowmetry was assessed by using interval measurements during two minutes on 
the same spot as well as contralaterally. Eight weeks postoperatively microcirculatory 
monitoring was stopped. Dressings and the thermoplast splints were removed as soon as 
sensory reinnervation could be detected. 
B.2.3 Sensory reinnervation 
In the initial period a withdrawal reaction to a pin-prick, in the awakening monkey was 
used as a guide to remove the thermoplast splint and dressings. 
Starting one year postoperatively, sensory reinnervation of the replant was assessed 
monthly over a year, by inducing a withdrawal reflex with a small electric current 
("sensiometer"). The contralateral side was used as a control. The conscious monkey was 
fixed in a specially designed chair (R/Restraint Chair, Primate Products, CA, USA). The 
"sensiometer" consisted of a stimulation electrode connected to a bipolar 50Hz (sinusoidal) 
current source stimulator, delivering currents between 0.14 and 1.8 milliAmpere. The 
electrode had two metal bars, each I mm in diameter and with a separation of 1.5 mm. 
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Stimulation sites on the skin were separated 0.5 em along three distinct lines covering the 
replant. The lines were designed in accordance with the expected skin innervation areas of 
the median, superficial radial, palmar cutaneous branch of the median nerve and the lateral 
antebrachial cutaneous nerve. The latter was not reconnected and served therefore as a 
negative control. A current of 1. 8 milliAmpere (approximately 1.5 times the threshold for a 
withdrawal reflex in the contralateral hand) was delivered at each site. False positive 
reactions were minimized by changing the patterns of stimulation of the skin. 
The number of sites demonstrating a withdrawal reaction on stimulation was related to the 
total number of measuring sites (range 30-40, depending on the size of the replant). Sensory 
reinnervation was thus expressed as the ratio between these two numbers. 
In one monkey (TP), the median nerve was surgically exposed three years postoperatively. 
Electrical stimulation with a ringelectrode at the tip of the thumb was performed to detect 
sensory potentials proximal to the anastomosis of the median nerve. 
B.2.4 Motor reinnervation 
The methods used to examine motor function recovery were electromyography 
(R/Medelec, PN6), histology and function tasks. 
B. 2.4.1 Electromyography 
The median nerve was stimulated supramaximally and transcutaneously at elbow and wrist 
and proximal to the anastomosis, under ketamin (R/Fetelar) anaesthesia. The contralateral 
side served as a control. Surface electrodes were placed in a belly tendon position on the 
abductor pollicis brevis muscle. To rule out stimulation of the ulnar nerve at the same time a 
sensory potential was determined at the fifth finger. Latency (in a temperature controlled 
environment) and amplitude of Compound Motor Action Potentials (CMAP) were compared 
monthly, starting one year postoperatively, over six months. Latency of CMAP was 
measured from the moment of stimulation to the peak of the negative deflection in 
milliseconds. Amplitude of CMAP was measured from the peak of the negative deflection to 
the baseline, in millivolts. Measurements were related to the contralateral side and expressed 
as a percentage. To detect latency and amplitude of the CMAP of the thenar muscles by 
surface electrode, direct stimulation proximal to the anastomosis of the exposed median 
nerve was performed. 
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B.2.4.2 Histology 
In one monkey (BM) the opponens pollicis and abductor pollicis brevis muscles were 
removed, 18 months following operation, from origin to insertion from the operated as well 
as the contralateral hand and snapfrozen in liquid nitrogen chilled isopenthane. The 
distribution and occurrence of nerve bundles and functional motor end plates over the muscle 
were inspected microscopically. The activity of acetylcholine- esterase, as described by 
Karnovsky et a!. in 1964", was used to detect vital motor end plates. As well, an 
immunohistochemical staining method specific for neurofilaments15 was performed on 
formalin fixed paraffine embedded tissue. This latter method detects the presence of axons 
within a histologically visible nerve. 
B.2.4.3 Function tasks 
Functional tasks such as picking up small particles of food with thumb and index finger 
after bandaging the contralateral hand, were recorded on video. 
B.3 Results 
B.J.l Anatomical dissection 
Only anatomical findings relevant to the research model are mentioned. 
B.J.l.l Vessels 
The distal radial artery divided into a superficial volar branch to form the superficial 
palmar arch and a dorsal branch which became the first dorsal metacarpal artery. In all 
dissections, except one, the superficial volar branch ran beneath the flexor pollicis brevis 
muscle to give off a branch to the thumb. The two dorsal arteries to the thumb were provided 
by the first dorsal metacarpal artery. A larger venous branch on the dorsum halfway along 
the first metacarpal provided the main drainage to the cephalic vein (six out of eight). 
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B.3.1.2 Nerves 
The superficial radial nerve varied in four out of eight monkeys. There were either one or 
two branches to the thumb. The anatomy of the superficial radial nerve was consistent where 
it pierced the brachioradialis tendon. The median nerve was very consistent at wrist level. 
Under the distal retinaculum flexorum the median nerve divided mostly into four and 
sometimes into three branches (two monkeys). The palmar cutaneous branch of the median 
nerve originated halfway along the forearm and was positioned equally to either radial or 
ulnar sides of the median nerve. When running ulnarly, this branch crossed the median nerve 
before reaching the skin of the thenar eminence. The anatomy of the motor branch of the 
ulnar nerve was very consistent regarding the adductor pollicis muscle (the branch was not 
dissected further). 
Table 1. Results of autologous replantation of the radial side of the hand in rhesus monkeys. 
Results Complications 
rhesus 
monkey 
wound 
healing 
LDF' sensory 
recovery 
splint 
decubitus 
haemorraghe death 
BM normal normal + +' 
DV normal normal + +' 
TP normal normal + 
2585' + 
1This monkey did not recover from the anaesthesia and died on day 1 postoperatively due to cardiac 
arrythmias. 
2LDF, Laser Doppler Flowmeter to monitor microcirculatory flow of the skin. 
3Transient. 
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B.3.1.3 Muscles 
The flexor pollicis longus muscle originated from the third tendon of the flexor digitorum 
profundus just distal to the radiocarpal joint. This tendon is thinner than the tendons to the 
fingers (in all cases). The extensor pollicis brevis muscle was not encountered in the 
dissections. The abductor pollicis longus muscle inserted partly onto the radial side of the 
base of the first metacarpal bone and partly upon the adjacent radial sesamoid. Apart from 
the adductor pollicis muscle all intrinsic muscles to the thumb originated from the 
retinaculum flexorum. Co-origins from the carpal bones were present in all thenar muscles. 
B.3.2 Replantations 
The four replantations of the radial side of the hand were technically successful. 
Unfortunately, one rhesus monkey (2585) did not recover from the anaesthesia. The monkey 
died on the first postoperative day due to cardiac arrythmias. Before actual 
death, the replant was still well vascularized. Wound healing was uneventful in the other 
three monkeys, except for a minor and transient postoperative hemorrhage in one monkey 
and splint decubitus in another (table 1). 
Laser doppler flowmetry of the flap and pulp of the thumb showed a higher value in the 
initial eight days postoperative (approximately twice the contralateral thumb). After the 
initial period values stabilized and were comparable to the contralateral side. 
B. 3. 3 Sensory reinnervation 
Following a reproducible positive withdrawal reflex, from the pin-prick test, the splint was 
removed in the monkeys BM, DV and TP at the postoperative day 57, 59 and 45, 
respectively. Complications, such as neurotrophic ulcers or self inflicted damage of the 
replant, were not seen after removal of the splint. 
Figure 3 shows the percentage of sensory reinnervation in the reconnected and control skin 
areas. In three monkeys, 22 months postoperatively, the percentage of positive withdrawal 
reactions of the median and superficial radial nerve skin area was 96% with the sensiometer. 
The area of skin innervated by the palmar cutaneous branch of the median nerve was 
enclosed in the median nerve area. 
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TP 
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Figure 3. Sensory reinnervation of the radial side of the hand following replantation. In the three 
monkeys (DV, BM and TP) the median nerve and superficial radial nerve are reconnected. The 
lateral antebrachial cutaneous nerve is not reconnected. 
The area of skin, corresponding to the unreconnected lateral antebrachial cutaneous nerve 
showed a positive withdrawal reaction percentage of 38% with the same method. 
In monkey DV a small area of the tip of the thumb did not react to stimulation. 
Sensory potentials of the median nerve in monkey TP were detected and are demonstrated in 
figure 4a. 
B.3.4 Motor reinnervation 
B.3.4.1 Electromyography 
Mean latency and amplitude of CMAP's of the three replanted thenar muscles following 
stimulation at the elbow were 93% and 88% respectively, when compared to the latency and 
amplitudes ofCMAP's of the thenar muscles of the contralateral side. Latency and amplitude 
of CMAP's measured by stimulation of the exposed median nerve of the rhesus monkey (TP) 
are displayed in figure 4b. 
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Figure 4a. Compound Sensory Action Potential (CSAP) recorded from the exposed median nerve in 
the forearm evoked by stimulation of the tip of the thumb by ringelectrode. 
The CSAP's of the median nerve of the normal contralateral radial side of the hand and the replanted 
side in the same monkey are comparable with respect to amplitude and onset of the CSAP. Polyphasia 
in the CSAP of the median nerve of the replanted side reveals the presence of fibres with delayed 
conduction. Figure 4b. Compound Motor Action Potential (CMAP) of the thenar muscles recorded 
by surface electrode following stimulation of the exposed median nerve in the forearm. The CMAP's 
of the thenar muscles of the normal contralateral radial side of the hand and the replanted side are 
comparable with respect to amplitude and onset of CMAP. The width of the CMAP in the replant 
indicates the presence of the delayed conduction of a number of fibres. 
106 ---------------------------------------- Chapter II; study B -----------------------------------------
B.3.4.2 Histology 
Immunohistochemical staining for neurofilaments showed the same amount of staining in 
the replanted muscles as well as on the contralateral side. Staining for acetylcholine-esterase 
activity as evidence of vital motor end plates revealed a definite amount of staining in the 
replanted muscles (+)although less than in the contralateral side ( + + + ). 
B.3.4.2 Function tasks 
The monkeys BM and TP could easily pick up small particles of food between thumb and 
index fmger, while monkey DV could not easily do this. 
B.4 Discussion 
The anatomy and functional use of the hand of the rhesus monkey (Macacca Mulatta) are 
closely related to the human being". Our anatomical dissections showed that with regard to 
the vessels, the princeps pollicis artery is mostly small or absent in the rhesus monkey and 
the superficial palmar arch is dominant. This is in contrast to the human being where the 
dominant artery to the thumb is mostly the princeps pollicis artery from the deep palmar 
arch11. 1s. 
As emphasis was put on reproducibility of functional recovery of the replant, variations of 
anatomy regarding nerves had to be minimized. Therefore anastomoses of the nerves were 
always made at the least variable site. For the median nerve this was just proximal to the 
junction of sensory and motor branches under the retinaculum flexorum; for the superficial 
radial nerve just dorsal to the brachioradialis tendon and for the motor branch of the ulnar 
nerve where it entered the adductor pollicis muscle. Our anatomical dissections of the ulnar 
nerve did not go beyond the adductor pollicis muscle. When evaluating thenar muscle 
function in the rhesus monkey however, it is important to know that the motor branch of the 
ulnar nerve innervates the deep head of the flexor pollicis brevis muscle in 15% and the 
opponens pollicis muscle in 28% ". In the human hand these figures are quite different, 96% 
and 4% , respectively"'. 
In all dissections in the monkey the flexor pollicis longus muscle originated from the deep 
flexor tendon to the third digit, which is concordant with other primate studies". The muscle 
tends to separate, however not as completely as in the human being. Clearly the more 
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independent the flexor pollicis muscle is, the more refined thumb movement will be. The 
"absence" (or confluence with the abductor longus muscle) of the extensor pollicis brevis 
muscle and the more proximal insertion of the abductor pollicis longus muscle, observed in 
our dissections, lead to less active abduction and less stabilization of the 
metacarpophalangeal joint in relation to the human thumb"·". 
The replantations of the radial side of the hand in the rhesus monkey were technically 
successful and therefore the research model is technically feasible. The advantage of the 
accessory radial forearm flap was not only to give sufficient skin area for monitoring, but it 
also enabled more proximal anastomosis of the vessels resulting in a larger diameter (range 
0.8 - 1.1 mm) for microvascular surgery. In our replantations arthrodesis of the first 
carpometacarpal joint was performed, which impairs opposability. As function recovery was 
an objective, in the allogeneic transplantation project the carpometacarpal joint was left 
intact and an osteotomy was carried out at the proximal metacarpal level. 
In an attempt to predict vascular compromise per- and postoperatively Laser doppler 
flowmetry was used, as has been well described in microvascular surgery"· 25 • The inital high 
flow values after operation are in accordance with clinical replantations (submitted). 
This research model resulted in good sensory and motor function recovery as evidenced by 
the "sensiometer", electromyography, histology and functional tasks. Longitudinal follow-
up, assessed in conscious monkeys, demonstrated a mean sensory reinnervation in 96% of 
the skin area, corresponding to the median and superficial radial nerve. The 38% positive 
withdrawal reflex in the skin area of the unreconnected lateral antebrachial cutaneous nerve, 
could possibly be due to collateral nerve sprouting from neighbouring skin regions"'. Also 
overlap from median and superficial radial nerve skin distribution areas can cause this 
positive reaction. 
Electromyography, in the second and third year after operation, demonstrated thenar 
muscle reinnervation. The slightly lower mean amplitude of the CMAP of the thenar muscles 
and the even less prolonged mean latency of CMAP when compared to the contralateral side 
(80% and 93%, respectively) are consistent with other studies concerning 
electromyographical evaluation of muscle reinnervation following a nerve lesion27• 28 ' 29 • 
Further evidence of thenar muscle reinnervation has been provided by histological staining 
for vital motor end plates", although the number of vital motor end plates is less then in the 
contralateral side. This is similar to recovery after repair in human peripheral nerve 
injuries30 • 
Properly executed functional tasks following replantation of the aforementioned research 
model was the main objective of this study. In this respect the monkeys BM and TP could 
easily pick up small particles of food between thumb and index finger, although the radial 
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digital nerve to the index finger was never restored. In monkey DV, who showed no 
withdrawal reflex in the tip of the thumb, small particles of food slipped frequently out of the 
thumb and index finger. This could well be caused by a decrease of sensation of the index 
finger as well as the tip of the thumb. These observations were recorded by video. 
The thumb was obviously reintegrated into the functioning of the hand again after 
replantation, although the extent of the thenar muscle involvement in relation to the extrinsic 
muscles could not be quantified or qualified. Dynamic electromyographical studies during 
function tasks could possibly clarify this problem". 
In conclusion, despite the differences in the anatomy of the hand between rhesus monkey 
and man, extrapolation of results seems to be justified. This study has demonstrated the 
technical feasibility of replantation of the radial side of the hand in the rhesus monkey and 
has clearly shown evidence of sensory and motor function recovery. The way to allogeneic 
composite tissue transplantation using the radial side of the hand of the rhesus monkey seems 
to be opened. 
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C.l Introduction 
Over the centuries materials used to immobilise extremities have developed from parallel 
fixed pieces of wood to circular plaster of Paris and thermoplastic splints. The last of these 
materials has gained wide acceptance due to its light weight, strength, durability, easy 
moulding and remoulding in different positions. Even under extreme circumstances such as 
immobilisation of extremities in nonhuman primates, thermoplastic splints have proved to be 
adequate'. In this study perforated thermoplast was used to protect the forearm and hand of 
rhesus monkeys after experimental surgery. 
C.2 Materials and Methods 
C.2.1 Animals and housing 
Rhesus monkeys (Macaca mulatta) were born and raised in the TNO Primate Center, 
Rijswijk employing a harem type breeding system. The animals were individually housed in 
metal cages of 0.6 x 0.6 x 0.8 m'. Average weight was 7.5 kg. Age varied from 9 to 24 years 
and male to female ratio was 2: I. 
C.2.2 Description of the splint 
The arm of the anaesthetised monkey was shaved to prevent the damage to the skin which 
often occurs when hairy skin is covered by a dressing. After wrapping the individual fingers, 
hand and arm up to the axilla with synthetic wadding (Soffban', T.J. Smith and Nephew Ltd, 
Hoofddorp, The Netherlands) secured with elastic bandage (Bandafix', International Medical 
products, Zutphen, The Netherlands), a paper template was made to assess the size and form 
of the thermoplastic sheet. The thermoplastic sheet (San-Splinf XR, T .J. Smith and Nephew 
Ltd, Hoofddorp, The Netherlands) selected had preperforations, to allow some ventilation. 
After cutting the sheet to an appropriate size it was heated in a water bath to approximately 
70 oc. The surface cools down rapidly to approximately 40 oc whilst retaining its capacity to 
be moulded. 
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Figure 1. A rhesus monkey, wearing the thermoplastic splint. 
The cooled but malleable sheet was laid over the radial side of the outstretched arm of the 
monkey after the most proximal end of the sheet had been folded double to avoid a sharp 
edge and for strength. During hardening of the material the arm was flexed at the elbow to 
IIOo and the splint was moulded to its final form by joining the edges at the ulnar side. 
Finally the one piece splint was fixed either with 5 nuts and bolts at the broad ulnar margin 
or with circular tape (Fig. 1). Duration of the entire procedure described was approximately 
45 minutes. 
C.3 Results 
Thirty nine splints were evaluated, each custom made for a different monkey. Duration of 
splinting varied from 12 to 79 days. Complications consisted of transient pressure ulcers in 3 
rhesus monkeys, spontaneous removal of splint in 2 cases and twisting of the arm within the 
splint in one monkey. In none of the cases did breakdown of the splint occur. However in 2 
cases the proximal side of the splint had to be stengthened after partial damage due to biting. 
C.4 Discnssiou 
A wide variety of materials is used for splinting in humans'·'. However due to the nature 
of caged nonhuman primates the use of most of these materials is inadvisable. For example a 
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plaster of Paris splint would be too heavy and too susceptible to breakdown by wetting or 
biting. Also in the case of pressure ulcers local adjustment of the splint would not be 
possible necessitating a total replacement. A splint on a glass fibre base would be too rigid, 
too sharp, too expensive and too laborious to make. Furtbermore it would make removal of 
tbe cast for inspection of tbe arm very difficult. The tbermoplastic splint, however, could be 
easily moulded and reshaped if necessary. It was light in weight witb an average of 300 
grams and proved to be strong and durable. Even under difficult circumstances following 
microvascular surgery or in an immunosuppressed animal with a wound highly susceptible to 
infection, tbe operation site and wound could be adequately protected. 
Pressure ulcers ocurred in three cases at the elbow and ulnar side of tbe wrist. Local 
adjustment of tbe splint could easily be performed witb the heatgun and resulted in tbe 
healing of all ulcers. Fixation witb eitber nuts and bolts or circular tape appeared to be 
adequate in most of tbe cases, apart from two spontaneous removals. These were probably 
due to a combination of lack of flexion at the elbow and too wide an opening at tbe upper 
arm. In one case the arm was twisted within the splint, presumably as a result of unusual 
movements during restraint of the monkey and a lack of flexion at tbe elbow. A slight 
increase in the degree of flexion of the splint proved to be adequate to prevent recurrence. 
Preconditioning of tbe monkey to the splint was not necessary. Removal and refixation of 
the one piece splint could easiliy be performed by one person. It could be done frequently 
without damaging the splint, even if the splint had not been used for half a year or more. 
Although thermoplast has not been compared with otber materials it seems an appropriate 
material for provison of immobilisation and protection of the arm and hand in the non-human 
primate. 
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D.l Introduction 
Selective intervention by monoclonal antibodies (MAbs) directed against T cells (CD3 + 
lymphocytes) has demonstrated to be effective in suppressing cellular immune responses, both 
in man' and rhesus monkey'. Also MAbs specific for CD4 or CDS positive cells which are both 
involved in the process of graft rejection3 , can prolong skin allograft survival in rhesus 
monkeys4'~. Furthermore, MHC antigens were shown play a key role in cellular immune 
responses like allotransplant rejection'. 
To investigate the importance of these surface markers in the process of graft rejection 
MAbs specific for these antigens have, so far, mainly been tested individually. This study, 
however, focussed on the immuno-suppressive effect of a combination of MAbs specific for 
CD3 +, CD4 +, CDS+ and MHC class II positive cells in a rhesus monkey skin allograft model 
to investigate whether a potent immunosuppressive cocktail of monoclonal antibodies could be 
established. 
D.2 Materials and methods 
D.2.1 Experimental design 
Skin grafts were exchanged between non-immunized unrelated outbred rhesus monkeys 
(Macaca mulatta) that were born and raised in the TNO Primate Center, Rijswijk. Donor and 
recipients were mismatched for MHC class I and II antigens. The number of class I mismatches 
in groups 1 to 5 was one, while in groups 6 to 8 it was four. 
The skin graft experiment concerned eight different experimental groups (Table 1). 
D.2.2 Monoclonal antibodies used for in vivo treatment 
The following MAbs were used for in vivo treatment: FN187 , IgGl and 5Bll, IgG2a both 
specific for CD3; RIV6 and RIV7, both IgG2a and specific for CD4', FKlS, IgG3, specific for 
CDS"·'; BS.12", IgG2b and 7.5.10.1", IgG2a both are specific for HLA-DR. The dosages used 
in this study are given in table I. Recipients received their MAbs as an i.v. bolus injection for 
the duration of 10 days starting day -1, one day before skin transplantation. All MAbs used in 
this study were crossreactive with rhesus lymphocytes. They were purified by absorption to 
protein A and sterilized, prior to in vivo administration. 
After the first injection of the cocktail of MAbs or its anti-T cell fraction in the above 
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mentioned dose or a 20 to 40 % of this dose, minor side effects occurred in two out of eight 
cases (gall expectoration in one case, short period of drowsiness in another). In one out of eight 
cases, shock like symptoms developed and the monkey was euthanized. 
D.2.3 Immunological monitoring 
Levels of circulating injected MAbs and titers of antibody formation against the injected 
MAbs were determined using an ELISA technique. 
All allograft recipients were monitored frequently with respect to total leucocyte and 
lymphocyte counts and relative numbers of CD3+, CD4+, CD8+ and MHC class II+ cells, 
using an indirect immunofluorescence technique and analysis by flow cytometry (FACScan, 
Becton Dickinson, Mountain View, CA). 
Immunohistological staining of punch biopsy specimens taken at regular intervals from the 
allogeneic skin in groupS, was performed with MAbs specific for MHC class I and II antigen 
expression, CD3+, CD4+ and CDS+ cells. Parallel hematoxylin and azofloxine-stained 
sections were processed in a routine matter. 
D.3 Results and discussion 
Allogeneic skin grafting in rhesus monkeys, treated prophylactically with MAbs against 
lymphocyte (sub)populations, is a well established animal model to test immunosuppressive 
potencies of such antibodies in the non-human prirnate12 . Previous studies demonstrated that 
FN18 specific for CD3+, RIV7 specific for CD4+ and FKlS specific for CDS+ cells could 
prolong allograft survival in a rhesus monkey skin transplantation model (Table 1)'·'. Further 
results concern groups 6, 7 and S. A combination B8.12 and 7.5.10.1 (group 7) could prolong 
skin graft survival to ll.S +I- 0.3 days compared to the control group of 8.3 +I- 0. 7 days. 
However, the combination of seven MAbs specific for CD3 +, CD4+, CDS+ and MHC class 
II positive cells (groupS), prolonged skin graft survival to 19.3 +I- 1.3 days, compared to the 
same control group (see Table 1 and materials and methods section for description of the 
MAbs). Results suggest, that the combination these MAbs tends to induce addition of their 
individual suppressive effects on the immune response. This tendency of addition is clearly 
present, even though the increase of the number of mismatches has a significant effect on the 
reduction of the skin allograft survival times (groups 1 and 6, Mann-Whitney U test, p=O.Ol). 
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In all cases, the daily injected doses of MAbs were sufficient to maintain significant serum 
levels until the next injection was given 24 hours later. However, approximately 7 days after 
operation the appearance of anti-mouse-antibodies neutralized the injected MAbs. 
Skin graft recipients treated with the combination of MAbs specific for MHC class II 
antigens (group 7) showed a slight lymphopenia which lasted for 1 to 2 days. 24 Hours after the 
first injection, the MHC class II positive cells were coated by the injected MAb. Coating 
Table 1. Skin graft survival times in rhesus monkeys treated with MAbs specific for 
CD3+, CD4+, CDS+ and/or "MHC class II positive cells 
Individual 
survival 
Groupsa 
Injected 
dose 
MAb(s) (mglkg) Target (n) Subset effect times (days) MST + 1- SE 
I. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
-1-
FN18 
RIV6 
RIV7 
FK18 
-I-
B8.12 
7.5.10.1 
5Bll 
FN18 
RIV6 
RIV7 
FK18 
B8.12 
7.5.10.1 
1 
1.4 
1.4 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
control 
CD3 
CD4 
CD4 
CDS 
control 
MHCclassll 
CD3 
CD3 
CD4 
CD4 
CDS 
MHCclassll 
MHCclassll 
42 
3 
2 
4 
4 
10 
2 
2 
elimination, 
modulation 
coating 
coating 
elimination 
coating 
coating 
16 16 18 
99 
8.591019 
8 12.5 14 15 
11.5 12 
18 20.5 
9.3 +I- 0.3 
16.7 +1-0.7 
9.0 
11.6 +1-4.3 
12.4 +1-2.7 
8.3 +I- 0.7 
11.8 +1-0.3 
19.3 +1-1.3 
aThe number of MHC class I mismatches in groups 1 to 5 was one, while in groups 6 to 8 it was four. 
hMST + 1- SE; mean skin graft survival time +/-standard error 
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gradually decreased within 6 days after the first injection, while relative numbers ofMHC class II 
positive cells did not change significantly. No fluctuations in CD3+, CD4+ or CDS+ cells could 
be seen. Skin graft recipients treated with the cocktail of seven MAbs showed a lymphopenia to 11% 
of pretreatment levels which was sustained till approximately five days after the first injection. 
Elimination of peripheral blood lymphocytes mainly concerned T cells of the CD3 and/or CDS-
positive phenotype. Almost all remaining lymphocytes were coated directly after injection. Coating 
gradually decreased and lasted until approximately day 5. Modulation could be observed for the 
CD3 surface antigens. It seems likely that the individual effects that MAbs have on lymphocyte 
subset distributions, remain present, when combined to a cocktail (Table 1). 
Results show that the combination ofMAbs specific for CD3 +, CD4+, CDS+ and MHC class 
II positive cells has a strong immunosuppressive effect which is comparable to polyclonal ATG 
preparations (Bainer, Van Vreeswijk et al, unpublished results). Addition of MAbs specific for 
CD4, CDS, and MHC class II antigens on top of anti-CD3 specific MAbs, seems to have an additive 
effect on prolongation of allograft survival times. This might be of practical use in the treatment of 
patients with a rejection crisis of their allotransplant. 
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E.l Introduction 
Much of our understanding of the immune response depends upon the study of cell 
interactions in animal models of human immunopathological conditions. The close 
phylogenetic relationship between man and rhesus monkey and the high degree of similarity 
of their immune systems makes this species a useful experimental animal for preclinical 
research, especially in the fields of bone-marrow and allogeneic organ transplantation [17,9] 
autoimmune diseases [30,3] and more recently in AIDS research [12,33]. Similarities in 
function and structure of rhesus major histocompatibility complex (MHC) class I and II 
antigens [49,41] as well as of many lymphocyte antigens [19,34] and cytokines [46] made it 
possible to use human specific reagents like monoclonal antibodies (MAbs) for the study of 
the immune response in this species. However, not all MAbs that had been demonstrated to 
be crossreactive using techniques like fluorescent activated cell sorting (FACS), 
immunoprecipitation and bioassays, appeared to be effective in immunohistochemical 
studies, using an indirect immunoperoxidase technique. As a prerequisite for further studies 
of nonhuman primate immunohistology, this report describes the labelling patterns of 
several MAbs specific for MHC class I, II-DR, -DQ and -DP antigens, the leucocyte 
markers CD!, CD2, CD3, CD4, CDS, CD14, CD16, CD25, CD57; a proliferation 
associated nuclear antigen (Ki67) and the lymphokines interferon-gamma (IFN-y) and tumor 
necrosis factor-alpha (TNF-a) on frozen sections in a number of rhesus monkey tissues. 
E.2 Materials and methods 
E. 2.1 Tissues for (immuno)histo/ogy 
Lymph node, thymus, liver and skin biopsies were taken from different rhesus monkeys, 
all born and raised in the Rijswijk Primate Center. Skin biopsies originated from allogeneic 
partial hand transplant recipients, treated with cyclosporine A and prednisolone. Biopsies 
were taken during onset of rejection to ensure activation of cell surface markers and the 
presence of activated (host) lymphocytes and macrophages [ 45]. After harvesting, each 
biopsy was cut in half, longitudinally. One half was fixed in buffered formalin and 
processed routinely for histology on hematoxylin and azofloxine-stained sections. For 
parallel immunohistochemical studies the other half was snap-frozen in liquid nitrogen 
chilled isopentane. Cryostat sections of 6 I'm thickness were cut, air-dried, fixed in acetone 
and stored at -70"C until use. 
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Table 1. Crossreactivity of anti-human mAbs with their rhesus homologous counterpart 
Antibody Target" Reference Technique Reference Prep.' 
W6/32' MHC-A,B 4 IPrecip 37 l 
HLA-DR' MHC-DR 31 FACS 2 I 
BS.12' MHC-DR 36 FACS 36 I 
7.5.10.1' MHC-DR,DQ,DP 28 FACS 47 I 
Genox 3.53' MHC-DQwl 10 FACS 23 I 
anti-LeulOb MHC-DQ 11 IPrecip 8 I 
anti-HLA-DPb MHC-DP 50 IPrecip s I 
anti-Leu6b CD! 52 immPO 22 I 
Tll' CD2 21 FACS 26 II 
anti-Leu5bb CD2 5 FACS 26 I 
5Bll' CD3 26 FACS 26 I 
FN!S" CD3 36 FACS 36 I 
OKT4+4A' CD4 29 FACS 26 I 
M-T310' CD4 39 FACS 26 III 
RIV6' CD4 25 FACS 26 l 
RIV7' CD4 25 FACS 26 I 
GM9" CDS 24 FACS 24 
FK!S' CDS 27 FACS 26 I 
JMLH14' CD14 15 FACS 26 III 
anti-LeuM3b CD14 13 immPO 2 
WT14" CD14 6 immPO hi' II 
UCHMI" CD14A 20 FACS 26 Ill 
My4" CD14 18 immPO hi' I 
anti-Leullbb CD16 38 immPO hi' I 
2A3' CD25 4S FACS 26 I 
33B3.1' CD25 44 FACS 26 I 
anti-Leu?b CD 57 1 immPO hi' I 
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Table 1. Continued. 
Antibody Target~ Reference Technique Reference Prep.' 
MDI' IFN--y 35 bioassay' 46 I 
61E71' TNF-<> 32 bioassay" 46 I 
Ki67r hu-nucl. Ag 16 immPO hl' II 
Sourse: aseralab, Crawley Down, UK; bBecton Dickinson, Sunnyvale, CA, USA; 'Dr C. Mawas, 
Marseille, France; dDr F. Koning, Bloodbank, University Hospital, Leiden, The Netherlands; "Dr 
W .F .Dodmer, London, UK; f'J)ak:opatts, Glostrup, Denmark; KDr R. van Lier, Central 
Laboratory of the Blood Transfusion Service, Amsterdam, The Netherlands; hDr M. Jonker, 
Institute for Applied Radiobiology and Immunology, Rijswijk, The Netherlands; 10rtho 
Diagnostic Systems, Raritan, NJ, USA; JDr E.P. Rieber, Munchen, FRG; kRIVM, Nijmegen, 
The Netherlands; 'Dr M.M. Yokoyama, Fukooka, Japan; •or W. Tax, Nijmegen, The 
Netherlands; "Dr P.C.L Beverly, London, England; "Coulter Clone, Hialeah, FL, USA; 'Dr J.P 
Soulillou, Nantes, France; "~Dr W.A. Buurman, Biomedical Center, University of Limburg, The 
Netherlands. 
Technique: FACS: indirect immunofluorescence staining technique and analysis by flow 
cytometry (FACScan, Becton Dickinson, Mountain View, CA, USA); IPrecip: 
immunoprecipitation; immPO: indirect immunoperoxidase staining; bioassay": cytopathic 
inhibition assay in Hep-2 cells with vesicular stomatitis virus as challenge; bioassay": bioassay 
with a murine WEHI 164 clone 13 fibrosarcoma cell line. 
Material used in this study: I) ascites purified by protein A affinity chromatography; II) tissue 
culture supernatant; III) unpurified ascites; 
11 Abbreviations used: Prep. = Antibody preparation used for this study; :MHC = Major 
Histocompatibility Complex antigens class I or II; CD = Cluster of Differentiation, as defined 
during the Leucocyte Typing Conferences (Paris, 1982; Boston, 1984; Oxford, 1986; Vienna, 
1989); IFN-'Y = Interferon gamma; TNF-a = Tumor Necrosis Factor alpha; hu-nucl. Ag = 
human nuclear antigen; hi = hoc loci, this study. 
E.2.2 Monoclonal antibodies used for immunohistochemical staining 
All MAbs used in this study are listed in table 1. Twenty-five of the tested MAbs were 
known for their crossreactivity with the homologous rhesus counterpart antigens in indirect 
immuno-fluorescence studies, immunoprecipitation studies or in bioassays. Five MAbs of 
which crossreactivity had not been assessed previously, were also included in this study, as 
their target structures are of particular interest. Table I lists the specificity and original 
source of the antibodies, the technique (and reference) previously used for demonstrating 
crossreactivity with rhesus monkey cells as well as the method of purification of the 
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antibody used for this study. Except for the MAbs FN18 [36] and GM9 [24], that were 
developed against rhesus antigens, all other MAbs used in this study were originally raised 
against human antigens. 
E.2.3 Immunohistochemical staining technique. 
Incubation was performed using an indirect immune-peroxidase stammg technique. 
Briefly, slides were thawed at room temperature for 15 min, washed with PBS, and then 
incubated with the tested MAb (Table 1) for 60 min at room temperature. Slides were 
washed again and subsequently incubated for 30 min with horseradish peroxidase-coupled 
rabbit anti-mouse immunoglobulin (Dakopatts, Copenhagen, Denmark) diluted 1:100 in PBS 
containing 5% heat-inactivated (30 min., 56'C) normal rhesus serum and 5% normal rabbit 
serum. After rinsing, conjugate binding was visualized with a solution of 0.5 mg/ml 3,3,-
diaminobenzidine tetrahydroch1oride (Fluka Chemika, FRG) and 0.03% H,O, in PBS. Slides 
were washed and counterstained with Mayer's hematoxylin for 1 minute, dehydrated and 
fmally embedded in Malinol (Chroma Gesellschaft, Kongen, FRG). Of each MAb a titration 
with a minimum of 4 different dilutions was performed. In control incubations the primary 
antibody was omitted. Immunohistochemical reactivity of each MAb was scored 
semiquantitatively: - for absence of, + for low, + + for moderate and + + + for high 
intensity of staining. Both staining of the relevant target structure and aspecific background 
staining were assessed. Only the results of the most optimal dilution of each tested MAb are 
presented in tables 2 through 5. 
E.4 Results 
In tables 2 through 5, the immunohistochemical reactivity of 30 different MAbs with 
various rhesus tissues is presented. 
In table 2, results are given of seven MAbs specific for MHC class I and II antigens, 
tested on lymph node and allogeneic skin. W6/32, anti-HLA-DR and B8.12, the former 
specific for MHC class I antigens and the latter two specific for MHC class II-DR antigens, 
proved to stain target structures intensely, without significant non-specific background 
staining. Intense cellular staining of lymphocytes could be seen both in lymph nodes and 
cellular infiltrates of the skin. Moreover, a clear expression of MHC class I and II-DR 
antigens by epidermal and dermal cells in a skin biopsy was also observed (Fig. Ia). 
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Table 2. Immunohistochemical reactivity" of mAbs specific for Major Histocompatibility 
Complex class I and II antigens in the rh~us monkey. 
Target: REACTIVITY IN 
MAb MHC class Lymph node Skin 
W6/32 A,B +++!- +++/-
anti-HLA-DR DR +++!- +++!-
B8.12 DR +++!- +++!-
7.5.10.1 DR,DQ,DP +I- +I+ 
Genox 3.53 DQwl +++!- +++/+ 
anti-LeulO DQ ++/- -/-
anti-HLA-DP DP ++/- -I-
"Reactivity of the tested mAb is scored semiquantitatively: - for absence of, + for low, + + for 
moderate and + + + for high intensity of staining. Both staining of the relevant target structure and 
aspecific background staining were assessed and are presented in this order, divided by a slash. Only 
the results of the most favorable dilution of each tested mAb are presented. 
MAbs specific for MHC class II-DP and -DQ antigens showed a moderate staining reaction 
with a minority of lymphoid cells in lymph nodes. These cells were exclusively found 
diffusely in the paracortical areas of lymph nodes. 
In table 3, 12 MAbs are listed, specific for T cell antigens CD2, CD3, CD4, CDS or 
CD25. These MAbs were tested on lymph node, thymus and allogeneic skin. Tll most 
specificly and intensively stained mature T cells, whereas anti-Leu5b did not. Though all 
MAbs specific for CD3 also stained lymphocytes intensively, slight background staining was 
noted in all tissue tested. FN18 strongly crossreacted with hair follicles in skin specimens. 
The combination of OKT4 and OKT4A appeared to be highly reactive with the CD4+ T cell 
subset in lymph nodes as well as in thymus and skin biopsies. The MAb GM9, directed 
against rhesus CDS, yielded more specific staining results than FK18, though both MAbs 
showed intense target staining (Fig. lb). The MAb 2A3 was found to stain with lymphocytes 
expressing the CD25 marker in lymph nodes and thymus. Expression of the CD25 surface 
antigen was, however, not detectable on skin allograft infiltrating lymphocytes and 
histiocytes with this MAb. With 33B3.1 no target staining was detectable. 
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Table 3. Immunohistochemical reactivitf of mAbs specific for 
lymphocytes markers in the rhesus monkey. 
REACTIVITY IN 
MAb Target Lymph node Thymus Skin 
Tll CD2 +++!- +++!- +++!-
anti-LeuSb CD2 -I- -/- -/-
5Bll CD3 +++!+ +++!+ +++!+ 
FNI8 CD3 +++!+ +++!+ +++I+ +b 
OKT4+4A CD4 +++!- +++!- +++!-
M-T310 CD4 +I- +I- +I-
RIV6 CD4 -/- -/- -/-
RIV7 CD4 -1- -/- -I-
GM9 CD8 +++!- +++!- +++!-
FKI8 CD8 +++!+ +++!+ +++!+ 
2A3 CD25 +++!+ ++1- +I+ 
33B3.1 CD25 -1- -1- +I+ 
·see legend Table 2. 
'In this case background staining also included the staining of hair follicles. 
In table 4, eight MAbs are listed, specific for the leucocyte markers CD!, CD14, CD16 
and CD57, respectively. These MAbs were tested on lymph node, liver and grafted 
allogeneic skin. The MAb anti-Leu6 (COl-specific) very intensively stained dendritic cells 
that were mainly located in the epidermis. JML-Hl4 was the only one out of five MAbs 
specific for CD14(A), that proved to stain effectively Kupffer cells in the liver and 
histiocytes in lymph nodes and in infiltrating lymphocytes of allogeneic skin grafts (Fig. !c). 
Anti-Leu? (CD57-specific) showed a moderate staining reaction on small numbers of 
lymphoid cells in lymph nodes. CD16 could not be stained immunohistochemically with anti-
Leullb, not in lymphoid tissue nor in allogeneic skin during rejection. 
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Table 4, Immunohistochemical reactivity" of MAbs specific for leucocyte markers 
CDl, CD14, CD14A, CD16 and CDS7, in the rhesus monkey. 
REACTIVITY IN 
MAb Target Lymph node Liver Skin 
anti-Leu6 CD! +++1- nt' +++1-
JML-H14 CD14 +++1- +++1- +++1-
anti-LeuM3 CD14 +++I+ +I- +I+ 
WT14 CD14 +I- ++1- -1-
UCHMI CD14A -I- +I- ++1-
My4 CDI4 -I- ++1- +I+ 
anti-Leullb CD16 -I- nt +I+ 
anti-Leu7 CD 57 +++I+ nt +I+ 
·see legend Table 2. 
bnt = not tested 
Table 5. Immunohistochemical reactivity" of MAbs specific for lymphokines 
and proliferating cells in the rhesus monkey. 
MAb Target 
MDI !FN--y 
61E71 TNF-" 
Ki67' hu-nucl. Ag" 
·see legend Table 2. 
REACTIVITY IN 
Lymph node 
+++I++ 
+++I+ 
+++1-
Skin 
+I+ 
+I+ 
+++!+ 
bin thymus, positive cells were mainly located in the cortex and rarely in the medulla. 
'hu-nucl. Ag: human nuclear antigen 
In table 5, results are given with regard to MAbs specific for IFN--y, TNF-" and human 
nuclear antigen, tested on lymph node and skin. Several cells showed intense pericellular 
staining with MDI and 61E71, respectively specific for IFN--y and TNF-". However, the 
incidence of reactive cells during skin allograft rejection was very low. 
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Figure la. Staining with anti-HLA-DR of an allogeneic skin biopsy during rejection 
demonstrated the extensive MHC class II-DR antigens expression on epidermal and dermal 
cells and lymphocytes in the rejection infiltrate. Also Langerhans cells were stained (arrow). 
Figure lb. Staining with the MAb GM9 directed against rhesus CD8 lymphocytes yielded 
intense pericellular target staining in an allogeneic skin biopsy during rejection. 
Also an aspecific background staining and diffuse intercellular staining was observed in skin 
sections. Ki67, directed against a proliferation associated nuclear antigen in human tissues, 
yielded a clear nuclear staining reaction of cells in thymus, lymph nodes and skin (Fig. ld). 
In thymus, positive cells were mainly located in the cortex and rarely in the medulla. In 
peripheral lymphoid tissue, many cells in germinal centers were reactive. In skin biopsies, 
Ki67 often reacted with the cytoplasm of the basal epithelial cells of epidermis and hair 
follicles, but preferentially labelled nuclei of the basal cell layer. 
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d 
Figure lc. The MAb JML·H14 specific for CD14 effectively stained Kupffer cells in the liver 
(arrow). 
Figure ld. In allogeneic skin biopsies, the MAb Ki67 reacted with the cytoplasm of the basal 
epithelial cells of epidermis and occasionally with the nuclei of the basal cell layer. Also the nuclei of 
several cells in the rejection infiltrate showed expression of the proliferation associated nuclear 
antigen (In all figures the magnification used is 300x). 
E.4 Discussion 
In this study it is confirmed that human specific monoclonal antibodies that are known to 
crossreact with their homologous counterpart in the rhesus monkey using indirect 
immunofluorescene staining techniques, immunoprecipitation studies or bioassays, are not 
per se equally effective in immunohistochemical analysis of different tissues. More 
importantly, 23 MAbs are presented that can be used effectively for indirect 
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immunoperoxidase immunohistochemical studies in the rhesus monkey on frozen sections of 
lymph node, thymus, liver and skin. In this respect, a previous report by Sandusky eta! [43] 
dealing with the reactivity of several human specific MAbs with different leucocyte markers 
in lymph nodes is extended with 20 other MAbs. 
Approximately 60% of all MAbs with an 'excellent' target staining in FACS analysis, 
provided strong target marking and minor or no aspecific background coloring in frozen 
tissue sections using the indirect immunoperoxidase staining technique. Although a 
somewhat lower affinity of some MAbs in monkey tissues should be anticipated, the indirect 
conjugated peroxidase technique proved to be sufficiently sensitive for the visualization of 
antigen-antibody interaction in the majority of the MAbs tested. Thus, the need for a more 
sensitive immuno-histochemical staining technique, such as the avidin-biotin peroxidase 
complex method [22] is not indicated by this study. 
The anti-human MAbs W6/32, anti-LeulO, and anti-HLA-DP which are known to be 
crossreactive with rhesus antigens using immunoprecipitation studies [37,8] could be used 
effective for immunohistochemical staining of target cells in lymphoid tissue. Remarkably, 
using anti-LeulO and anti-HLA-DP no cells were positively stained in the allogeneic skin 
grafts. However, Genox 3.53, directed against the same molecule as anti-LeulO, did appear 
to stain lymphoid and stromal cells both in lymph node and the allogeneic skin. These 
observations might be an indication that also in the rhesus monkey, certain epitopes of the 
MHC class II antigens may not be exhibited constitutively. A similar phenomenon has been 
described with regard to the expression of HLA-DR (endothelial monocyte) antigens on B 
cells in man [7]. 
The two MAbs MDI and 61E71, fully crossreacting with rhesus IFN-y and TNF-01 as 
demonstrated in a bioassay, both yielded very intense pericellular staining of small numbers 
of cells in lymph nodes. Similar observations were described for antibodies directed against 
IFN-y in rejection infiltrates after kidney transplantation in the rat [42]. Therefore, it seems 
likely that MDI and 61E71 demonstrate lymphokine producing cells in the rhesus monkey. 
A drawback of these MAbs was the presence of diffuse background staining in skin graft 
biopsies. This diffuse intercellular staining might be the result of free IFN-y or free TNF-a. 
The two MAbs FN18 and GM9, raised against rhesus CD3 and CD8 surface antigens 
respectively, indeed gave an intense specific staining reaction of lymphoid cells. However, 
FN18 also crossreacted with hair follicles in skin biopsies. Therefore, the MAb Til, human 
CD2 specific, might be more advantageous than FN18 as it fully crossreacted with the rhesus 
pan T cell population without staining irrelevant structures in lymph node, thymus or skin. 
Similar results for Til and lymph node staining have been demonstrated previously [43]. In 
this elegant study, also reactivity ofanti-Leu5b could be demonstrated with rhesus lymphoid 
cells. This could not be confirmed in our study. Possibly the use of more senstive avidin 
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biotin technique by Sandusky eta!. accounted for this discrepancy. 
It was confirmed that anti-Leu6, CDl-specific very specifically stained mainly epidermal 
dendritic cells and also some dermal dendritic cells. Similar results have been described 
recently by Ringler et a!. [40], in their paper on the reactivity of 28 MAbs specific for 
dendritic cells in the skin of the rhesus monkey. 
Four out of the five MAbs of which crossreactivity had not been assessed previously, 
proved to be effective for immunohistochemical staining (see tables 4 and 5). Though further 
study is required to determine whether or not the same functional surface markers are 
stained, it can be stated that the MAbs specific for CD14, CD57 and a proliferation 
associated human nuclear antigen defined by Ki67, yielded labelling patterns that excellently 
matched the situation in man. 
Firstly, this was the case for the majority of the CD14 specific MAbs that recognized 
macrophage-like cells in the lymph node and Kupffer cells in the liver (Table 4). In skin, 
histiocytes could be identified by light microscopy. However, the immunoperoxidase 
staining reaction with all MAbs, except for IML-Hl4, was faint and often accompanied by 
background staining. These observations suggest, that histiocytes in the nonhuman primate 
might exhibit similar specific morphologic and tissue-specific characteristics expressing 
distinct immunologic phenotypes as found in the human mononuclear phagocytic system 
[51]. 
Secondly, anti-Leu?, specific for CD57, expressed by T cell and Natural Killer cell 
subsets, proved to be the only MAb with a staining reaction in lymph node, though rather 
faint (Table 4). The Mab anti-Leullb, specific for CD16 expressed by Natural Killer cells 
and neutrophils, did not show any crossreactivity with rhesus antigens in this study. 
Thirdly, MAb Ki67, directed against the proliferation associated nuclear antigen, yielded 
a very clear nuclear staining reaction in all rhesus tissues. The staining pattern corresponded 
very well with human staining patterns, most notably in thymus. This result extends a 
previous report pointing out the evolutionary conservation in many mammalian species of 
this particular epitope [14]. Thus, it can be assumed that also in the rhesus monkey Ki67 
stains cells that are not in GO phase of the cell cycle. This MAb might be very functional for 
cell kinetic studies in the nonhuman primate. 
In conclusion, we have demonstrated that membrane glycoproteins of different kinds of 
rhesus cells as well as a rhesus proliferation associated nuclear antigen can also be 
selectively identified immunohistochemically on frozen tissue sections by using anti-human 
monoclonal antibodies. We expect that the selected MAbs will be useful in studying cell 
interactions of the immune response in rhesus monkey models of human disease. 
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A.l Introduction 
The way to allogeneic transplantation of extremities seems to be open, for the 
immunosuppressive agent Cyclosporin A (CyA) has made it possible to obtain long term 
graft survival of clinical allotransplantations of kidney', heart', liver' and other organs'· '. 
Furthermore, experimental and clinical allotransplantation of bone and joints6 , muscle\ 
nerve8 and skin9 has been performed with promising results 10 • Experimental transplantation 
of a composite of these tissues (i.e. the limb), utilizing CyA, has been performed in the rat 
by the groups of Furnas", Fritz" and Kim et al". Prolonged survival of limb allografts 
treated with CyA could be established even across a strong mismatch, i.e. a major 
histocompatibility (MHC) border. In the non human primate, transplantation of the hand has 
only been performed by Daniel et al in 1986"·" and Stark et al in 1987"·". Total hand 
transplants were performed by these groups in baboons under continuous, high dose CyA 
and Prednisone treatment. Graft survival longer than 70 days, was achieved in two out of 
four and one out of eight cases, respectively. Both studies showed that recovery of motor and 
sensory function after hand transplantation could be achieved. In our studies the radial side 
of the hand was transplanted in a rhesus monkey model since the anatomy and functional use 
of the hand of the monkey is closely related to the human hand. The radial side of the hand 
(the first ray) is a composite tissue unit in which sensory and motor function recovery can be 
evaluated. Transplantation of only the radial side of the hand is also more ethical since basic 
hand function can still be maintained in the monkey. The rhesus immune system, including 
MHC antigens, shows great similarity with the human immune system. Therefore results 
obtained in this research model allow for better extrapolation to the situation in the human 
being. 
General practicability of the research model and functional recovery has been demonstrated 
in an autologous (replant) situation, previously. To determine the value of monoclonal 
antibodies (mAbs) for reversal of rejection episodes of the radial hand, a combination of 
mAbs (specific for several surface markers on immunocompetent cells) was developed in 
skin transplantation studies". Furthermore preoperative third party blood transfusions are 
known to exert a protective effect on organ allograft survival"·"'. The value of blood 
transfusions in non human primate composite tissue transplantation has yet to be determined, 
for this reason they were added to our study. Laser Doppler flowmetry (LDF) and 
temperature recordings have demonstrated their beneficial use with regard to monitoring of 
the microcirculation after microvascular surgery21 '22 • These devices were used for monitoring 
of the microcirculation in the transplant model. 
This paper concerns the feasibility of allogeneic transplantation of the radial side of the 
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hand, the value of monitoring of the microcirculation and a preliminary report on functional 
recovery in an allogeneic model in the rhesus monkey. 
A.2 Material and methods 
A.2.1 Animals 
Rhesus monkeys (Macaca Mulatta) were born and raised in the TNO Primate Center, 
Rijswijk, the Netherlands, employing a "harem type" breeding system. Average weight was 
7.5 kg, age varied from nine to 24 years and male to female ratio was two to one. The 
animals were selected on absence of prior alloimmunization, on normal kidney and liver 
functions and non-injured, relatively large hands. If possible left or right handedness was 
assessed. 
Animal care complied with the "Principles of Laboratory Animal Care" and the "Guide for 
the care and use oflaboratory animals" (NIH publication no. 80-23, revised 1978). 
A. 2. 2 Experimental groups and immunosuppressive therapy 
The protocol, designed in cooperation with the department of biostatistics, consisted of 
twelve successful allogeneic transplantations of the radial side of the hand in the rhesus 
monkey. Transplantations were performed in unrelated donor-recipient combinations, 
mismatched for rhesus major histocompatibility (RhLA) -A, -Band DR-antigens. A group of 
twelve monkeys was divided at random into four different treatment subgroups with three 
monkeys per subgroup in a statistical factorial design according to Fisher (table I). In this 
scheme the effects of two factors alone and in combination could be determined in the same 
study. These factors were preoperative third party blood transfusions and monoclonal 
antibodies (mAbs) for the treatment of rejection episodes. 
All recipients received immunosuppressive treatment consisting of Cyclosporine A (CyA) 
and Prednisone (DiadresonFaquaosum = DAF). CyA was administered by subcutaneous 
injections twice daily (25 mg/kg/d, dissolved in Miglyol 812 and absolute ethanol as per 
Sandoz), to obtain whole blood trough levels of 400- 1000 ng/ml". DAF was given in an 
initial high dosage (12 mg/kg/day) for the first three days postoperatively and then was 
tapered slowly until a maintenance dose (1 mg/kg/day) was reached twelve days later. 
Following the protocol in table I, six monkeys received three third party blood transf-
usions, consisting of 20 mi. of fresh whole citrated blood from random donors, completely 
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mismatched for the transplant recipient and donor RhLA antigens. Blood transfusions were 
given at biweekly intervals (-6, -4 and -2 weeks) before transplantation. 
Onset of rejection was defined as the first obvious sign of swelling, erythema and blister 
formation of the transplant together with histological confirmation for the presence of 
rejection infiltrate, edema, hemorraghes and epidermiolysis. In case of rejection six monkeys 
were treated with an increase in DAF to the initial dosage (12 mg/kg/d), followed by the 
same tapering scheme as mentioned before. In the six, rejection was treated with a 
combination of rn.Abs, specific for different surface antigens on immunocompetent cells 
administered as an intravenous bolus injection for a period of ten days25 . 
A.2. 3 Anesthesia, medication and monitoring 
Apart from routine general anesthesia with standard monitoring of physiological 
parameters a continuous axillary plexus block was administered (mepivacaine and 
adrenaline, 20 mi 1% and 0.1 mg respectively, per eight hours). An intravenous infusion of 
Dextran 40 (Rheomacrodex, 1.5 gr/kg) was given during and directly after operation for 
hemodilution. Cefamandol (R/Mandol, 100 mg/kg/d in two dosages) was administered 
intramuscularly for five days starting an half hour before operation as antibiotic prophylaxis. 
Acetylsalicylic acid (R/Aspegic, one dosage of 100 mg) was given intramuscularly on the 
day of operation to decrease platelet aggregation. 
The microcirculation was monitored during and directly after surgery with temperature 
recordings of the transplant compared to a control temperature of the ipsilateral middle 
finger. Also Laser Doppler flowmetry (R/Perimed, PF2, Sweden) was used to measure 
blood flow in the microcirculation of the skin of the transplant". Measurements were 
performed after dissection at the donor site with the transplant on its vascular pedicle and 
after reanastomizing of the vascular pedicle at the recipient site. The monkeys were kept 
tranquilized for the first 4-6 hours after surgery for general and microcirculatory monitoring. 
After this period appropriate dressings and a custom made thermoplastic splint were applied 
to protect the operated upper extremity". 
A.2.4 Operation 
Before operation the donor and recipient arm were shaved. After general anaesthesia the 
donor rhesus monkey was placed in lateral position with the arm abducted. 
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The transplant, consisting of the first 
ray of the hand enlarged with the 
radial forearm flap (for monitoring 
and biopsies, size approximately 20 
em')" was marked (see fig. 1). All 
operations were performed under 
sterile conditions using tourniquet 
control. 1n the forearm, the radial 
forearm flap was dissected. The 
flexor, extensor and abductor pollicis 
longus muscles were cut at the wrist 
and marked, the adductor muscle was 
freed from its origin. The median 
nerve, the palmar cutaneous branch 
of the median nerve, the motor 
branch of the ulnar nerve beneath the 
adductor muscle and the superficial 
radial nerve branch to the thumb 
were identified, dissected, cut 
proximally and separately marked. 
The cephalic vein and the radial 
artery were the vascular pedicle to 
the transplant. They were dissected 
proximal to the radial forearm flap. 
An osteotomy was performed at the 
base of the first metacarpal bone. The 
tourniquet was freed at the upper arm 
after careful hemostasis by bipolar 
ventral 
' a.p.l. 
l 
S.R.n. 
~ v v 
C.v. 
dorsal 
Figure 1. The transplant model. The doned line 
marks the radial hand unit. Ventral: A = adductor 
muscle; T = thenar muscle; U.n. = ulnar nerve; 
M.n. = median nerve; f.p.l. = flexor pollicis 
longus; a.p.l. = abductor pollicis longus; r.a. = 
radial artery. Dorsal: e.p.l. = extensor pollicis 
longus; a.p.l. = abductor pollicis longus; s.r.n. = 
superficial radial nerve~ c.v. = cephalic vein. 
coagulation, the transplant was monitored with LDF and temperaturerecordings. During 
dissection of the donor site the recipient monkey was given general anaesthesia and an 
axillary plexus block on another operating table. Skin incisions were performed in the same 
manner as the donor site and adjusted for size discrepancies. The same nerves and tendons 
were identified and marked. They were cut distally to adjust for size difference and to allow 
nerve anastomoses without tension. The recipient's thumb was amputated proximally at the 
first metacarpal bone, with thenar muscles and adductor muscle. After tourniquet release 
hemostasis was ensured. Following transection of the vascular pedicle of the transplant at the 
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donor site, the defect was reduced by excision of the trapezium and covered with a full 
thickness graft from the belly. 
After receipt of the donor transplant at the recipient site (fig. 2a and 2b), osteosynthesis 
was performed at the donor and recipient metacarpal bone with transosseus wiring. The 
adductor muscle of the transplant was reinserted at the third metacarpal bone. Subsequently 
the nerve ends of the motor branch of the ulnar nerve, the common trunk of the median 
nerve, the palmar cutaneous nerve and the superficial radial nerve were anastomosed with 
lOxO nylon sutures (BV 6, R/Ethilon) under the microscope after adjustment for length. The 
tendons of the flexor pollicis longus, the extensor pollicis and abductor pollicis longus were 
sutured with 5x0 nylon. Recipient radial artery and cephalic vein were anastomosed with 
their donor counter parts end-to-end with lOxO nylon sutures (BV-6, R/Ethilon) under the 
microscope. Before the vessels were sutured the transplant artery was flushed with dextran 
40 - heparin solution to rinse the transplant from donor serum and blood cells as much as 
possible. The skin was loosely approximated and drains were applied. After release of the 
small vessel clamps the transplant was monitored immediately with a pinprick test for 
bleeding as well as temperature and Laser Doppler flowmetry recording. 
A. 2. 5 Postoperative care 
Wound inspection, assessment of bodyweight and central temperature were carried out 
regularly. After removal of the splint six to nine weeks postoperatively wound inspection 
could be performed daily. 
The microcirculation of the flap was monitored in the same frequency as mentioned 
above, by using the pin-prick test, capillary refill assessment if possible and temperature 
recordings of the flap and pulp of the thumb as well as the pulp of the middle finger. 
Temperature recordings were always done in the same manner in a controlled temperature 
environment. LDF of the forearm flap was done by placing the probe holder on a marked 
spot and measuring four independent values for the duration of one minute. To determine the 
predictive value of LDF measurements with regard to onset of rejection, trends over one 
week and over two weeks before starting anti-rejection therapy were evaluated. For statisti-
cal analysis a minimum of two measurements in the first seven or four in the first fourteen 
days prior to onset of anti-rejection therapy were evaluated. 
All tests (laboratory, immunological and histology tests) were taken regularly and in case 
of rejection the frequency of testing was increased. 
Laboratory tests included red and white blood cell counts as well as assessment of levels 
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of electrolytes and kidney and liver function. 
Immunological tests consisted of assessment of CyA whole blood trough levels, with a 
specific radioimmunoassay (RIA, Sandimmun-kit, Sandoz Ltd., Basle, Switzerland). Further 
immunological details on tests and results are presented elsewhere". 
Regularly, full thickness biopsy punches (diameter 3 mm) were taken. The biopsy was 
fixated with formalin 4% and processed routinely for hematoxylin-azofloxine analysis. 
Histological findings were scored semiquantitatively under light microscopy. 
A.2.6 Sensory and motor JUnction recovery 
To evaluate sensory nerve regeneration, the sensitiVIty to noxious stimulation was 
assessed weekly by means of a small electric current (1.8 milliAmpere) applied locally to the 
skin of the conscious monkey to provoke a withdrawal reflex. The number of sites rendering 
positive (withdrawal) reactions in relation to the total number of measuring sites gives the 
percentage of sensory reinnervation. 
Motor reinnervation was evaluated by detection of Compound Motor Action Potentials 
(CMAP) by electromyography of the thenar muscles after ruling out inadvertent stimulation 
of the ulnar nerve. Temperature corrected amplitude of CMAP of the abductor pollicis 
brevis muscle in the transplanted and contra-lateral side were compared weekly starting 
immediately postoperatively. Further details and histology concerning reinnervation will be 
provided elsewhereu. 
A.2. 7 Statistical analysis 
When appropriate, Fisher's exact-test, Mann-Whitney U test, two sample t-test, single 
regression analysis and log-rank test were performed for hypothesis testing. Differences 
were considered significant if P < 0.05. 
A.3 Results 
A.J.l Experimental groups 
In a consecutive series 14 transplantations of the radial side of the hand were performed, of 
which 12 were successful. Two technical failures, due to vascular occlusion were excluded. 
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Graft survival times were short in six cases (21-33 days) and long in the other six (79-179 
days, see table 1 and fig. 2c and 2d). CyA whole blood trough levels were above the minimal 
required doses of 400 ng/ml" in 83% of all cases. In the long term survival group the mean 
CyA level was 1025 (SD=l93) ng/ml, with 86% above the therapeutic margin. In the 
animals where the allografts were rejected before day 33, 74% of all postoperative CyA 
levels were in the therapeutic range and of the CyA levels after the 5th postoperative day 
even 92%. Long term and short term survivors showed no significant difference between 
CyA levels during day 5 and start of anti-rejection therapy (P>0.05, Mann-Whitney U). 
There was no significant correlation between allograft survival times and Cy A levels during 
the experiment (P>0.05, regression analysis). 
Between the two groups of animals that did or did not receive preoperative third party 
blood transfusions, no significant difference in the onset of allograft rejection could be 
observed, nor did it facilitate reversal of graft rejection (P > 0.05, log-rank). 
Table 1. Allogeneic partial hand transplantation in 12 rhesus monkeys 
under cyclosporine A (CyA) and prednisone (DAF) 
Protocor Monkey Start of rejection Rejection Graft survival 
no. therapy (days) reversed time (days) 
!(+,+) 2799 79 79" 
4023 62 + 
Ill + 121" 
2988 15 22" 
ll(+,-) 3992 139 144 
3439 41 + 
75 +'partial 97" 
3308 179" 
ill(-,+) 2596 13 30 
21 21 29" 
3310 85" 
IV (-,-) 1FU 21 33 
1550 21 33 
3212 12 21 
•Protocol: I(+,+) = cocktail of monoclonal antibodies during rejection (mAbs), pre-operative third 
party blood transfusions (transf.); II(+,-) = mAbs, no transf; III(-,+) = raise in DAF during 
rejection, transf; IV (-,-) = DAF, no transf. 
bdeath of rhesus monkey (spontaneously or due to euthanasia). 
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Figure 2a. Arm of recipient rhesus monkey (#3308) at operation. The radial unit of donor rhesus 
monkey (#2AC) is shown at the top of the photograph just before transplantation. The lower recipient 
thumb is discarded. 
Figure 2b. After completion of the radial hand transplantation (#2AC to #3308). 
Figure 2c. Rhesus monkey (#3308) 148 days after transplantation. Normale skin texture with normal 
appearance of the allograft. 
Figure 2d. Example of a transplant rejection in a rhesus monkey (#3439) 43 days after 
transplantation. Note the swelling and skin slough. 
Swelling, dermal hemorrhages, epidermolysis of the allograft, histologically confirmed to be 
rejection, occurred in ten out of 12 recipients (table 1). Histologically slight to severe 
lymphohistiocytic infiltrates, edema, hemorraghies and epidermolysis were seen (fig. 3a). In 
all transplants skin was more rapidly rejected than nerve and muscle. Five monkeys received 
the combination of mAbs for treatment of the rejection episode. In two out of five cases, 
graft rejection could be reversed (table 1, fig. 3b). 
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Figure 3a. A H&A stained section of the allograft of monkey 3439; 43 days postoperatively, two 
days after the onset ofMAbs anti-rejection therapy. The immune response of the host has resulted in 
total loss of the skin of the allograft (arrow), hemorraghe and also a diffuse infiltrate of lymphocytes 
and macrophages is visible (magnification 300x). 
Figure 3b. A H&A stained section of the allograft of the same monkey (3439). 47 days 
postoperatively, after seven days of anti-rejection therapy with MAbs. Reversal of rejection has 
allowed for regeneration of the epidermis. The number of infiltrated cells has greatly diminished 
(magnification 300x). 
In these monkeys also a second rejection episode could be treated successfully. In the other 
five partial hand recipients, graft rejection was treated by increasing the doses of DAF. In 
none of these cases. could graft rejection be reversed. MAb anti-rejection therapy prolonged 
graft survival significantly longer than an increase in steroids (P=0,015, log-rank). 
Furthermore, histological severity of rejection at onset of anti-rejection therapy did not 
influence outcome of rejection treatment (P>0.05). 
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A.3.2 Anesthesia and operation 
No complications of anesthesia were encountered. Operating time varied from 5 to 9 
hours. 
A.3.3 Postoperative care 
Postoperative pin-prick test in the pulp of the thumb showed instant bright red blood drops 
in most cases. Regarding temperature recordings one technical failure was already indicated 
in retrospect by temperatures of 28-29" Celsius of the thumb directly after operation. In 
rejection cases with necrosis of the thumb temperatures were below 30" Celsius. In all other 
cases where the transplants were viable, temperatures were above 30" Celsius. In the two 
technical failures LDF measurements were below 10 perfusion units three days after 
operation. To determine the predictive value of LDF measurements with regard to onset of 
rejection, trends over seven and over fourteen days prior to onset of rejection, were 
evaluated. Values measured over one week, nor over two weeks prior to therapy allowed any 
conclusion. 
At onset of anti-rejection therapy allograft infiltration ranged from slight to severe diffuse. 
In the two monkeys with mAbs therapy (4023 and 3439) where reversal of rejection was 
established, already after 4-7 days of treatment only a slight focal infiltrate remained. In 
monkeys where rejection was not reversible graft rejection was complete in 4-10 days after 
onset of therapy, except for one monkey (2I) that died eight days after anti-rejection 
treatment. 
A.3.4 Sensory and motor function recovery 
In the six monkeys with short graft survival times (21 - 33 days) rejection occurred before 
sensory recovery could be shown. In the six monkeys with long term graft survival (79 - 179 
days) first signs of sensory recovery appeared in the median nerve distribution after a mean 
of 42 days postoperatively (range 27-64 days). As soon as the first sign of sensory recovery 
was detected and reconfirmed, the custom made splint was no longer applied (mean : 38.7 
days; range 32-57 days)(table II). 
The percentage of median nerve reinnervation increased in time, episodes of rejection almost 
immediately decreased this area. In case of reversal of allograft rejection renewed 
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reinnervation was seen, within two weeks after the initial decrease (or initial absence) of 
reinnervation. 
In six monkeys first signs of motor recovery could be assessed at a mean of 43,8 days 
postoperatively (range: 31-56 days). 
In two out of six monkeys with short term graft survival (21 - 33 days) thenar muscle 
reinnervation could be detected even after onset of rejection. The quality of conduction 
Monkey 
2799 
4023 
3992 
3439 
3308 
2! 
3310 
IFU 
Table 2. Sensory and motor function recovery after allogeneic partial hand 
transplantation in the rhesus monkey 
First sign of Maximal percentage First sign of 
Start of rejection of sensory of median nerve motor recovery 
therapy (days) (days) reinnervation" (days) 
79 27 75 72' 
62 41 91 23 
Ill 
139 35 80 79' 
41 56 14 37 
75 
64 100 25 
21 22 
29 84 28 
21 33 
"The percentage of median nerve reinnervation is calculated by dividing the number of 
positive measurements through the total number of measurement sites on the skin supplied 
by the median nerve. 
bFirst measurement by electromyograph. 
(amplitude of CMAP) as well as the velocity of conduction (latency of CMAP) increased in 
time. More detailed information on sensory and motor function recovery is described 
elsewhere28 • 
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A.3.5 Complications 
During immunosuppressive therapy overall weight loss was 13.4% in relation to 
preoperative weight. In the six long term survivors weight loss was observed ranging from 8 
to 40% with an average of22.4%. 
Elevated levels of creatinine occurred in five out of twelve cases. Clearly elevated levels of 
lactate dehydrogenase and aspartate transaminase were observed in three cases, in four cases 
liver function parameters were incidentally elevated. 
In four monkeys lymphoid tumor was found of which three died due to cachexia and tumor 
growth. In the first, a histiocytic sarcoma (2988) occurred 22 days after operation, in the 
second a malignant lymphoma (B cell type, 3439) 97 days after treatment with CyA, DAF 
and mAbs and two rejection episodes, and a histiocytic and fibrocytic sarcoma 179 days after 
operation without occurrence of rejection in the third monkey. 
Three monkeys died of sepsis. One of these three (4023) died of multiple organ failure and 
sepsis after treatment with CyA, DAF and mAbs and two rejection episodes. There was 
evidence of tumor development in lymphoid tissue in this monkey. Of the other two one died 
of organ failure and sepsis after 29 days (2I) and the other (3310) died of sepsis presumably 
from the skin with dissemination to the central nervous system. One monkey (2799) died of 
shock and irreversible coma after administration of the first intravenous dosage of the mAbs 
cocktail. MAbs therapy did not have a significant effect on death in general (P > 0.05)". 
A.4 Discussion 
Long term survival combined with functional recovery is obligatory before allogeneic 
transplantation of extremities is considered. Experimental allogeneic composite tissue 
transplantation has long been focussed on the improvement of survival6•11•12'13 . More recently, 
functional recovery has been under investigation14'17'30 • This study was designed to investigate 
survival as well as functional recovery of a composite tissue allograft in the nonhuman 
primate. 
To suppress the host-immune response against composite tissue allografts the combination 
of continuous high dosage of CyA (20-25 mg/kg/day) and prednisone is needed to establish 
long term allograft survival. This is demonstrated in various studies in rat11 '13 as well as 
monkeyl4,17,24. 
In the present study the same regime was chosen. Although CyA levels were above the 
therapeutic margin of 400 mg/ml still ten out of twelve hand transplantations showed rejec-
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tion. 
Mean skin graft survival times without immunosuppressive treatment are normally not 
longer than ten days">'. In the short term survival group of this study graft survival time 
varied in six rhesus monkeys from 21 - 33 days. As the earliest rejection started much longer 
than ten days following operation unresponsiveness to CyA is unlikely. Furthermore, 
retrospective analysis ruled out a possible negative influence on allograft survival in female 
recipients, due to prior sensitization. 
Onset of rejection was treated in our study either with an increase in DAF or with the 
mAbs therapy. Daniel eta!." and Stark et a!." reported reversal of rejection with an increase 
in prednisone in two out of four and one out of eight hand transplantations in baboons 
respectively. However, in their studies still two out of three showed skin problems after 
reversal. In our project, all radial hand transplants treated with an increase in steroids in case 
of rejection, did not show any signs of reversal. Regarding the use of mAbs in the treatment 
of acute graft rejection the beneficial use was first demonstrated by Cosimi eta! in 1981" in 
the treatment of a rejection crisis following kidney transplantation. This has been 
reconfirmed by others". In our study, mAbs therapy could reverse graft rejection in two out 
of five monkeys, on two occasions. Even though two out of the three other monkeys in this 
group died during mAbs anti-rejection therapy before the allograft was completely rejected, 
graft survival could be prolonged significantly longer than an increase in steroids. Data 
concerning lymphocytic subset distributions in the peripheral blood as well as in the allograft 
itself is presented elsewhere". 
Third party and donor-specific blood transfusions have been proven to exert a protective 
effect on allograft survival, even under CyA therapy"·"·". However in our study third party 
blood transfusions did not postpone the onset of graft rejection significantly, nor did they 
facilitate reversal of graft rejection. Possibly the high dosage of CyA masks the effect of 
blood transfusions. 
Monitoring of microvascular surgery, as for instance LDF and temperature recordings, can 
be a helpful tool in detecting vascular compromise. Particularly if monitoring is performed 
continuously. As far as technical failures are concerned, one case could not be predicted as it 
occurred two days after surgery, the other had in retrospect low monitoring values directly 
after operation. 
Black et a!." have demonstrated that a decline of the muscle temperature proved to be a 
reliable quantitative determination of limb allograft survival. In our study skin temperature 
recordings could not predict a rejection episode. Only skin necrosis produced a drop in skin 
temperature below 30o Celsius. Probably muscle temperature is less influenced by rejection 
or environment than skin temperature. To determine a predictive value of LDF 
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measurements with regard to onset of rejection very frequent measurements are needed 
without too much variability between measuring sessions. No conclusions could be drawn in 
this respect due to the variability of the values and the inability to measure caged monkeys 
very often. In allogeneic limb transplantation in rats where LDF values were less variable 
and more frequently measured, they correlated well with graft rejection although a predictive 
value could not be established". 
Sensory and motor recovery occurred in all long term survivors. First sign of sensory 
recovery, assessed in conscious monkeys, was found after a mean of 41.8 days 
postoperatively (range: 27-64 days). Episodes of rejection almost immediately decreased the 
area of sensory recovery. As sensory receptors are localized in the dermal-epidermal 
junction they are bound to be affected as this area appears to be the main target of 
rejection37-39 • Reversal of graft rejection enabled renewed reinnervation within two weeks 
after the initial decrease of reinnervation, thus host axons can reestablish reinnervation after 
rejection in allogeneic tissue. 
First signs of motor reinnervation appeared after a mean of 43.8 days postoperatively 
(range: 31-56 days). In both monkeys in which reversal of rejection was demonstrated, also a 
negative effect on latency and amplitude of the compound motor action potential was 
observed28 • A decrease in motor and sensory function after rejection, have also been 
described by others14'38 • 
Side effects of the immunosuppressive therapy in this study mainly concerned weight loss 
due to anorexia in the long term survivors. Though aberrant biochemical values were 
present, no severe nephro- and hepatotoxicity were observed. However, if similar high 
doses are administered in clinical transplantation, more severe kidney and liver damage are 
likely to occur"·"'. As three monkeys died of the consequences of lymphoid tumor 
development and three due to opportunistic bacterial infections the immunosuppressive 
treatment might have been too aggressive although similar doses of CyA and DAF were 
administered in baboons with hand transplants for longer periods without such side 
effects"·". A possible reason could be that the baboons were young, jungle caught without 
previous history in contrast to older, inbred rhesus monkeys with a case history, varying 
from kidney donorship to testis radiation. 
In conclusion, technical feasibility of allogeneic transplantation of the radial side of the 
hand in the rhesus monkey has been demonstrated. Graft survival was never longer than 180 
days after surgery even under high dosages of Cyclosporine A and prednisone. 
Reversal of graft rejection could be established twice in two out of five cases with 
monoclonal antibodies anti-rejection therapy and resulted in a significant prolongation of 
allograft survival times. An increase in DAF as anti-rejection therapy could not prevent 
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further graft rejection. 
A predictive value for the onset of rejection could not be assessed by laser doppler 
flowmetry, due to variability of measurements and inability to measure more often. 
Sensory and motor function recovery occurred in all long term survivors. Rejection had a 
negative influence on sensory and motor function recovery. Reversal of rejection enabled 
renewed sensory reinnervation within two weeks after anti-rejection therapy was started. 
A more effective immunosuppressive regime is needed before actual allogeneic trans-
plantation of the human hand can be performed. 
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B.l Introduction 
Since Cyclosporioe A (CyA) has been introduced for experimental organ grafting in 1977' 
and for clinical use in 1978', it has been used successfully for the suppression of the host 
immune response after allogeneic transplantation of many organs, experimentally' as well as 
clinically~'. In the last two decades, as a consequence of the recent advances that have been 
made in clinical microsurgery, it also became feasible to explore the possibility of surgical 
reconstruction of the upper extremity with composite tissue allografts (CTAs)'""··""•. 
Allogeneic limb transplantation in the rat has been performed successfully with long term 
allograft survival, provided that treatment with moderate doses of CyA was continuous8•9 • 
Tolerance to limb allografts in rats could, probably, partly or totally be attributed to the 
development of donor-host lymphoid chimeras". However, for the study into the feasibility 
of allogeneic hand transplantation in man, research in rodents only yields limited information 
and results can not be extrapolated directly to the situation man. For anatomical, functional, 
immunological and phylogenetic reasons the nonhuman primate is obviously a more 
representative experimental animal. 
So far only two hand transplantation studies in the nonhuman primate (baboon) have been 
reported 11'12 • In this species, even high doses of CyA in combination with Prednisolone 
(DAF) could not prevent rejection of the allogeneic hand transplant in the majority of the 
cases, nor could a rise in steroid treatment reverse all rejection episodes adequately. 
Therefore, in the allogeneic partial hand transplantation model in the rhesus monkey, a more 
specific anti-rejection therapy was incorporated, apart from continuous administration of 
CyA and DAF. A combination of monoclonal antibodies (MAbs) was designated with high 
immunosuppressive potential, consisting of seven MAbs specific for CD3, CD4, CD8 and 
major histocompatibility complex (MHC) class II antigens. It was demonstrated previously, 
that this combination of MAbs prolonged skin allograft survival times significantly from 8.3 
(SD=0.7) to 19.3 (SD=l.8) days". MAbs are relatively new and very selective tools in 
modulating the immune response. Especially anti-leucocyte MAbs have proven to be 
effective in reversing organ allograft rejection in the non-human primate14'15 as well as in 
man"·". Since preoperative third party blood transfusions are known to prolong allograft 
survival17'1s even under CyA treatmene9 , the value of such blood transfusions was tested also. 
This study focussed on the general, intravascular and intra-transplant effects of modulating 
the host immune response against a CTA by the afore mentioned agents. 
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B.2 Material and methods 
B.2.1 Animals 
Adult rhesus monkeys (Macaca mulatta), ranging from 7 to 21 years in age and not 
alloimmunized prior to these experiments, were used. Unrelated donor-recipient 
combinations were mismatched for rhesus MHC class I and II antigens. 
B.2.2 Experimental model 
The transplant consisted of the first ray of the hand (the thumb) enlarged with a radial 
forearm flap of approximately 20 em' (submitted'). Dissection and amputation of the partial 
hands were performed under sterile conditions, using tourniquet hemostasis and an antibiotic 
prophylaxis. All donor structures (metacarpal bone, radial artery, cephalic vein, tendons, 
nerves and skin) were reconnected at the appropriate recipient sites. Postoperatively, the 
extremities were immobilized in a custom made arm protective thermoplast splinf20 • 
MAb 
B8.12 
7.5.10.1 
5BII 
FNI8 
RIV6 
RIV7 
FK18 
Table 1. The composition of the combination of monoclonal antibodies (MAbs) 
that was used for the treatment of rejection episodes of allogeneic 
partial hand transplants in the rhesus monkey". 
specificity' dose (mg/kg) reference 
MHC-DR I 22 
MHC-DR,-DQ,-DP I 23 
CD3 0.5 24 
CD3 0.5 22 
CD4 0.5 25 
CD4 0.5 25 
CDS 0.5 26 
"For treatment of rejection episodes this combination of seven MAbs was administered once daily 
as an intravenous bolus injection for a period of ten days. 
bAbbreviations used: MHC = Major Histocompatibility Complex antigens class IT; CD = Cluster 
of Differentiation as defined during the Leucocyte Typing Conferences (Paris, 1982; Boston, 
1984; Oxford, 1986; Vienna, 1989). 
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B.2.3 Experimental groups and immunosuppression 
This study concerned 12 successful transplantations of the partial hand. Recipients were 
divided randomly into four different treatment subgroups following a statistical design 
according to Fisher" in order to economize on monkeys and enable evaluation of the effects 
of preoperative third party blood transfusions and MAb anti-rejection therapy (Table 2). 
Basic immunosuppressive treatment starting one day preoperatively consisted of (s.c.) 
administration 25 mg/kg/day CyA in Miglyol-812. An initial high dose of 12 mg/kg/day of 
DAF was added (im), starting on the day of operation and tapered every three days until a 
maintenance dose of one mglkglday was reached at the 12th postoperative day. 
If rejection was observed macroscopically (swelling, erythema and blister formation) and 
could be confirmed histologically, in subgroups I and !!, rejection was treated with a 
combination of MAbs, administered once daily as an intravenous bolus injection for a period 
of ten days. Its composition is presented in Table 1 together with the relevant specificity of 
each MAb and the concentration used for injection. All MAbs used in this study are 
crossreactive with rhesus lymphocytes22•24•25 ·•ubm. 
In subgroups lll & IV, rejection was treated by increasing the DAF dose to 12 mglkglday 
again. Tapering of the DAF dose was done as described above. 
The therapeutic value of these anti-rejection treatment protocols was tested, as well as the 
value of preoperative third party blood transfusions (Table 2). Blood transfusions consisted 
of 20 ml fresh citrated whole blood from donors, fully mismatched for rhesus MHC class I 
and II antigens of both graft donor and recipient. Three third party blood transfusions were 
given at biweekly intervals (-6,-4,-2 weeks) before transplantation to monkeys in treatment 
subgroups I & lll. Endpoint of experiment was reached when either the allograft was 
completely rejected or the graft recipient died. 
B.2.4 Assessment ofperipheral blood parameters 
By means of a specific radioimmuno-assay {RIA, Sandimmun-Kit; Sandoz Ltd., Basle, 
Switzerland)" it was demonstrated that whole blood CyA trough levels were above the 
minimal required concentration of 400 nglml" in 83% of all postoperative samples and in 
92% of all samples after day five. (Correction factor to compare our data measured by the 
monoclonal RIA with data measured by the polyclonal RIA is set to 50%"). CyA levels from 
day 5 to start of anti-rejection therapy did not differ significantly between long term and 
short term survivors (P>0.05, Mann-Whitney U test). Median CyA levels were 861 (SD= 
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272) and 676 (SD~256) ng/ml, respectively. 
Levels of circulating injected MAbs and titers of antibody formation against the injected 
MAbs were determined using a sandwich enzyme-linked immunosorbent assay technique 
(ELISA) as described previously"', 
All allograft recipients were monitored frequently with respect to total leucocyte and 
lymphocyte counts and relative numbers of CD3+, CD4+, CDS+ and MHC class II+ 
cells, using an indirect immunofluorescence technique and analysis by flow cytometry 
(F ACScan, Becton Dickinson, Mountain View, CA) as described elsewhere", 
B.2.5 Histological studies 
After operation skin biopsies were taken from the transplant weekly. During rejection, 
biopsies were taken two to three times per week. After excision with a 3 mm2 biopsy stance, 
one half of the biopsy was fixed in buffered formalin and processed routinely on 
hematoxylin-azofloxine stained sections. Severeness of rejection was scored 
semiquantitatively; light ( +) for slight edema, small infiltrates of lymphocytes and 
histiocytes; moderate ( + +) for diffuse edema, larger lymphohistiocytic infiltrates, capillary 
destruction, hemorraghes, (sub )epidermal bulla formation; severe ( + + +) for massive 
lymphohistiocytic infiltrates, extensive hemmorraghe, epidermiolysis; complete graft 
rejection (CGR) was typified by a severe rejection score plus crust formation. 
The remaining other half of the biopsy, snapfrozen in li'!uid nitrogen chilled isopentane, 
was used for parallel immunohistochemical studies. Technique and a semiquantitative 
scoring method for distribution and intensity of staining are described previously"'·'"'". A 
previously described selection of MAbs:l() was used to demonstrate expression of the 
following rhesus antigens: MHC class I, MHC class II-DR, CD2 (pan T cell), CD4 and 
CDS. In control incubations the primary antibody was omitted. 
B. 2. 6 Statistical analysis. 
When appropriate, Fisher's exact test, Mann-Whitney U test, two sample t-test, and log-
rank test were performed for hypothesis testing. Differences were considered significant if 
P<0.05. 
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B.3 Results 
B. 3.1 Allograft survival times and rejection 
Twelve allogeneic transplantations of the partial hand were performed successfully. Graft 
survival times were short in six cases (21-33 days) and long in another six (79-179 days; 
Table 2, Fig. Ia). 
Third party blood transfusions did not induce a significant difference in the moment of 
onset of allograft rejection (days of onset of rejection in groups I and lli versus those in 
groups II and IV: P > 0.05, t-test). 
Table2. Allogeneic partial hand transplantation in 12 rhesus monkeys treated with 
CyA, steroids, third party blood transfusions and monoclonal antibodies. 
Protocol" Monkey Start of rejection Rejection Graft survival 
therapy (days) reversed time (days) 
!: 2799 79 79' 
MAbs and 4023 62 + 
b1oodtrf. 111' + 121' 
2988 15 22' 
ll: 3992 139 144 
MAbs, 3439 41 + 
no bloodtrf. 75' +,partially 97' 
3308 179' 
Ill: 2596 13 30 
DAF and 21 21 29' 
b1oodtrf. 3310 85' 
IV: 1FU 21 33 
DAF, 1550 21 33 
no bloodtrf. 3212 12 21 
"Immunosuppressive protocol, abbreviations used: MAbs: anti-rejection therapy consisted of a 
combination of seven monoclonal antibodies, as described in Table 1; bloodtrf.: three third party 
blood transfusions were given to the recipient, preoperatively; DAF: anti-rejection therapy 
consisted of a raise in steroid treatment. 
bsecond rejection episode in monkeys #4023 and #3439, respectively. 
edeath of rhesus monkey (spontaneously or due to euthanasia). 
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Blood transfusions neither facilitated reversal of graft rejection (P>0.05, Fisher's exact 
test) nor had a significant effect on allograft survival, in this study (P > 0.05, log-rank). 
Overall, rejection of the allograft occurred in ten partial hand recipients. Five monkeys 
received the combination of MAbs for treatment of rejection crises. In two out of these five 
monkeys, graft rejection could be reversed completely (Fig. lb-d). 
Also a second rejection episode was reversible, although in one monkey only partially, 
using the same combination of MAbs. In two out of the three monkeys, where the MAbs 
therapy had not reversed graft rejection, MAbs had not been administered for the proposed 
duration of ten days. Due to side effects like drowsiness and vomiting, one monkey received 
four doses on alternating days, the other monkey, unfortunately, died due to a shock after the 
first dose of MAbs. In five other recipients, graft rejection was treated by increasing the 
DAF dose. In none of these cases, graft rejection could be reversed. There was no significant 
difference in the moment of onset of allograft rejection in groups I & II compared to groups 
III & IV (P > 0.05, log-rank test). However, if MAb anti-rejection therapy was used (groups 
I & II), graft survival was prolonged significantly longer than if rejection was treated by a 
raise in steroids (groups Ill & IV, P=0.015, log-rank test). 
B.3.2 Effects on periphRral blood parameters: Antibody serum levels 
Serum trough levels of the injected MAbs varied from four to 120 ng/ml during the 
period of MAbs administration. Moreover, in all monkeys serum levels remained detectable 
up to three to ten days after the last injection. In both monkeys where the episodes of 
allograft rejection could be reversed and CyA and DAF treatment was continued, no 
neutralizing monkey-anti-mouse antibodies could be detected. 
B.3.3 Hematology and lymphocyte subsets 
If rejection was treated with a raise in steroids, no leucopenia nor lymphopenia in 
absolute numbers was seen. However, if rejection was treated with the combination of 
MAbs, in all monkeys the absolute number of leucocytes was reduced to 50%, that of 
lymphocytes even to 14% of pretreatment levels, already within ten minutes after the first 
injection. Lymphopenia and leucopenia sustained till approximately six days after the first 
injection. 
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Figure la. Complication free graft survival of an allogeneic partial hand in monkey #3308, 148 days 
postoperative) y. 
Figure lb. Full blown rejection with macroscopical swelling (due to edema), erythema (due to 
dermal hemorraghes) and blister formation (due to epidermolysis) of the allogeneic partial hand in 
rhesus monkey #3439, 43 days postoperatively. The 10 day course of anti-rejection therapy with the 
combination of monoclonal antibodies as described in Table 1, was started on day 42. 
Figure lc. 6 Days after onset of MAbs anti-rejection therapy in monkey #3439, first macroscopical 
signs of successful reversal of rejection are visible. 
Figure ld. 26 Days after onset of successful MAb anti-rejection therapy. The integrity of the 
transplant of rhesus monkey #3439 has fully been restored. 
In all cases, ten minutes after the first injection of MAbs, over 90% of the peripheral 
blood lymphocytes (PBLs) that had not been eliminated, was coated as was demonstrated by 
incubating with the fluorescent goat-anti-mouse lgG alone (Fig. 2). As soon as coating of 
PBLs decreased, the relative number ofMHC class II positive cells increased to pretreatment 
levels. Coating of PBLs disappeared, after approximately 20 days. 
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Figure 2. Lymphocyte subset fluctuations in monkey #3439, representative for the intravascular 
events that could be observed every time a monkey was treated with a ten day course of the 
combination of seven MAbs described in Table 1. MAb administration is indicated by the black bar. 
The surface of the shaded area 'A' depicts the relative number of coated cells. Until approximately 20 
days after the first injection, no cells expressing the CD3 and CD8 surface marker are detectable (see 
point 'B'). Detection of CD4+ cells without the concomittant expression of CD3 (see point 'C'), 
indicates modulation of the CD3 surface antigen. 
Elimination of CD3+ and CDS+ lymphocytes lasted approximately equally long. 
Modulation of the CD3 antigen occurred also (Fig 2). In the monkeys in which MAbs 
therapy did not reverse rejection PBLs had been eliminated to the same extent, but CD3 + 
and CDS+ subset-elimination lasted shorter. Also coating ofPBLs was of less intensity and 
of shorter duration. 
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B.3.4 General histology 
In all cases where rejection was not reversible, the allograft was completely rejected 
within five to ten days after onset of rejection therapy (Table 3). If reversal of rejection could 
be established with MAb therapy, diffuse histiolymphocytic inftltrates and dermal 
hemorraghes were eliminated within approximately three days. A slight focal 
infiltrate of mainly lymphocytes remained (Table 3, Fig. 3c,d). When (focal) epidermolysis 
had occurred, complete re-epithelization developed within five days. Only after the second 
rejection episode, parts of the skin of the thumb of monkey #3439 became necrotic. The 
thenar muscle was still vital and skin defects healed within the next 14 days. 
Table 3. Histological observations during anti-rejection treatment with high-dose steroids or a 
combination of monoclonal antibodies in rhesus monkey allogeneic partial hand recipients". 
Anti-
rejection day day day day Reversal of 
therapy Monkey -210" 114 519 10115 rejection 
Steroids 2596 D++ D+++ D+++,C.G.R. 
21 D+l++ D++ F+ +I++ +d N.A.d 
IFU D+f++ D+l++ D+++ C.G.R. 
1550 F++l+++ D+++ D+++ C.G.R. 
3212 D++l+++ D+++ D+++ C.G.R. 
MAbs 2799' D++/+++d N.A.' 
2988 D+l- D+ D+++,C.G.R. 
3992' D+l++ D++ D+++,C.G.R. 
······························································································································ 
4023btepio<:doo D+f++ D+l++ F+ F+l++ 
343913'~ D++f+++ D++l+++ (n) F+ 
4023""- F-D+I+ + F+l++ F-D+ F-D+ 
3439""- D+ F++ F+ F+l++ 
"Severeness of rejection was scored semiquantitatively (Materials & methods); F =focal, 
D =diffuse, n = nonnal, C. G .R. =complete graft rejection. 
bDay 0 = day of start of anti-rejection therapy 
'Monkeys #2799 and #3992 received one and four doses ofMAb therapy, respectively 
dDue to death of the monkey reversal of graft rejection was not assessable (N .A.) 
<This time reversal of rejection was partial: a part of the volar side of the thumb was rejected 
+ 
+ 
+ 
+" 
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B.3.5 Immunohistology 
During an~-rejection treatment with a raise in steroids, changes in relative numbers of 
CD2+, CD4+ and CD8+ lymphocytes did not correlate significantly with parameters 
associated with clinical rejection. Succesful MAb anti-rejection therapy caused coating of 
graft infiltrated lymphocytes, histiocytes as well as dermal and epidermal cells (Fig. 3a,b). 
This coating lasted from the first to approximately the sixth day after onset of MAb therapy. 
Moreover, successful MAbs therapy eliminated the majority of the rejection infiltrate which 
was predominantly composed of CD2 +CD8 + lymphocytes. 
Until the next rejection episode, numbers of infiltrated cells remained low, mainly located 
perivascularly (Fig. 3c,d). In those monkeys where the MAb therapy could not reverse 
allograft rejection, coating and elimination all lasted shorter. Altough lymphocytes were first 
eliminated vigorously, they returned in pretreatment ratios and numbers within four to six 
days, whereas if anti-rejection therapy was successful this would last ten to 28 days. It was 
further noted that HLA class I and II-DR antigen expression was increased during rejection 
on all cells in the allograft. If rejection could be reversed, MHC class II-DR expression was 
reduced vigourously while MHC class I antigen expression was also reduced but to a lesser 
degree. 
B.3.6 Complications of the immunosuppressive therapy 
Major side effects of the immunosuppressive therapy concerned the death of seven 
monkeys of which one died due to shock, three died due to lymphoid tumor development and 
three due to opportunistic bacterial infections. Further analysis of what factors might have 
influenced this high rate of death are presented elsewhere". 
B.4 Discussion 
Technically, transplantation of the (partial) hand in the nonhuman primate can be realized 
and functional recovery can be obtained11 '12'""bm. However, before such ·an operation can be 
performed in the human being, many problems should be solved first. Most importantly, 
long term uneventful graft survival can still not be realized. This study focussed on the 
general, intravascular and intra-transplant effects of some of the most potent 
immunosuppressants available today in a partial hand transplantation model in the rhesus 
monkey. 
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Figure 3a. Negative control section for immunohistology from the transplant of monkey #4023, 61 
days postoperatively, during standard CyA and DAF therapy. Primary antibody was omitted in the 
staining procedure. Neither cellular infiltrates nor pre-existing tissue is positively stained 
Figure 3b. Negative control section for immunohistology from the transplant of monkey #4023, 65 
days postoperatively, three days after onset of MAbs anti-rejection therapy. Intravascularly, 
agglutination of coated lymphocytes is visible (closed arrows). Also, extravacular lymphocytes are 
coated by the injected antibodies. Even, cells in the epidermis are coated (open arrows). 
Various recent studies in nonhuman primates stressed the inevitability to use continuous 
high doses of CyA (20-48 mg/kg/day) to obtain prolonged allograft survival of CTAs11•12.28 • 
In the present study, 25 mg/kg/day CyA in combination with a maintenance dose of steroids 
was used, yielding allograft survival times ranging between 21 and 179 days. Based on 
survival times of fully mismatched skin grafts in the rhesus monkey, it can be assumed that 
without this base line immunosuppression allografts would have been rejected within 7 to 10 
daysl3,33. 
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Figure 3c. A biopsy from the transplant of monkey #3439, 71 days after operation at the time of 
onset of rejection, histochemically stained with anti-CD8 MAb. The majority of the rejection 
infiltrate is composed of CD8+ T-cells. Also lymphocytes infiltrated into the epidermis are of the 
CDS phenotype (arrow). 
Figure 3d. A transplant biospy from the same monkey, 11 days later, seven days after onset of MAb 
anti-rejection therapy and stained with the same MAb, shows that the majority of the rejection 
infiltrate has been eliminated. Only perivascularly, a few CD8 + lymphocytes are still present 
(arrow, in all cases magnification: 300x). 
The absence of a protective effect of third party blood transfusions on CTA survival, 
could be due to the usage of high doses of CyA and DAF masking the expected effect. 
Alternatively, the difference in antigenicity of a CT A including skin compared to a kidney or 
heart allograft might have impaired an anticipated transfusion effecf4. 
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Anti-rejection therapy with a combination ofMAbs, specific for CD3+, CD4+, CD8+ 
and MHC class II-positive cells, was demonstrated to prolong CTA survival significantly 
longer than conventional anti-rejection therapy by a raise in steroids. These results confirm 
other clinical kidney and liver transplantation studies in which the MAb OKT3 (CD3-
specific) was more effective in reversing graft rejection than anti-rejection therapy with 
steroids35 • Furthermore, also in two monkeys a second rejection episode could be reversed 
successfully, using the same combination of MAbs. Most likely this was achievable due to 
the fact that, in this study, no neutralizing monkey-anti-mouse antibodies were formed in any 
of the monkeys in which CyA and DAF therapy was continued during and after reversal of 
allograft rejection. Without CyA and DAF, the same MAbs used in a skin transplantation 
study, did induce an antibody response detectable from the 7th day after the first injection 
onwards13 • 
Baseline therapy with CyA and DAF nor anti-rejection therapy with steroids induced 
significant fluctuations in the relative and absolute number of leucocytes and PBLs. MAbs 
anti-rejection therapy, however, did induce leucopenia as well as lymphopenia in a similar 
degree as was found in previous skin transplantation studies"·". Most likely, due to the 
absence of an antibody response, elimination of T cells and coating of all remaining cells 
lasted 10 to 20 days longer and subsequent modulation of the CD3 antigens occurred later 
than in previous studies13•37 • 
Coating of cells within the allograft lasted for three to six days which is about 14 to 16 
days shorter than the observed coating of PBLs. At this time, serum levels of injected MAbs 
fluctuated between four and 45 ng/ml. Apparently, once the majority of the rejection 
infiltrate was eliminated within approximately three days, diffusion of the circulating MAbs 
into the allograft became more difficult. This could have been due to a decrease in vascular 
permeability. This would correlate well with the observation that edema minimalized 
simultaneously. 
Elimination ofthe CD2+CD8+ lymphocyte subset from the allograft as well as from the 
peripheral blood, correlated best with reversal of rejection and thus with prolongation of 
allograft survival times. It therefore, seems likely that CDS+ T cells play a major role in the 
process leading to graft destruction of a fully mismatched CTA in the rhesus monkey. 
Nevertheless, anti-CD8 as well as anti-CD4 MAbs are both known to prolong skin allograft 
survival"·" implying involvement of both CD4+ and CD8+ cells in the procesess rejection. 
Possibly, it is a matter of preference of the host to reject fully mismatched CTAs by a cell 
mediated cytotoxicity dominated by CD8+ cells, despite alternatives". 
When MAbs therapy reversed rejection, MHC antigen expression in the allograft was 
reduced or even completely disappeared. The elimination of the rejection infiltrate, that 
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tended to occur slightly ahead MHC antigen decrease, may have abrogated locallymphokine 
production, hindering the upregulation of MHC antigen expression and associated 
allogeneicity of the graft. These findings are in line with previous data on MHC antigen 
modulation during acute rejection of skin"' and liver allografts". 
As seven monkeys died during experiment, one might assume that the immunosuppressive 
treatment was too aggressive32 • However, addition ofMAbs anti-rejection therapy to baseline 
immunosuppression did not correlate to incidence of death, significantlf2 • Similar doses of 
CyA and DAF were administered for periods over one year in baboons and no such side 
effects were reported11 '12 • Momentarily, it is under investigation whether inflicted case 
histories of the monkeys involved, might have precipitated the (earlier?) occurrence of the 
side effects. 
In conclusion, technical feasibility and the fact that recovery of function can be achieved, 
bring transplantation of the hand for reconstruction of upper extremity deformities, closer to 
reality. But at the same time, even continuous high doses of the most potent 
imrnunosuppressiva available today can not guarantee uneventful graft survival. 
Promisingly, MAb therapy could reverse rejection and prolonged allograft survival times 
significantly in fully mismatched donor/recipient combinations in the rhesus monkey. Graft 
reversal was associated with a dramatic elimination of CD2+,CD3+ and CD8+ 
lymphocytes in the peripheral blood as well as in the allograft itself. However, before actual 
transplantation of the hand can be performed in the human being, to our opinion a more 
adequate, less toxic immunosuppressive regimen should become available first. 
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C.l Introduction 
Surgeons are often confronted by their inability to replant a severed crushed hand. 
Allogeneic hand transplantation could provide a solution for such a case. This procedure 
would, however, only be indicated, if uneventful long term graft survival and functional 
recovery could be achieved. Experimental studies of composite tissue allografts should 
therefore be performed in which functional recovery could be tested thoroughly. 
Following limb transplantation in rats, sciatic nerve stimulation proximal and distal to the 
nerve repair showed contraction of the soleus and gastrocnemius muscles 1'2 • More recently, 
sensory and motor recovery has been demonstrated in allogeneic hand transplants in 
baboons3• 4 • Electrophysiological tests in those studies revealed sensory reinnervation of 
transplanted skin as well as reinnervation of donor muscle following electrical stimulation of 
the recipients median and ulnar nerves· 6 • However their animals were not conscious during 
sensory reinnervation testing and there was no longitudinal evaluation of functional 
recovery. 
Technical feasibility of allogeneic transplantation of the radial side of the hand in the 
rhesus monkey has been previously demonstrate(F. In this study, data are presented 
regarding longitudinal studies of sensory and motor reinnervation of the composite tissue 
allograft. 
C.2 Material and Methods 
C.2.1 Animals 
Rhesus monkeys (Macaca Mulatta) were born and raised at the TNO Primate Center, 
Rijswijk, the Netherlands, employing a "harem-type" breeding system. Average weight was 
7.5 kg, age varied from nine to 24 years and male to female ratio was two to one. The 
animals were selected on absence of prior alloimmunization, on normal kidney and liver 
function and non-injured, relatively large hands. If possible left or right handedness was 
assessed. 
Animal care complied with the "Principles of Laboratory Animal Care" and the "Guide for 
the care and use oflaboratory animals" (NIH publication no. 80-23, revised 1978). 
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Figure Sa. H&A stained section of the thenar of the allograft of monkey 4023, 114 days 
postoperatively, three days after the onset of the second anti-rejection therapy. Vital foreign Pacinian 
corpuscles are still present (magnification 300x). Figure Sb. Enzymhistochemical staining for 
acetylcholine-esterase activity demonstrating the distribution of vital motor end plates over the 
muscle of monkey BM in the unoperated thenar muscle. The black lining on the surface of the muscle 
cells (see arrows) indicates the positively stained motor end plates (magnification 300x). Figure Sc. 
With the same technique as in Sb, the thenar muscle of monkey BM, 18 months after autologous 
replantation shows a comparable staining pattern on the majority of its muscle cells (arrows, 
magnification 300x). Figure Sd. With the same technique as in Sb, the thenar muscle of monkey 
3310, 85 days after allogeneic transplantation also clearly shows positive motor end plates (closed 
arrows). Some rejection infiltrate is present (open arrow; magnification 300x). 
C.2.2 Experimental model 
The transplant consisted of the first ray of the hand (the thumb) enlarged with a radial 
forearm flap and thus involved bone, muscles, vessels, nerves and skin. 
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Following amputation at the donor site all 
structures were reanastomozed to corres-
ponding structures at the recipient site of 
another animal (figure Ia). Detailed infor-
mation about the transplantation technique 
has been previously described'. Recovery 
of function of the transplant was evaluated 
in three adult monkeys following autolo-
gous replantation and in twelve adult 
rhesus monkeys following allogeneic trans-
plantation. Autologous replantations had 
been carried out to demonstrate the feasi-
bility of the research model (submitted). 
The functional recovery of these three 
monkeys was also used as a control for the 
twelve transplantation cases. 
For evaluation of sensory recovery, only 
the median nerve distribution area was con-
sidered, as it showed the most consistent 
anatomy at the level of the junction of the 
sensory and motor branch to the thumb. A 
nerve anastomosis in this area proved to be 
very reliable, enabling good comparison of 
reinnervation between the different 
monkeys. The proximal part of the radial 
forearm flap is mainly innervated by the 
lateral antebrachial cutaneous nerve. This 
nerve was ·not rea.nastomozed, the corres-
ponding skin area served as a control. For 
evaluation of motor recovery the thenar 
muscle action was investigated. Although 
handedness in macaques is not as clear as 
in chimpanzees and man8• 9' 10 , the dominant 
hand was determined preoperatively by 
assessing which hand was mostly used by 
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Figure la. Research model. The dotted line marks 
the radial side of the hand with the radial forearm 
flap. Nerves: U.n. =ulnar nerve; M.n. =median 
nerve; S.R.n. = superficial radial nerve. 
Figure lb. Sensory recovery was assessed by 
means of a small electric current applied locally to 
the skin of the conscious monkey to provoke a 
withdrawal reflex. The measuring sites were 5 mm 
apart along the indicated thick black lines on the 
model. The skin areas corresponding to the 
appropriate nerves are marked. M.n. = median 
nerve; S.R.n. = superficial radial nerve; L.a.c. = 
lateral antebrachial cutaneous nerve. 
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the monkey to retrieve food offered from different directions. To stimulate functional 
recovery, the hand of preference was operated upon. 
The experi11_1ent was terminated when there was complete rejection of the transplant or 
death of the monkey. 
C. 2.3 Immunosuppression 
Basic immunosuppression consisted of continuous high doses of Cyclosporin A (CyA, 25 
mg/kg/d) in combination with an initial high dosage of prednisone (DiAdreson Faquosum 
(DAF), 12 mg/kg/d), which was decreased stepwise to a maintenance dosage of 1 mg/kg/d in 
twelve days. Swelling, erythema and blister formation were considered to be macroscopical 
signs of rejection. After histological confirmation (oedema, epidermolysis, dermal 
hemorrhage and lymphohistiocytic infiltrate) anti-rejection therapy was started. In half of the 
animals, anti-rejection therapy consisted of a 10 day course of a combination of monoclonal 
antibodies specific for different immunocompetent cells11 ' 12 • In the other half, rejection was 
treated by increasing the DAF dosage to 12 mg/kg/d, again followed by a decrease to 
maintenance doses as described above. 
C. 2. 4 Assessment of sensory recovery 
To evaluate the ingrowth of sensory nerves, the sensitivity to electrical stimulation of the 
skin was assessed weekly, starting from the first week postoperatively. In order to provoke a 
withdrawal reflex, a small electric current was applied locally to the skin of a conscious 
monkey, which had been fixed in a specially designed chair (Restraint Chair', Primate 
Products, CA, USA). A bipolar 50 Hz (sinusoidal) current source stimulator was used, 
delivering currents between 0.14 and 1.8 milliAmpere. The stimulation electrode consisted 
of two metal bars, each 1 mm in diameter and with a separation of 1.5 mm. The electrode 
was placed on the skin, at stimulation sites along three lines covering the transplant from 
distal to proximal (figure !b). The contralateral side was used as a control. Stimulation sites 
were separated 0.5 em along these lines. A continuous current of 1.8 milliAmpere 
(approximately 1.5 times the threshold for a withdrawal reflex at the contralateral hand) was 
delivered. The skin of the transplant was divided into distribution areas based on general 
human and rhesus monkey anatomical knowledge, in order to provide landmarks for 
consistent stimulation. The number of sites (range 30-40, depending on the size of the 
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replant) with positive withdrawal reactions related to the total number of measuring sites, 
provided the percentage of reinnervation. 
C.2.5 Assessment ojmotor recovery 
Motor reinnervation was evaluated by detection of Compound Motor Action Potentials 
(CMAP) of the thenar muscles after signal amplification with an electromyograph (MedelecR, 
PN6). Signals were photographed from an oscilloscope. Under Ketamin (Fetelar') anesthesia 
the median nerve was stimulated supramaximally, transcutaneously and proximal to the 
anastomosis, at elbow and wrist. Surface electrodes were placed over the belly of the 
abductor pollicis brevis muscle. At the same time a sensory potential was determined from 
the fifth finger to rule out inadvertent stimulation of the ulnar nerve. Latency (in a 
temperature controlled environment) and amplitude of CMAP of the thenar muscle in the 
transplanted- and contra-lateral side were compared weekly. Latency of CMAP was 
measured in milliseconds from stimululus artefact to the peak of the negative deflection. 
Amplitude of CMAP was measured in millivolts from the peak of the negative deflection to 
the baseline. 
Sensory and motor reinnervation in the three replantation cases was evaluated monthly 
starting one year postoperatively. The twelve transplantation cases were evaluated weekly 
starting immediately postoperatively. 
C.2.6 Histology 
To examine nerve ingrowth, and thenar muscle reinnervation, the composite tissue grafts 
of three monkeys (two allografts and one autograft) were analyzed immunohistochemically. 
The opponens pollicis and the abductor pollicis brevis muscle in the thenar eminence of the 
operated as well as the contralateral hand were removed from origin to insertion and 
snapfrozen in liquid nitrogen chilled isopenthane. The presence and distribution of nerve 
bundles and functional motor end plates over the muscle were inspected microscopically. 
The detection of vital motor end plates was assessed using the histochemical method 
described by Karnovsky and Roots". To detect the presence of axons within morphologically 
visible nerves, immunohistochemical staining with the monoclonal antibody 2Fll" specific 
for neurofilaments was carried out, on formalin fixed paraffin embedded tissue. 
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C. 2. 7 FunctioiUll tasks 
Video recordings of the operated hand of transplanted monkey no. 3439, and all replant 
cases, were made to evaluate overall function, whilst the animals were handling small 
particles of food. 
C.3 
C.3.1 
Results 
Graft survival 
The three autologous replantations had complication free graft survival. The twelve 
successfully transplanted allografts had survival times that were short in six monkeys (21-33 
days) and long in the other six (79-179 days). Ten out of twelve transplantations showed 
graft rejection. If macroscopical signs of rejection were observed, histological data were 
confirmative and revealed oedema, epidermolysis, dermal hemorrhage and lymphohistiocytic 
infiltrate. In five monkeys graft rejection was treated with the combination of monoclonal 
antibodies". In two monkeys (4023 and 3439) rejection could be reversed successfully, in 
both monkeys on two occasions. In five other monkeys where graft rejection was treated 
with an increase in steroid dosage, reversal of rejection did not occur. The remaining two 
monkeys (3310 and 3308) had to be euthanized before rejection occurred, at 85 and 179 days 
postoperatively. 
Other complications such as organ failure, lymphoid tumour development and death of the 
monkey are described elsewhere15 • 
C.3.2 Sensory recovery 
In the three monkeys in which an autologous replantation was performed, the percentage 
of positive withdrawal reactions of the median and superficial radial nerve skin area was 
96%, when tested 2 years postoperatively. 
In the allogeneic situation, six out of twelve allografts showed rejection before the return 
of sensibility could be demonstrated. The first signs of sensory recovery in the other six 
monkeys appeared after a mean of 41,8 days postoperatively (range 27-64 days; see table 1). 
The first positive withdrawal reaction occurred in the median nerve area in five monkeys, at 
the volar side of the thumb, just distal to the metacarpophalangeal joint, and in one monkey 
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at the level of the wrist. The percentage of median 
nerve reinnervation increased in time. The maximal 
sensory median nerve reinnervation for the six 
monkeys was 100, 91, 84, 80, 75 and 14% respec-
tively (figure 2). In the monkeys with rejection of 
the transplant, longitudinal evaluation showed an 
immediate decrease in sensory recovery in monkey 
4023 from day 55-62 and from day 104 onwards, in 
monkey 3439 from day 64 and in monkey 3992 
from day 135. Rejection reversal showed a resto-
ration of sensory recovery within a week in monkey 
4023. In monkey 3439 the first sign of sensory 
recovery was demonstrated 10 days after reversal of 
a rejection episode (figure 2, table 1). 
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Table 1. First signs of functional 
recovery after transplantation. 
Monkey Motor Sensory 
3308 42 
3310 56 
3439 46 
4023 31 
3992 <72' 
2799 <79' 
&£irst measurement with EMG 
brejection episode at day 41 
-,. Rejection 
64 
29 
56' 
41 
34 
27 
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Figure. 2. Sensory reinnervation of the median nerve following radial hand transplantation in the 
rhesus monkey. 
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Figure 3a. The amplitude of the compound motor action potentials of the thenar muscles following 
stimulation of the median nerve at the elbow. 
A comparison of the transplanted side to the contralateral side in monkey 3308. 
Figure 3b. The distal thenar muscle latency time following stimulation of the median nerve at the 
elbow. A comparison of the transplanted side to the contralateral side in monkey 3308. 
C.3.3 Motor recovery 
In all long term survivors CMAP' s could be measured. In four monkeys with an allograft, 
the first sign of motor recovery of the transplant could be detected after a mean of 43.8 days 
(range: 31-56 days). In two allograft recipients (2799 and 3992) for logistic reasons the 
electromyograph was first used at 72 and 79 days after transplantation respectively. At that 
time CMAP's of the thenar muscles of the allograft were present, so in these two monkeys 
the onset of motor recovery could not be established (see table I). 
Amplitudes of CMAP's increased in time. The ratio of amplitudes of CMAP's of the 
thenar muscles in the three replanted monkeys was 88%, when compared to the amplitudes 
of CMAP' s of the contralateral side one and a half year postoperatively. In two rejection free 
monkeys (3308 and 3310) evaluation of the amplitudes showed a similar pattern, following 
stimulation at the elbow as well as after stimulation at the wrist (figure 3a, monkey 3308). If 
rejection occurred, amplitudes of the CMAP's decreased. In monkey 3992, the amplitude of 
the CMAP decreased from 1.6 mV on day 128 to 0.9 mV on day 138 (a fall of 44%), while 
anti-rejection therapy was started on day 139 following transplantation. 
182 --------------------------------------- Chapter III; study C -----------------------------------
10 Normal > 
E 5 
0.. 
<t 0 a 
:2 
' 
u Stim. 
-5 
10 
> 
Replant 
E 5 
a.. b <t 0 :2 
'--s u 
-5 t1m. 
10 Transplant 
> 
..s 5 
a.. 
<t 0 
:2 
' 
c u Stim. 
-5 
0 3 6 9 12 15 18 
Time lms) 
Figure 4a. CMAP (Compound Motor Action Potential) of the thenar muscles of the normal 
contralateral radial side of the hand of monkey TP. Figure 4b. CMAP of the thenar muscles of the 
replanted radial side of the hand of monkey TP. Figure 4c. CMAP of the thenar muscles of the 
allogeneic transplanted radial side of the hand of monkey 4023, recorded during the second rejection 
episode at day 121 postoperatively in a terminal experiment. All CMAP's of the thenar muscles are 
evoked by stimulation of the surgically exposed median nerve in the forearm at equal distances. 
The amplitudes are comparable in all CMAP"s. The onset of the CMAP"s is comparable in (4a) and 
(4b). There is clearly delayed conduction indicating incomplete maturation in the median nerve of the 
transplant during the second rejection period (4c). 
In monkey 4023, the amplitude decreased from 0,5 mV to 0,28 mV on day 83 (a fall of 
44%), while anti-rejection therapy had started on day 62. After reversal of rejection, in this 
monkey the amplitude increased again to 0,5 mV on day 104, to decrease again to 0,4 mV (a 
fall of 20%) while the second anti-rejection therapy had started on day 111 after 
transplantation. 
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The ratio of the latency of CMAP of the thenar muscles in the three replanted monkeys 
was 93%, when compared to the contralateral side one and a half year postoperatively. 
Latency time of CMAP decreased in relation to the time following transplantation (figure 
3b, monkey 3308). 
In a terminal experiment in the allograft recipient 4023 and in one replant, the median nerve 
was dissected and stimulated directly at the perineurium. During this assessment a CMAP of 
the thenar muscles could be recorded (figure 4). 
C.3.4 Histology 
The histological data confirmed actual thenar muscle re-innervation. Host nerve fibers 
clearly penetrated into both the auto- and allografts. Acetylcholine-esterase activity as 
evidence of vital motor end plates could be demonstrated in the thenar muscles of the 
investigated monkeys (figure 5). 
Furthermore the presence of axons, more specifically neurofilaments, were demonstrated 
in the transplant, using immunohistochemical methods14 • 
C.3.5 Function tasks 
Videorecordings showed that in the replants as well as in the long term allograft recipients 
small particles of food could be picked up between thumb and index finger. 
C.4 Discussion 
In the present study functional recovery following allogeneic transplantation of the radial 
side of the hand was evaluated in twelve rhesus monkeys and in three monkeys following 
autologous replantation as controls. With regard to the allogeneic transplants, longitudinal 
follow-up assessed in conscious monkeys demonstrated sensory reinnervation in six 
monkeys. In the other six, early rejection made it impossible to test the return of sensation. 
The initial return of sensory reinnervation in the skin area corresponding to the median nerve 
occured at a mean of 41,8 days postoperatively (range : 27-64 days). If rejection occurred, 
an instant decrease was induced in the area in which a withdrawal reflex could be provoked. 
This is probably due to the fact that the first and primary target of the host immune response 
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against allogeneic composite tissue containing skin, appears to be the derma-epidermal 
junction in which the sensory receptors are localized3' s, 6 • In the two cases where rejection 
could be reversed successfully with the monoclonal antibody therapy (figure 2, monkeys 
4023 and 3439), the reduction or initial absence of sensory reinnervation was reversible. A 
subsequent reduction in reinnervation after a second episode of rejection in these monkeys 
prevented development of a recovery pattern comparable to that of the other monkeys with 
sensory reinnervation. This could imply that multiple rejection episodes impair complete 
sensory reinnervation, and confirm data presented by Samulack et al6 • 
The order of sensory recovery in replanted digits is pressure, touch, pain, cold, warmth 
and perspiration". Application of a small electrical current to the skin of the transplant 
mainly invokes pain sensation and probably some elements of pressure and touch sensation. 
Therefore the onset of sensory reinnervation is likely to be not the first sign of actual sensory 
reinnervation. The ingrowth of host axons into the allogeneic transplant, even under 
agressive immunosuppression reappeared with a mean of 42 days, over a distance of about 4 
centimeters (anastomosis to tip of the thumb). In comparison the mean time of reappearance 
of sensation in clinically replanted digits following quillotine amputation at the proximal 
phalanx was 44 days". Although the recovery times in allogeneic transplants and clinically 
replanted digits cannot be strictly compared it does give one an idea of the speed of recovery. 
Longitudinal follow up demonstrated motor reinnervation in six monkeys with allogeneic 
transplants of the radial side of the hand, in the other six monkeys, early rejection prevented 
return of motor function. Initial return of thenar muscle reinnervation occurred after a mean 
of 43,8 days (range 31-56 days) postoperatively, measured by electromyography. Stark et al' 
reported active movement of the thumb 21 weeks and of the long fingers 22 weeks after 
operation. In our study after removal of the splint, movement of the thumb could be 
demonstrated in all six monkeys with long term graft survival, during tasks where food 
manipulation had to be carried out. However it could not be differentiated whether this 
thumb movement was mediated with or without assistance from thenar muscles. Dynamic 
electromyography during functional tasks could possibly solve this question'". 
The amplitude of the CMAP evoked in the allogeneic thenar muscles was decreased 
compared to the contralateral CMAP. The amplitude increased in time, postoperatively. This 
is in concordance with other studies concerning electrophysiological evaluation of muscle 
reinnervation after a nerve (crush)lesion 19' 20' 21 • The increase in amplitude in relation to 
postoperative time was possibly related to an increase in the number of regenerated axons 
and reinnervated muscle fibers. An increase in amplitude is proportional to the increase in 
the number of muscle fibers in the motor unit22' 23 • 
The decrease of the amplitude of CMAP in the monkeys who showed rejection, suggests a 
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negative influence of rejection on the quality of motor recovery, especially monkey 4023 
which showed a decrease in amplitude of CMAP at the time of the first rejection episode. 
The amplitude increased to original values again, following reversal of rejection, and before 
the second episode of rejection started. Further investigation will be needed to determine the 
influence of rejection on motor recovery of allografted muscles. 
Gulati and Zalewski also, histologically demonstrated the presence of neuromuscular 
function in rat muscle allografts24 • Immunohistochemical staining of sections of autologous 
and allogeneic grafts in our study yielded additional evidence for actual thenar muscle re-
innervation. Vital motor-end plates could be demonstrated in the thenar muscles investigated 
(figure 5). Further evidence was retrieved from a terminal experiment in monkey (4023) 
where direct stimulation of the perineurium of the median nerve in the forearm produced 
CMAP at the heterologous thenar muscles (figure 4). These data are consistent with other 
primate studieS4' 5 • 
For the first time a longitudinal follow up of functional recovery following composite 
tissue allogeneic transplantation is presented. Clearly, there is substantial evidence of 
sensory and motor reinnervation of the allogeneic transplant by means of sensory 
measurements, electromyography (transcutaneously and intraoperatively), (immuno-
)histology and the ability to perform specific motor tasks. It has to be taken into account, 
however, that improvement of motor and sensory function after nerve lesions or digital 
replantation may take years. Therefore, it can be expected that complication-free allograft 
survival for several years will allow an even better level of functional repair. 
The complications which occurred in the monkeys due to the immunosuppressive regime 
varied from subclinical organ failure to lymphoid tumour development and death in seven 
out of twelve monkeys (submitted). Therefore significant immunological advancements will 
have to be made before heterologous transplantation of the upper extremity can be cartied 
out in man. Further research will have to be done in the field of more specific and less toxic 
immunosuppressive agents. 
Nevertheless it can be concluded that target tissues in composite allografts in non-human 
primates appeared to be re-innervated by host axons. The results for sensory and motor 
recovery, following allogeneic transplantation of the radial side of the hand, are from this 
point of view promising. 
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D.l Introduction 
Allotransplantation of a donor hand to a patient, lacking one or both hands due to trauma 
or congenital malformation, seems to become a more realistic alternative than it ever has 
been. Already, preclinical studies in nonhuman primates have been performed demonstrating 
the technical feasibility of transplantation of such a composite tissue allograft (CTAr. 
Moreover, promising results were obtained with regard to sensory and motor function 
recovery of the CTA5-7 • Reversal of rejection, even enabled renewed sensory reinnervation of 
CTAs within two weeks after onset of successful anti-rejection therapy with monoclonal 
antibodies (MAbs)'. However, the limiting factor that impasses reluctance upon actual hand 
transplantation in man, is the fact that the present immunosuppressive therapy can not ensure 
long-term complication free CTA survival. In previous studies in baboons, rejection 
occurred in three out of four' and six out of six' successfully transplantated allogeneic hands. 
In the latter study, one monkey died due to anesthesiological problems. Previously, we 
reported that ten out of 12 successfully transplanted allogeneic hands in the rhesus monkeys 
developed a rejection episode of their CTA'"·'. Furthermore, seven out of 12 monkeys died 
during experiment. 
This study focussed on the relation between the immunological aspects of allogeneic 
partial hand transplantation in the rhesus monkey, the case history of the monkeys involved 
and the complications encountered. 
D.2 Materials and methods 
D.2.1 Experimental model 
In a preclinical model, transplantation of the partial hand was performed in adult rhesus 
monkeys (Macaca mulatta), as there is a close phylogenetic, anatomical, functional and 
immunological relationship between these monkeys and humans. CTA recipients were not 
alloimmunized prior to these experiments. However, in previous experiments three CTA 
recipients had donated a kindney and five monkeys had undergone experimental radiation of 
the testis as part of a previous unrelated procedure. Four monkeys had positive titers for 
Simian T -leukemia virus (STL V, Table I). Another three monkeys became STL V-
seropositive after blood transfusions or CTA acceptance from STLV positive donors. 
Twelve technically successful allogeneic transplantations of the partial hand were 
performed in unrelated donor-recipient combinations, mismatched for rhesus major 
histocompatibility (RhLA) -A, -B and -DR antigens. The transplant consisted of the first ray 
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of the hand (the thumb) enlarged with a radial forearm flap of approximately 20 em'. 
Surgical aspects have been decribed previously3•4 • 
D.2.2 Immunosuppressive treatment 
Baseline immunosuppressive treatment incorporated daily subcutaneous administeration of 
25 mg/kg Cyclosporine A (CyA) dissolved in Miglyol-812, starting one day before 
operation. Additionaly, an initial high dose ofDAF (12 mg/kg/day) was administered for the 
first three postoperative days and tapered slowly until a maintenance dose of I mg/kg/day 
was reached after 12 days. If rejection was observed macroscopically (swelling, erythema, 
blister formation) and could be confirmed histologically (edema, hemorraghes, 
epidermiolysis, lymphohistiocytic infiltrates), then half of the group was treated by returning 
to the high dose (12 mg/kg/d) of DAF. Tapering of the DAF dose was done as described 
before. In the other half of the partial hand recipients, rejection was treated with a 
combination of MAbs, consisting of seven MAbs specific for CD3 +, CD4 + CDS+ and 
MHC class II-DR positive cells as described previously'·'. All MAbs used in this study were 
crossreactive with rhesus lymphocytes, and were administered as an intravenous (iv) bolus 
injection for a period of ten days. Moreover, in this combination the cocktail of MAbs was 
capable to prolong skin allograft survival significantly to !9.3 (SD=l.8) days compared 
to a control group of 8.3 (SD=O. 7) days'. 
Additionaly, the effect of preoperative third party blood transfusions was tested. Three 
blood transfusions, consisting of 20 ml of fresh whole citrated blood from donors that were 
fully mismatched with graft donors as well as graft recipients, were given at biweekly 
intervals before transplantation. The last transfusion was given 2 weeks before 
transplantation. 
D.2.3 Monitoring and statistical analysis 
CyA whole blood trough levels were measured with a specific radioimmunoassay 
(Sandimmun-Kit; Sandoz Ltd., Basle, Switzerland). 
In the event of high morbidity or death, an complete autopsy was performed. 
When appropriate, Fisher's exact-test, two sample t-test, single regression analysis and 
log-rank test were performed for hypothesis testing. Differences were considered significant 
ifP<0.05. 
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D.3 Results and discussion 
Transplantation of the (partial) hand in the nonhuman primate is technically feasibleH and 
results for functional recovery are promising5-7 • In humans, however, such an operation can 
only be performed after many problems are solved first. Also ethical aspects require 
thorough attention. Most importantly, long term uneventful survival of a functional graft 
ought to be achievable. 
Rejection of a CTA still is a major problem in the nonhuman primate. Various studies 
performed recently in this species, stressed the inevitablilty to use continuous high doses of 
CyA (20-48 mg/kg/day) to ensure long term allograft survival ofCTAs'·'·". However, in the 
baboon, using 20 mg/kg/day CyA and a maintenance dose of steroids, rejection occurred in 
three out of four' and six out of six' successfully transplantated allogeneic hands. Anti-
rejection treatment with steroids could reverse one out of three and one out of six rejection 
episodes, respectively. In our study in the rhesus monkey, using 25 mg/kg/day CyA and a 
maintenance dose of steroids, ten out of 12 successfully transplanted allogeneic hands in the 
rhesus monkeys developed a rejection episode of their CTA. This happened, despite the fact 
that median CyA whole blood trough levels between day five and the day of onset of anti-
rejection therapy ranged from 420 to 1253 ng/ml. Even 92% of all samples after day five 
was above the minimal required dose of 400 ng/ml'. Increased steroid treatment could not 
reverse allograft rejection (Table 1). MAbs therapy, however, did reverse CTA rejection in 
two out of five monkeys, and in both monkeys also a second rejection episode could be 
reversed. The log-rank tests revealed that if rejection of a CTA was treated with MAbs 
therapy, allograft survival times could be prolonged significantly longer than if than 
rejection was treated with a raise in steroids (P=0.015). This is in agreement with other 
clincal studies in which the MAb OKT3 (CD3-specific) was more effective in reversing 
rejection of allogeneic kidney and liver transplant, respectively"·". Regarding these data, the 
minimal required CyA whole blood trough level to prevent CTA-rejection might even be 
higher than 400 ng/ml and anti-rejection therapy with immunosuppressive MAbs might, 
indeed, offer a better alternative for the treatment of rejection crises of CTAs, than 
increasing the steroid dose. 
However, directly related to administration of multiple potent immunosuppressive drugs 
for a longer period of time, the occurence of side effects is increased. In our study, minor 
side effects of long term immunosuppressive therapy were primarily limited to weight loss 
due to anorexia. In the CTA-recipients that had graft survival longer than 70 days, weight 
loss ranged from eight to 40% (average 22%) in relation to preoperative weight. 
Table 1. Allogeneic partial hand transplantation in the rhesus monkey; Case history, effects of Cyclosporine A, Prednisone and 
monoclonal antibodies on graft survival and encountered major complicationsc. 
Case history 
Kidney Testis a-STLV Rejection Graft survival Cause of 
Age donor radiation titer Monkey Protocol reversal times (days) death 
15' + + 2799 MAbs 79' shock 
6' + sc 4023 & + 
transf. +' 121' sepsis/PTLP-disorder development 
14' + sc 2988 22' PTLP-disorder 
................................ 
19 + + 3992 MAbs 144 
13' It 3439 + 
+b,d 97' PTLP-disorder 
13' + 3308 no rejection 179' PTLP-disorder 
•·••·······················••·•• 
15' + 2596 DAF 30 
13 + 21 & 29' sepsis 
14' + nt 3310 trans f. no rejection 85' sepsis 
................................ 
7 sc lFU DAF 33 
19' + 1550 33 
14' + 3212 21 
ajungle caught monkeys, approximately 2-5 years older than tabulated; ~>second rejection episode; cdeath, spontaneously or due to euthanasia; dreversal of 
rejection was partial: skin on the palmar side of the thumb and thenar was rejected. 
Abbreviations: STLV: Simian T Leukemia Virus; sc: seroconversion; MAbs: anti-rejection therapy consisted of a ten day course of a combination of seven 
monoclonal antibodies; transf.: three third party blood transfusions were given to the recipient, preoperatively; DAF: anti-rejection therapy implied a raise 
in steroids; It: low titer; nt: not tested; PTLP: posttransplantation lymphoproliferative (disorder). 
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During immunosuppressive treatment, levels of creatinine were elevated in five monkeys; 
levels of lactate dehydrogenase and aspartate transaminase were raised in three monkeys and 
in four other monkeys liver function parameters were elevated incidentally. Nevertheless, no 
severe nephro- and/or hepatotoxicity were observed. Using similar high doses of CyA and 
DAF, more severe kidney and liver damage may occur in the humans". Gingival 
hyperplasia, hypertrichosis and neurotoxicity have not been observed. 
Major side effects of the immunosuppressive therapy concerned the death of seven 
monkeys, during experiment (Table 1). One monkey died due to an irreversible shock 
directly after the first injection of MAbs. Anti-CD3 and anti-CD8 MAbs are known to, 
incidentally, induce shock-like side effects directly after administration. Most likely these 
effects are related to stimulation ofT cells to produce lymphokines and/or to the rapid cell 
clearance". Possibly, temporary addition of MAbs specific for lymphokines such as tumor 
necrosis factor-alpha, which is known for its important role during lymphokine-related 
shock", might reduce the threat of this particular side effect. Three monkeys died due to 
opportunistic bacterial infections, 29, 85 and 121 days after operation. Three others died 
from multiple organ failure, due to the presence of posttransplantation lymphoproliferative 
(PTLP)-disorders, 22, 97 and 179 days after transplantation. In a fourth monkey that died 
due to sepsis, also PTLP-disorder development was observed at autopsy. 
Overall, no correlation between CyA whole blood trough levels and occurrence of death 
either by sepsis or PTLP-disorder was present (t-test, P>0.05). Similar doses of CyA and 
DAF were administered for periods over one year in baboons and no such side effects were 
reported'·'. Addition ofMAbs anti-rejection therapy to baseline immunosuppression did not 
correlate significantly to occurrence of death (P > 0. 05, Fisher test). 
Though our population is small, an enhanced predisposition in the monkeys that received 
MAbs anti-rejection therapy is found to PTLP-disorder development (P=0.03, one-sided 
Fisher test). It might be a consequence of addition of a third potent immunosuppresive agent 
to baseline therapy". On the other hand, the used MAbs were specifically aimed at 
lymphocytes, which might have precipitated lymphoid lesions, rather than other 
malignancies. Alternatively, virus infections, notably Epstein-Barr" and HTLV-virus 
infections", have a possible etiologic link with the development of lymphoma. In some CTA 
recipients, serum antibody titers against STL V have been demonstrated (Table 1). However, 
no significant correlation occurred between the presence of anti-STL V titers and lymphoma 
development (P >0.05, Fisher test). 
Neither did other historic burdens like kidney donorship or testis radiation correlate to 
occurrence of death in general nor death by spesis or PTLP-disorders nor PTLP-disorder 
development (P > 0.05, Fisher test). 
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In conclusion, a more effective, less toxic immunosuppressive regimen is needed before 
actual allogeneic transplantation of the hand should be performed in human patients, though 
it was demonstrated previously that it is technically feasible and that results for functional 
recovery are promising. 
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E.l Introduction 
Various types of 1ymphoproliferative disorders have been described in human transplant 
patients following transplantation in the presence of Cyclosporine A (CyA) and Prednisone 
immunosuppression22'2'i,zs,:l4. A previous study noted a strong association of proliferative 
lymphoid1esions in transplant patients with Epstein-Barr virus (EBV) and a spectrum oflesions 
ranging from those of mononucleosis to malignant lymphoma10'12 • An additionally important 
virus for consideration is HTLV-1, the etiologic agent of an aggressive form of adult T-cell 
lymphoma, frequently described in southern Japan' and the Caribean"'. Lymphoma in man 
associated with HTLV -I commonly presents with cutaneous lesions, hypercalcemia and has a 
mature T-cell phenotype but variable morphologic appearance". The incidence oflymphoma 
in normal healthy individuals infected with HTLV-1 is low. Approximately Jess than 1% of 
HTLV -1 infected people are believed to develop cancer under normal conditions over an entire 
lifespan although the virus transforms cells in vitro'·". HTL V-I has also been demonstrated to 
transform monkey lymphocytes". In most primate species HTLV-Iike viruses, designated 
Simian T -cell leukemia viruses (STLV) occur with great frequency in large numbers of old 
world primates. Those strains which have been sequenced have been found to have more than 
90% sequence homology and have marked similarity in genomic structure and 
morphology7•13'24'35'37'38 • These viruses are very prevalent and occur naturally in a great number 
of primate species5'6'11'14'17'20'2u 9 • A spectrum oflymphoproliferativediseases have been described 
in a variety ofSTLV infected non-human primates1.16'23'26'27'36 • In captive colonies of non-human 
primates the seroprevalence can be greater than 30 percent11'17 • 
In this study in the Macaca mulatta the role of STLV during the development of post-
transplantation lymphoproliferative (PTLP) disorders was investigated. 
E.2 Materials and methods 
E.2.1 Clinical setup of the experiments 
Strong immunosuppressive therapy was instituted to prevent rejection of allografts in 12 
mature outbred rhesus monkeys (Macaca mulatta) having received a successfully transplanted 
allogeneic radial side of the hand"'. The immunosuppressive regime consisted of a daily 
maintenance dose of 25 mg/kg daily subcutaneous doses of CyA dissolved in Miglyol-812, 
starting one day preoperatively. An initial high dose of steroids (Di-Adreson-F,.,.= = DAF, 
12 mg/kg/day) was administered (im) for the first three postoperative days and tapered slowly 
until a maintenance dose of 1 mg/kg/day was reached after twelve days. 
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If rejection was observed macroscopically (swelling and erythema) and could be confirmed 
histologically, the animals were treated by increasing the immunosuppressive regime. Six 
animals were treated by an increase of the DAF dose to 12 mg/kg/day, followed by tapering of 
the DAF dose as described above. In the other six allograft recipients, rejection was treated 
with a combination ofMAbs, administered as an (iv) bolus injection for a period often days. 
This cocktail ofMAbs consisted ofB8.12 and 7.5.10.1 both specific for MHC class II-DR 
antigens, 1 mg/kg each; SEll and FN18, both CD3-specific; RIV6 and RIV7, both CD4-
specific; and FK18, specific for CDS+ cells, the latter 5 MAbs were given in a dose of0.5 
mg/kg". All MAbs used in this study were crossreactive with rhesus monkey lymphocytes. 
The therapeutic value of these rejection treatment protocols was tested, in combination with 
preoperative third party blood transfusions. Six animals received three third party blood 
transfusions, consisting of20 ml of fresh whole citrated blood from random donors, were given 
at biweekly intervals before transplantation. The last transfusion was given 2 weeks before 
transplantation. 
Following successful surgery, seven animals became terminally ill during the post-
transplantion period. They were euthanized and a complete autopsy was performed. Tissues 
were fixed in 10% neutral buffered formalin and examined by routine histochemistry. When 
possible fresh tissues including, lesions, draining lymph nodes and graft sites were quickly 
frozen in liquid nitrogen for further analysis. 
E. 2.2 Immunohistochemical characterization of PTLP-disorders 
The presence or absence of PTLP-disorders was confirmed histologically and classified 
morphologically according to the NCI working formulation. For this purpose, tissue sections 
harvested at autopsy were fixed in buffered formalin and processed routinely for histology on 
hematoxylin and azofloxine (H/A) stained sections. Parallel biopsy material was snap-frozen 
in liquid nitrogen chilled isopentane and used for immunohistochemical studies. Tissue bound 
primary antibody was reacted with horseradish peroxidase-coupled rabbit anti-mouse 
immunoglobulin (Dakopatts, Copenhagen, Denmark) diluted 1: 100 in PBS containing 5% heat-
inactivated normal rhesus serum and 5% normal rabbit serum. Conjugate binding was 
visualized with a solution of 0.5 mg/ml 3,3,-diaminobenzidine tetrahydrochloride (Fluka 
Chemika, FRG) and 0.03% H,O, in PBS. The following MAbs were used: Tll, specific for 
CD2 (Dakopatts, Glostrup, Denmark), OKT4 specific for CD4, (Ortho Diagnostic Systems, 
Raritan N.J.), FKlS specific for CDS, (Dr F. Koning, Bloodbank, University ofLeiden, The 
Netherlands), A-K specificfor k-lightchain, A-L specificforl\-lightchain, (Jonker M, Primate 
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Center-TNO, Rijswijk, The Netherlands) anti-MHC class II specific for MHC class II antigens 
(Becton Dickinson, Sunnyvale CA) and theMAb Ki67, (Dakopatts) specific for a proliferation 
associated nuclear antigen (Chapter II. study E). To control for possible background staining, 
incubations of primary antibody were omitted in control slides of each tissue. 
E.2.3 Serological assessment HTL V-1 related virus infections 
Previous screening of the rhesus colony for various viruses had indicated a high prevalence 
of STLV (30-40% of the colony, J.L. Heeney, 1989 Annual Report ITRI-TNO), a simian 
retrovirus found in a wide range of non-human primate species. HTLV-1 enzyme-linked 
immunoenzyme assays (ELISA) were commercially obtained (Du Pont de Nemours 
International S.A., Geneva) and tested for cross reactivity with STLV using positive and 
negative serum from colony infected monkeys. This test was used to screen monkeys involved 
in the experiments. To further confirm ELISA results and the relatedness of these viruses to 
HTL V -1, various serum samples found to be ELISA positive were tested for antigenic 
similarity on HTLV-1 western blots and compared the results with serum from HTLV-1 
infected patients. 
Serum samples were obtained from the rhesus monkey colony at TNO Rijswijk and from 
animals in this study from time points; 1) prior to pre-operative third party blood transfusions, 
2) following transfusions but before transplantation and, 3) several months post-transplantation. 
E.2.4 Assessment ofHTLV-Jlike provirus infection at DNA level 
When sufficient tissues were available following phenotypic analysis, remaining tissue was 
used to prepare DNA for southern blot analysis. 
DNA was extracted from PTLP-tissue by lysis in 20 ug proteinase K, 0.5% sarcosyl 
solution, incubated at 50 'C and extracted at least twice in PCIA (phenol, chloroform, 
isoamylalcohol, 24:24: 1). The aqueous phase was then centrifuged in a CsCI step gradient. 
DNA was dialyzed against 10mM Tris-HCI, lmM EDTA, pH 8.0, ethanol precipitated and 
digested with Hind III. After electrophoresis and 4 M NaOH transfer to Biotrace nylon blotting 
medium the DNA was probed with full length, 32P labeled 9 kb full length (minus LTRs) 
pCS-HTLV-I clone (D. Derse, NCL, Frederick MD) or partial fragments consisting of the 
envelope or tax regions and hybridized in 50% formamide, lOX Denhardt reagent, 100 ug of 
human placental DNA, 0.2% SDS, and 6X SSC for 48 hours. Blots were washed for 1 hour 
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in IX sse at 25'C, 1 hour in IX sse at 37'C and O.IX sse at 50'C. 
E. 2.5 Statistical analysis 
When appropriate, Fisher's exact-test, two sample t-test and log-rank test were performed 
for hypothesis testing. Differences were considered significant if P < 0.05. 
E.3 Results 
E.3.1 FiiUiings at necrospy 
Following immunosuppressive therapy for allogeneic transplantation of the radial side of the 
hand"', seven monkeys died during the experimental period (Table 1). In the remaining five 
other monkeys, the experimental protocol was continued untill an irreversible immune response 
had completely rejected the allograft. Detailed information on technical, immunological and 
functional aspects of these experiments is described elsewhere"·"' (Chapter III study A.B. C). 
In the group of transplant recipients that had received pre-tansplant blood transfusions and 
was treated with MAbs-anti-rejection therapy ifneccessary, one monkey (#2799) died due to 
an irreversible shock directly after the first administration ofMAbs, 79 days postoperatively. 
Monkey #4023 that twice received MAb therapy died due to spesis, 10 days after onset of the 
second episode of graft rejection. At autopsy of this monkey, evidence of wide-spread 
lymphoproliferation was observed. Monkey #2988 died due to multicentric PTLP-disorder 22 
days after operation. At this time the allograft was fully rejected despite seven days of MAbs 
administration30 • 
In the group of transplant recipients that had not received pre-tansplant blood transfusions 
but was treated with MAbs-anti-rejection therapy if indicated, one monkey (#3439) died due to 
a malignant follicle center cell PTLP-disorder, 22 days after onset of the second episode of 
rejection treatment with MAbs. Another monkey (#3308) died before rejection had occurred 
from a multicentric PTLP-disorder 179 days postoperatively. 
Complications in the group of transplant recipients that recieved pre-transplant blood 
transfusions and wich were treated with an increase in DAF if allograft rejection occurred were 
as follows; one monkey (#21) died due to sepsis 29 days postoperatively, monkey #3310 
suffered from sepsis 85 days following transplantation. Primary sites of infection were a skin 
phlegmone and a skin abces, respectively. 
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Table l. Allogeneic transplantation of the radial side of the hand in the rhesus monkey: 
anti-STL V titers in serum specification, duration of 
Monkey 
2799 
4023 
2988 
3992 
3439 
3308 
2596 
2! 
3310 
1FU 
1550 
3212 
anti-
STLV 
titer 
+ 
sc 
sc 
It 
+ 
nt 
sc 
+ 
+ 
administered immunosuppressive therapy' and cause or death. 
Duration of basic 
immunosuppressive 
Protocol 
MAbs 
& 
trans f. 
MAbs, 
no transf. 
DAF 
& 
trans f. 
DAF, 
no transf. 
therapy (days)' 
79' 
121' 
22' 
144 
97' 
179' 
30 
29' 
85' 
33 
33 
21 
Duration of 
anti-rejection 
therapy (days) 
!xi" 
2xl0 
lx7" 
ix4" 
2xl0 
1x12 
lx8" 
1x12 
1x12 
lx9c 
Cause of 
death 
shock 
sepsis/PTLP-disorder 
multicentric PTLP-disorder 
follicle center cell PTLP-disorder 
multicentric PTLP-disorder 
sepsis 
sepsis 
"Daily maintanance doses of immunosuppression consisted of25 mg/kg CyA and 1 mg/kg DAF; bdeath, 
spontaneously or due to euthanasia; '11Ie proposed duration of anti-rejection therapy (10 days for MAb-
therapy and 12 days for DAF-therapy) was not completed. 
Abbreviations: STLV: Simian T Leukemia Virus; PTLP-disorder: post-transplantation Iymphoproli-
ferativedisorder; sc: seroconversion; It: low titer; nt: not tested; MAbs: anti-rejection therapy consisted 
of a ten day course of a combination of seven monoclonal antibodies; trans f.: three third party blood 
transfusions were given to the recipient, preoperatively; DAF: anti-rejection therapy consisted of a raise 
in steroid treatment. 
In the last group of transplant recipients that did not receive pre-tansplant blood transfusions 
but was also treated with DAF-anti-rejection therapy if indicated, no monkeys died during 
experiment. However, it should be noted that allograft survival times in this group were shorter 
than in the treatment groups and thus received immunosuppression for a shorter period of time. 
In the four monkeys which were found to have PTLP-disorders, alllymphoproliferation was 
multicentric with varriable morphologic characteristics ranging from a lymphoreticular to 
follicular center cell morphology. 
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E.3.2 Influence of immunosuppressive treatmenJ and case history 
Addition of MAbs therapy to baseline immunosuppression did not have a significant effect 
on occurrence of death in general (P > 0. 05, Fisher's exact -test)". Though the population treated 
was small, an enhanced predisposition to PTLP-disorder development (P=0.03, one-sided 
Fisher's exact-test) was noted in monkeys which received MAb anti-rejection therapy, possibly 
as a consequence of additional, potent immunosuppression in addition to baseline therapy". 
Other factors in the case history of each animal like age, sex, CyA whole blond trough levels, 
kidney donorship and experimental low-dose radiation of the testis were examined for possible 
correlation with PTLP-disorder development but were found to be non-significant (P > 0.05, 
Fisher's exact-test)" (Chili· study D). 
E. 3. 3 Relevance of anti-STL V titers to PTLP-disorder development 
All animals were tested for the presence of anti-STL V antibodies before, during and after 
experiment. Four animals were seropositive before experiment. Four animals aquired anti-
STLV antibodies in the course of the experiment (Table 1). In each case of PTLP-<iisorder 
development, STLV-provirus was aquired during the experimental period. 
This was clearly evident serologically in two of these animals, and a third which had 
developed a low titer shortly before death (Table 2). In one other animal (#lFU), evidence of 
virus infection was also observed in the course of experiment but this animal has not developed 
tumor or any other complications to date. Of the seven animals which died in the experimental 
period for reasons other than PTLP-disorders, only one animal (#2799) was STLV seropositive. 
Retrospective testing demonstrated that this monkey was infected prior to the experiment and 
died of shock, presumably as a result of the MAb therapy". 
Serologically, virus transmission could be traced to havecomefromSTLV -positive monkeys, 
either by preoperative blond transfusions or by allograft donation through demonstration 
ofseroconversion for STLV titers in transplant recipients. 
Animals which retrospectively had serologic evidence of STLV infection prior to the 
experiment (n =4), did not develop PTLP-disorders sugesting that active STL V infection during 
immunosupressive therapy was an important factor in PTLP-disorder development. 
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Table 2. Detectable antibody titers against Simian T-Leucocyte Virus (STLV) in four rhesus 
monkeys with PI'LP-disorders after transplantion of the radial side of the hand; relation to 
the administration of pre-operative blood transfwions and transplantation"-. 
Monkey Donors"- Monkey Donors"- Monkey Donor" 
Time Interval #4023 Graft Blood #2988 Graft Blood #3439 Graft 
before Tx + + nt nt 
after transf. 
before Tx + 
after Tx + + It 
Monkey Donor" 
#3308 Graft 
aMonkeys that were fully mismatched for MHC class I and II antigens of the graft recipient as well as the 
graft donor, donated three 'third party' blood transfusions that were given to the graft recipient at 
biweekly intervals at -6, -4 and -2 weeks before the day of operation. On the day of operation the 
allogeneic radial side of the hand was transplanted from a fully mismatched graft donor to the transplant 
recipient. Abbreviations: Tx: transplantation; nt: not tested; It: low titer. 
E.3.4 Immunohistochemical staining oflymphoproliferative tissue 
Frozen sections oflesions collected at necropsy were assessed for phenotypic characteristics 
using the following pannel of phenotypic markers; CD2, CD4, CDS, k-light chain, f..- light 
chain, MHC-DR and the proliferation marker Ki67. In each case the staining patem varried and 
was frequently complicated by mixed population of residual benign leukocytes. All cases stained 
strong positive for the MHC class-!I DR marker and a small mixed population of light chain 
positive cells were frequenty seen in each case. In the frozen tissues available to us to study 
there were not sufficient sections of homogenous lymphoproliferative tissue to make a 
conclusive statement of the PTLP-disorder phenotype. 
E.3.5 Evidence of STL Vinfection at the DNA level 
Confirmatory evidence ofSTLV infection was determined by southern blot analysis of rhesus 
DNA extracted from available PTLP-tissue. Furthermore, this technique was used to attempt 
partial characterization of the HTL V-I like virus. 
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It was demonstrated that STL V -provirus was present in all four PTLP-disorder cases by 
southern blot (Fig. 1). Using partial HTLV-1 fragments as probes we confirmed that under 
conditions of high stringency the rhesus STL V had envelope, polymerase and gag regions were 
highly homologous with HTL V -1. We were not able to consistently demonstrate hybridization 
of the Tax region ofHTLV-1 with rhesus tumor DNA samples suggesting that differences in 
this region exist at the molecular level. 
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E.4 Discussion 
This study identified several important problems concerning selection of transplantation 
donors and recipients and has identified, for the first time, the oncogenic potential of STL V in 
rhesus macaques. Four of seven animals which died following allogeneic transplants of the 
radial side of the hand developed lymphoproliferatiev disorders which contained STL V-
provirus. In two of the four cases which developed lymphoid lesions following 
immunosupressive therapy we were able to demonstrate serologically that STL V was acquired 
from blood or organ donor. In another case which became seropositive post-transplantation the 
serologic status of the donor was not available. One monkey did not receive blood transfusions 
and after acceptance of a graft from a seronegative donor, never developed titers to STL V, but 
had STLV-provirus demonstratable in PTLP-tissue tissue. These two cases with low or 
undetectable STL V titers suggest that infection was acquired during the period of intensive post-
transplantation immunosupressive therapy and thatdetectableHTL V -1 cross-reacting antibodies 
did not develop to significant titers during this treatment and prior to PTLP-disorder 
development. This implicates that infection might also be possible via other routes than blood 
or an allograft. In this respect it is interesting to note that monkeys in this study were housed 
four by four in separate cages in the same room during experiment. 
The morphologic and phenotypic characteristics of these PTLP-disorders in macaca mulatta 
varied significantly. Furthermore, insufficient sections of homogeneous tissue were available 
making it difficult to assign a specific phenotype to the lymphoprolferative cells. If PTLP-
disorder development in this species infected with STL V is analogous to HTL V -1 associated 
lymphomas in man, then one would expect to identify a mature CD4 positive T -cell phenotype". 
This was not apparent in this study suggesting that the rhesus STL V causes PTLP-disorders of 
a more diverse cell type. 
In a recent study by Swinnen et a!'"' addition of OKT3 (an anti-CD3 MAb) to the 
immunosuppressive regimen increased the incidence of PTLP-disorder after clinical cardiac 
transplantation. Furthermore, a higher frequency of primary infection with EBV occurred in the 
group of patients that had lymphoid tumor development. However, there appeared not to be a 
causal relation between these two phenomena. Thus in concordance with previous reports 
primary EBV infection had been identified as carrying a higher risk than reactivated infection 
in the development of PTLP-disorders, but also anti-CD3 in itself does seem to precipitate 
lymphoid tumor development". In our study the finding that MAbs-anti-rejection therapy 
showed an enhanced predisposition to PTLP-disorder development (P =0. 03, one-sided Fisher's 
exact-test) coincided with the fact that in each case of PTLP-disorder development, STLV-
provirus was acquired during the experiment. This might indicate that two different mechanisms 
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both increased the chance of lymphoid proliferation, resulting in the variable morphologic 
characteristics of these disorders. 
Furthermore, it should be noted that PTLP-disorders in this study arose during heavy 
cyclosporine A treatment, which by itself can cause, or permit tumor development in heavy 
immunosupressive protocols2'3'4'15'22 • Recently it has been described that cyclosporine A acts 
through nuclear protiens involved in T-cell activation7 some of which interact with the HTLV-
1 tax gene suggesting a mechanism in which T -cell cancer can develop. 
This relationship between CyA and MAb (anti-CD3) therapy, HTLV-1 (STLV-1) infection 
and PTLP-disorder development in rhesus monkeys indicates the possible clinical risk of 
treating HTL V -1 infected patients with an immunosuppressive protocol which include these 
drugs. Based on the findings in this transplantation model in the Maccaca Mulata, the 
importance of screening blood or organ donors for HTLV -1 must be emphasized. 
E.S References 
1. Blakeslee, J.R., McClure, H.M., Anderson, D.C., Bauer, R.M., Huff, L.Y. and Olsen, L.Y., Chronic 
fatal disease in Gorillas seropositive for simian T-lymphotropic virus I antibodies. Cancer Lett., Oct. 
37 (1), 1-6 (1987). 
2. Borel, J.F., Cyclosporine: Historical perspectives. Transplant. Proc. 15, 2219-2229 (1983). 
3. Bunjes, D., Hardt, C., Rollinghoff, M. et al., Cyclosporin A mediates immunosuppression of primary 
cytotoxic T -cell responses by impairing the release ofinterleukin 1 and interleukin 2. Eur. J. Immunol. 
11,657-661 (1981). 
3a. Clark, J., Saxinger, C., Gibbs, W.N .• Loiters. W .• Langrande. L., Deceular, K., Ensroth. A., Robert-
Guroff, M., Gallo, R.C., Blattner, W.A., Seroepidermiologic studies of human T-cell leukemial 
lymphoma virus type I in Jamaica. Int. J. Cancer 36, 37-42 (1985). 
4. Cleary, M.L., Warnke, R., Sklar, J., Monoclonality oflymphoproliferative lesions in cardiac transplant 
recipients. N. Engl. J. Med. 310,477-482 (1984). 
5. Coursaget, P., Barres, J.L., Yvonnet, B., Chiron, J.P., Cornet, M., Ferrara, L. and Eyraud, M., 
Antibodies to human T-cellleukemia virus (HTLV-1) in non-human primates from Senegal. Biomed. 
Pharmacother. 39, 198-199 (1985). 
6. Dracopoli, N.C., Turner, T.R., Else, J.C., Jolly, C.J., Anthony, T., Gallo, R.C. and Saxinger, W.C., 
STL V-I antibodies in feral population of East African Vervet monkeys (Cercophithecus aethiops). Int. 
J. Cancer 83, 523-529 (1986). 
7. Emmel,E.A., Verwey, C.L.,Durand, D.B., Higgins,K.M.,Lacy,E. and Crabtree, G.R., Cyclosporin 
A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246, 1617-1620 
(1989). 
8. Guo, H. G., Wong-Staal, F. and Gallo, R.C. Novel vrial sequences related to human T-ceU!eukemia 
virus in T ce11s of a seropositive baboon. Science 223, 1195-1196 (1984). 
9. Hanaoka M: Clinical pathology of adult T-cellleukemia, Acta Haem Japanese 44:1420, 1981. 
10. Hanto DW, Gaji-Peczalska KJ, Frizzera G, Arthur DC, Balfour HH, McClain K, Simmons RL, 
Najarian JS. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-celllymphoproliferative 
diseases occurring after renal transplantation. Clinical, pathological, and virological findings and 
208 ---------------------------------------Chapter III; study E -----------------------------------------
implications for therapy. Ann Surg 198:356-159 (1983). 
11. Hay ami, M., Komuro, A., Nozawa, K., Shotak:e, T., Ishikawa, K.I., Yamamoto, K., Ishida, T., Honjo, 
S. and Hinuma, Y., Prevalence of antibody to adult T -cell leukemia virus-associated antigens (A TLA) 
in Japanese monkeys and other non-human primates. Int. J. Cancer 33, 179-183 (1984). 
12. Ho, M., Miller, G., Atchison, R.W., Breinig, M.K., Dummer, J.S., Andiman, W., Starzl, T.E., 
Eastman, R., Griffith, B.P., Hardesty, R.L., Bahnsen, H.T., Hakala, T.R. and Rosenthal, J.T., 
Epstein-Barr virus infection and DNA hybridization studies in post-transplant lymphoma and 
lymphoproliferative lesions: The role of primary Infection. J. Infect. Dis. 152, 876-886 (1985). 
13. Komuro, A., Watanabe, T., Miyoshi, I., Hayami, M., Tsujimoto, H., Seiki, M. and Yoshida, M., 
Detection and characterization of Simian retroviruses homologous to human T -cell leukemia virus type 
1. Virology 138, 373-378 (1984). 
14. Kubonishi, I. and Minezawa, M., Detection of type C virus particles in Japanese monkeys seropositive 
to adult T-cellleukemia-associated antigen. GANN 73, 848-849 (1982a). 
15. Lafferty, K.J., Borel, J.F. and Hodgkin, P., Cyclosporine-A (CsA): Models for the mechanism of 
action. Transplant. Proc. 15, 2242 (1983). 
16. Lapin, B.A., lakavleva, L.A., Voevodin, A.F., Indzhiia, L.A. and Agrba, V.Z., Study of 
virus-associated lymphomas in primates using a model of malignant lymphoma of the baboon. 
Vopr.-Onkol. 29 (12), 6Hi6 (1983). 
17. Lowenstine, L.J., Pedersen, N.L., Higgens, J., Pallis, K.L., Kyeda, A., Marx, P., Lerche, N.W., 
Munn, R.J. and Gardner, M.B., Seroepidemiologic survey of captive old-world primates for antibodies 
to human and Simian retroviruses , and isolation of Lentivirus from Sooty Mangabeys. Int. J. Cancer 
38, 563-574 (1986). 
18. Miyoshi, I., Kubonishi, I., Yoshimoto, S., Akagi, T., Ohtsuki, Y., Shiraishi, Y., Nagata, K., Hinuma, 
Y., Type C virus particles in a cord T cell line, derived by cocultivating normal human cord leukocytes 
and human leukemic T cells. Nature 294, 770-771 (1981). 
19. Miyoshi, I., Taguchi, H., Fujishita, M., Yoshimoto, S., Kubonishi, I., Ohtsuki, Y., Shiraishi, T. and 
Akagi, T., Transformation of monkey lymphocytes with adult T-cellleukemia virus. Lancer 1, 1016 
(1982). 
20. Miyoshi, 1., Fijishita, M., Taguchi, H., Matsubayashi, K., Miwa, N. and Tanioka, Y., Natural infection 
in non-human primates with adult T-cellleukemia virus or a closely related agent. Int. J. Cancer 32, 
333-336 (1983). 
21. Miyoshi, I., Yoshimoto, S., Fujishita, M., Taguchi, H., Kubonishi, I. and Niiya, K., Natural adult 
T-cellleukaemia virus infection in Japanese monkeys. Lancet 18, 658 (1982). 
22. Nalesnik, M.A. et al., The pathology of posttransplant lymphoproliferative disorder occuring in the 
setting of cyclosporineA-prednisone immunosuppression. Amer. J. Pathology 133 (1), 173-191 (1988). 
23. Noda, Y., Ishikawa, K., Sasagawa, A., Honjo, S., Mori, S. and Tsujimoto, H., Hematological 
abnormalities similar to the preleukemic state of adult T -cell leukemia in African green monkey naturally 
infected with Simian T-cellleukemia virus. Jpn. J. Cancer Res., Dec. 77 (12), 1227-1234 (1986). 
24. Ohtsuki, Y ., Takahashi, K., Akagi, T., Ultrastructural comparison of human and monkey derived type 
C virus particles in monkey lymphoid cell lines, positive adult T -cell leukemia associated antigen 
(ATLA). J. Clin. Electron. Microscopy 18, 652 (1983). 
25. Penn, I., Cancer following cyclosporine therapy. Transplantation 43, 32-35 (1987). 
26. Sahai Srivastava, B.C., Wong-Staal, F. and Getchell, J.P., Human T-cellleukemia virus: provirus and 
antibodies in a captive gorilla with non-Hodgkin's lymphoma. Cancer Res. 46, 4756-4758 (1986). 
27. Sakakibara, I., Sugimoto, Y., Sasagawa, A., Honjo, S., Nakamura, H. and Hayarni, M., Spontaneous 
malignant lymphoma in an African green monkey naturally infected with Simian T-lymphotropic virus 
(STLV). 
------- STLV-provirus positive lymphoproliferation ------- 209 
28. Starzl, T.E. et al., Reversibility of lymphomas and lymphoproliferative lesions developing under 
cyclosporine-steroid therapy. Lancet, March 17,787 (1984). 
29. Stevens HPJD, Hovius SER, Heeney JL, Nierop PWM, Jonker M; Immunological aspects and 
complications of composite tissue allografting for upper extremity reconstruction: a study in the rhesus 
monkey. Transpl Proc (in press), 1991; 23(1). 
30. Stevens HPJD, Hovius SER, Vuzevski VD, Nierop PWM van, Gotte M, Roche N.A. Jonker, M; 
Immunological aspects of allogeneic partial hand transplantation in the rhesus monkey. Transpl Proc 
22:2006, 1990. 
31. Stevens HPJD, Kwast ThH van der, Meide PH van der, Vuzevski VD, Buurman WA, Jonker M. 
Synergistic immuinosuppressive effects of interferon gamma and tumor necrosis factor aplha. A skin 
transplantation study in the rhesus monkey. Transplantation 1990; 50(5)(in press). 
32. Stevens HPJD, Roche N, Hovius SER, Jonker M: In vivo immunosuppressive effects of monoclonal 
antibodies specific for CD3+, CD4+, CDS+, and MHC class II positive cells. Transpl Proc 22:1783, 
1990. 
32a. SwinnenU, Costanzo-Nordin MR, Fisher SG et al. Increased incidenceoflymphoproliferative disorder 
after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Eng 
J Med 323:1723-8 (1990). 
33. Takatsuki K, Uchiyama T, Ueshima Y, Hal tori T, Toibana T, Tsudo M, Wano Y, Yodi J: Adult T-cell 
leukemia: Proposal as anew disease and cytogenetic, phenotypic and functional studies ofleukemic cells, 
Gann, Monograph on Cancer Research 28:13, 1982. 
34. Touraine, J.L., Bosi, E., El Yafi, M.S., Chapuis-Cellier, C., Blanc, N., Dubernard, J.M., Piatti, P.M., 
Chevalier, M., Pouteil-Noble, C., Lenoir, G., Trepo, C., Gelet, A., Creyssel, R. and Traeger, R., The 
infectious lymphoproliferative syndrome in transplant patients under immunosuppressive treatment. 
Transplant. Proc. 17, 96-98 (1985). 
35. Tsujimoto, A., Tsujimoto, H., Yanaihara, N., Abe, K., Hayani, M., Miwa, M. and Shimotohno, K., 
Detection of the X-gene product of Simian T-cellleukemia virus. FEBS-Letters, Febr. 17, 196 (2), 
301-304 (1986). 
36. Tsujomoto, H., Noda, Y., Ishikawa, K.I., Nakamura, H., Fukasawa, M., Sakakibara, I., Sasagawa, 
A., Honjo, S. and Hayami, M., Development of adult T-een leukemia like disease in African green 
monkey associated with clonal integration of Simian T-cellleukemia virus type I. Cancer Res. 47, 
269-274 (1987). 
37. Watanabe, T., Seiki, M., Tsujimoto, H., Miyoshi, 1., Hayami, M. and Yoshida, M., Sequence 
homology of the Simian retrovirus genome with human T-cellleukemia virus type 1. Virology 144, 
59-65 (1985). 
38. Watanabe, T., Seiri, M., Hirayama, Y., Yoshida, M., Human T-cellleukemia virus type 1 is a member 
of the African subtype of Simian viruses (STLV). Virology, Jan. 30, 148 (2), 385-388 (1986). 
39. Yamamoto, N., Hinuma, Y ., Zur Hausen, H., Schneider, J. and Hunsmann, G., African green monkeys 
are infected with adult T-cell leukemia virus or closely related agent. Lancet 1, 240-241 (1983). 

CHAPTER IV: NEW APPROACHES TO OPTIMIZE 
IMMUNOSUPPRESSIVE THERAPY; 
STUDY A 
A.l 
A.2 
A.2.1 
A.2.2 
A.2.3 
A.2.4 
A.2.5 
A.2.6 
A.2.7 
A.2.8 
A.2.9 
A.3 
A.3.1 
A.3.2 
A.3.3 
A.3.4 
A.3.5 
A.3.6 
A.4 
A.S 
Synergistic immunosuppressive effects of 
monoclonal antibodies specific for interferon-
gamma and tumor necrosis factor-alpha 
H.P.J.D. Stevens 
Transplantation Proceedings, 1990; 22: 1924-1925 
Transplantation, 1990; 50(5): 856-861 
Introduction 
Materials and methods 
Animals 
MAbs used for in vivo treatment 
Skin grafting 
Experimental groups 
Histological studies 
Hematology and subset analysis 
Determination oflevel of injected MAbs 
Determination of monkey-anti-mouse IgG antibodies 
Assays for the determination ofiFN-y and TNF-a 
Results 
Effects on skin allograft survival 
General histology 
Immunohistology 
Effect on hematology and lymphocyte subsets 
Serum levels of antibody 
Serum levels ofiFN-y and TNF-a 
Discussion 
References 
212 --------------------------------------- Chapter IV; study A ------------------------------------
A.l Introduction 
In the complex network of cellular interactions of the immune response, cytokines 
play a crucial regulatory role. They are involved in the recruitment of immuno-
competent cells into the site of inflammation and the amplification of the immune 
response, in which major histocompatibility complex (MHC) antigens play a key role. 
Interferon gamma (IFN--y) is known to exert a wide variety of immunomodulatory 
effects. It mediates the chemotactic migration and activation of T cells' and 
macrophages2 and enhances the cytotoxic activity of natural killer cells, monocytes, 
cytotoxic T cells and polymorphonuclear leucocytes'-'. IFN--y also enhances the 
expression of MHC class I and II antigens on almost every cell type, both in vitro'·' 
and in vivo7•8 and it induces de novo synthesis of receptors for other cytokines such 
as tumor necrosis factor alpha (TNF-a)'. 
Recent evidence shows that TNF-a, which was originally found to induce 
hemorrhagic necrosis in murine tumors 10 , also has widespread immunoregulatory 
activities. Like IFN--y, TNF-a increases the expression of membrane glycoproteins such 
as ICAM-1, relevant for the adhesion of circulating granulocytes, monocytes and 
lymphocytes to endothelial cells"·". TNF-a also exerts direct cytotoxic effects towards 
endothelial cells" and is involved in the regulation of both MHC class I and II antigen 
expression 14' 15 • Because of these properties, it can be assumed that IFN--y and TNF-a 
are both involved in the process of graft rejection. 
To test this assumption the immunosuppressive effects of two monoclonal antibodies 
(MAbs) specific for human IFN--y (MD 1)" and human TNF-a (61E71 )", were investi-
gated using an allogeneic skin graft model in rhesus monkeys. 
In vivo antibody-mediated interference with the function of lymphokines such as 
lFN--y and TNF-a has been demonstrated to be effective in various studies. Recently, 
it was shown that anti-IFN-'Y ameliorated experimental autoimmune diseases in 
rodents"·" and anti-TNF-a effected the pathophysiology of septic shock in mice and 
nonhuman primates"·"'. Both MDI and 61E71 were found to neutralize rhesus INF--y 
and rhesus TNF-" but not murine IFN--y or TNF-a. The rhesus monkey immune 
system, including the MHC gene products", show a high degree of similarity with the 
human counterparts. Therefore, results obtained in rhesus monkeys allow for better 
extrapolation to the human situation than data obtained from studies in rodents. 
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A.2 Materials and methods 
A.2.1 Animals 
Rhesus monkeys (Macaca mulatta) were born and raised in the TNO Primate Center, 
Rijswijk, employing a harem type breeding system. All monkeys were two to four 
years of age and typed for the rhesus leucocyte antigens (RhLA) -A, -B and 
-DR locus21'22 • 
A.2.2 MAbs used for in vivo treatment 
Monoclonal antibodies (MAbs) used for in vivo treatment were designated MD I, 
61E71 and HIOS-1.6. MDI (murine IgGI) was raised against recombinant human 
IFN-y' and proved to fully neutralize the biological activity of naturally derived rhesus 
monkey IFN--y. 61E71 (murine IgG,) was raised against recombinant human TNF-a" 
and also proved to effectively neutralize rhesus monkey TNF-a. Neither of these MAbs 
exerted a neutralizing effect towards IFN--y and TNF-" of rat or mouse origin. Hl05-
1.6 is a murine anti-human MAb (IgG,..) specific for human secretory component and 
not reactive with rhesus secretory component" 61E71 was produced in vitro (generously 
donated by Celltech, Ltd. Slough, Berkshire, UK). All other antibodies were purified 
from ascites by ammonium sulphate precipitation (50%) saturation. MDI and 61E71 
were also purified by adsorption to and elution from protein A. Prior to in vivo 
administration all MAbs were centrifuged for 20 minutes at 100.000 x g and sterilized 
by millipore filtration (0,22J.<M). 
A.2.3 Skin grafting 
Skin grafts were exchanged between non-immunized unrelated monkeys as described 
elsewhere". Major hemorrhages and crust formation over the entire graft was taken as 
the endpoint of graft survival. Donor and recipients differed for all MHC antigens, both 
class I (RhlA-A & B) and class II (RhLA-DR). 
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A. 2.4 Experimental groups 
The skin graft experiment concerned five different experimental groups. In group I, 
animals did not rec:eive a treatment. Five of these monkeys were historic controls25"". 
In group IT animals received H105-1.6. In this group skin graft recipients differed for 
one RhLA-A or -B antigen only. Results from group II have been published 
previously". In groups Ill and IV animals received either MD! or 61E71. Animals in 
group V were treated with the combination of MD! and 61E71. Based on previous 
experiments, doses were used that would establish a small excess in serum levels of 
each injected antibody. Recipients received a daily doses of 1.3 mg/kg of MD!, 2.0 
mg/kg of 61E71 or 1.0 mg/kg of HI05-106 as an i.v. bolus injection for the duration 
of 10 days starting day -1, one day before skin transplantation. 
A.2.5 Histological Studies 
At regular intervals after operation, biopsies were taken from the skin grafts of two 
animals in group I and all animals in groups IV and V. After excision with a 3 mm' 
biopsy stance a cylinder of full thickness skin was cut in half, longitudinally. One half 
was fixed in buffered formalin and processed routinely for histology on hematoxylin and 
azofloxine-stained sections. 
The remaining other half, snapfrozen in liquid nitrogen chilled isopentane, was used 
for parallel immunohistochemical studies as described elsewhere". Tissue bound primary 
antibody was reacted with horseradish peroxidase-coupled rabbit anti-mouse 
immunoglobulin (Dakopatts, Copenhagen, Denmark) diluted 1:100 in PBS containing 5% 
heat-inactivated normal rhesus serum and 5% normal rabbit serum. Conjugate binding 
was visualized with a solution of 0.5 mg/ml 3,3,-diaminobenzidine tetrahydrochloride 
(Fluka Chemika, FRG) and 0.03% H,O, in PBS. The following antibodies were used 
for immunohistological staining: W6/32" (Serotec, Blackthorn, GB) specific for MHC 
class I antigens; anti-HLA-DR specific for MHC class II-DR antigens" (Becton and 
aPrevious data have shown that in completely RhLA-A, -B and -DR mismatched donor-recipient 
combinations, mean skin graft survival time is 9.1 days (SE= 0.4 days, n=S) [25], while 
the day of operation was counted as day 1. However, in this study we prefer to regard the 
day of operation as day zero in accordance to international standards. 
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Dickinson, Mountainview, USA); the MAb Til" (DAKO-Tll, Dakopatts, Denmark) 
specific for CD2, as a pan T cell marker; a mixture of OKT4 and OKT4A"' (Ortho 
Pharmaceuticals Co., Raritan, NJ) specific for CD4+ cells and GM9" specific for 
CD8 + cells. All MAbs are fully reactive with rhesus monkey antigens. In control 
incubations the primary antibody was omitted. 
A. 2. 6 Hematology and Subset Analysis 
Blood samples were taken at regular time intervals and the total number of 
leucocytes as well as the relative number of lymphocytes, monocytes and granulocytes 
were determined in all animals. In groups II to V relative and absolute numbers of 
peripherally circulating mature T cells, CD4+, CD8+ and class II+ cells were 
determined, using an indirect immunofluorescence technique as described elsewhere32 • 
A.2. 7 Determination of level of injected MAb 
In all groups serum levels of injected MAb were determined in a sandwich enzyme-
linked immunosorbent assay (ELISA). The first layer was affinity purified goat anti-
mouse IgG (Pel-Freeze Biologicals, Rogers, AR) coated on flexible 96-well assay plates 
(Falcon 3911, Oxnard, CA). The intermediate layer was serum diluted 1/10 or MDI 
and 61E71 standards in a similar serum dilution. Binding was detected with affinity 
purified and peroxidase labelled goat anti-mouse IgG (Pel-Freeze). Color development 
was initiated with 0-phenylenediamine (Kodak, Rochester, NY) in 0.03% H,O, PBS and 
terminated with 2N H,SO,. The plates were read at 492 nm. (Titertek Multiskan PLUS 
MKII, Me Lean, Virginia). For quantitation of the amount of circulating MAb 
calibration curves were used of MDI and 61E71 of a koown concentration. 
A.2. 8 Determination of Monkey-anti-mouse lgG antibodies 
The presence of anti-mouse IgG antibodies was determined in serum samples by a 
similar ELISA technique". In this assay, the last ten-fold dilution that still showed a 
significant higher level (>2 times SD) of anti-mouse IgG antibodies to MDI or 61E71 
than the control, was taken as the titer of the sample. 
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A.2.9 Assays for the detennination of IFN--y and TNF-a 
In groups II to V, serum IFN--y levels were assessed semi-quantitatively in a 
cytopathic inhibition assay in HEp-2 cells with Vesicular Stomatitus Virus (VSV) as 
challenge". Cell death was monitored with 0.5% crystal-violet staining. 
The presence of biologically active TNF-a in serum was determined in a bioassay 
by measuring cell death of a murine WEill 164 clone 13 fibrosarcoma cell line" 
briefly WEill 164 cells were seeded at a density of 4xl0' cells per well in 96-well 
microliter plate in 100 1'1 RPM!, containing 10% FCS. An equal volume of each serum 
sample was added in serial two-fold dilutions and incubated at 37o C for 24 hours in 
a humidified CO, incubator. Subsequently cells death was assessed with the tetrazolium 
salt method". 
A.3 Results 
A.J.l Effects on skin allograft survival 
Untreated control animals had a mean skin graft survival time (MST) of 8.3 +/-
0.7 days (Table 1). MST were not significantly prolonged by the administration of the 
irrelevant MAb Hl05-1.6" nor by MDI. The MST values in these groups were 8.2 
and 9.5 days respectively. In the group of animals treated with only 61E71, a slight, 
non-significant prolongation of skin graft survival was observed (MST = 10 days) as 
compared with the untreated control group. However, prophylactic treatment with the 
combination of MDI and 61E71 (group V) resulted in a modest, but significant 
prolongation of graft survival times to a MST of 12.3 days (Mann-Whitney U test 
p<0.05). 
A.3.2 General histology 
Histology was performed on skin grafts of two monkeys in group I and all animals 
in groups IV and V. All allografts investigated showed a similar sequence of 
histopathological events, although at different rates. Infiltrates of lymphocytes and 
histiocytes, capillary destruction and hemorraghe started perivascularly. Subsequent 
microscopical changes reflected macroscopical findings of the proces of skin graft 
rejection. 
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Table 1. Skin allograft survival times in rhesus monkeys treated with MAbs 
specific for IFN-y and TNF-a. 
Experimental Injected Individual skin graft 
groups MAbs' Target survival times (days) 
---
I none 7, 7.5b, 8\ 8\ 8, 
8, 9b, 9b, 9, 9 
II Hl05-1.6' 8, 8, 8.5 
Ill MDI IFN-r 9, 9 
IV 61E71 TNF-01 10, 10 
v MDI & 61E71 IFN-r & TNF-01 10.5d, 12, 13, 13.5 
a) Monoclonal antibody (MAb) treatment was started I day before skin 
grafting and continued for 10 days. 
b) Historic controls 
c) H105-1.6 is an irrelevant murine IgG2a monoclonal antibody13 • 
d) rhesus monkey IZV. 
Lymphohistiocytic infiltrates and edema became more diffuse and finally extensive 
hemorraghe, epidermiolysis and crust formation developed as rejection of the slcin graft 
was definite. 
A.3.3 Immunohistology 
Immunohistology was confirmative. The intensity of MHC class I and II-DR antigen 
expression by the stromal cells of the papillar and reticulary dermis, vascular 
endothelium and epidermal cells increased when rejection progressed (Table 2). If 
infiltrates were only focal, MHC class II-DR expression was largely confined to the 
area around the infiltrating cells. At 9 days after transplantation all preexisting 
structures and infiltrates in the allografts of group I and IV showed very intense 
expression of MHC class I and II-DR antigens (Fig. la and lc). 
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Table 2. Immunohistological observations in rhesus monkey skin grafts 
after various treatments. 
Mean percentage of 
Expression on preexisting infiltrate with 
Days donor tissue of expression of 
Grou!ln) Therapy postop. MHCclassi MHCclassii CD2 CD4 CDS 
(2) 5 +++ + + (focal) 20 10 10 
7 +++ + + + (focal) 60 <5 60 
9 ++!+++ ++!+++ 80 <5 80 
IV (2) 61E71 5 + +I- nd nd nd 
7 --------------- not tested --------------------------------
9 +++ ++!+++ 85 <5 85 
13 ++ ++ 85 <5 85 
v (3) 61E71 5 +I- nd nd nd 
& MD! 7 + 30 <5 30 
9 ++ ++ 65 <5 65 
13 +I++ +I++ 50 <5 50 
v· (lZV) 61E71 5 + +I- nd nd nd 
& MD! 7 ++ ++ 70 <5 70 
9 +++ +++ 50 <5 50 
Data represent consistent observations made in all skin grafts of the experimental groups I 
(n=2). IV (n=2) and V except for monkey !ZV (n=3). Results for monkey lZV are given 
separately under v·. MAbs used for staining lymphocytes are described in section 2.7. Staining 
of the intensity of MHC class I and n antigen expression on the stroma of the papillary and 
reticulary dermis and on epidermal cells was scored semiquantitatively: + for low, + + for 
moderate, + + + for high intensity of antigen expression. nd = not determined as the number 
of infiltrated cells was too small to determine percentages. 
At the same time in group V. except for monkey lZV, allografts showed a less 
prominent expression of MHC class I and II-DR antigens (Fig. lb and ld). 
At 7 days after operation, in all allografts, less than 5% of the CD2+ cells were 
positive for OKT4 and 4A, implying that only very few CD4+ cells were present at 
the time of fullblown rejection. Almost all T cells were of the CD8 + phenotype. 
This CD4/CD8 ratio sustained throughout the rest of the rejection process. 
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Figure 1. Immunohistological stammg of skin biopsies with MAbs specific for MHC class I 
(fig la, lb) and MHC class II ( fig lc, ld) antigens. All biopsies were taken 9 days after 
skin grafting. At this time, intense expression of MHC class I and II antigens could be seen 
on epidermis, dermis and infiltrates of the allografts of the monkeys that had received 61E71 
(fig. la, lc). At the same time, MHC class I and II antigen expression on epidermis, dermis 
and infiltrates of the skin biopsies of the monkeys that had received the combination of MD 1 
and 61E71 was less prominent (fig. lb, ld; magnification 275x). 
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A.3.4 Effect on hemtUology and lymphocyte subsets 
Lymphopenia did not occur, nor was there a depression in platelet, leucocyte, 
granulocyte, or monocyte counts during or after the 10-day course of intravenous 
therapy in any of the animals. 
The fluctuations in absolute or relative numbers of CD3+, CD4+, CDS+ and 
MHC class II-DR+ PBLs did not significantly differ from preoperative levels and thus 
no correlations were found between subset fluctuations in peripheral blood and clinical 
events such as skin transplantation, administration of MAbs or rejection of the allograft 
(data not shown). 
A. 3. 5 Serum levels of antibody 
In all cases, the daily injected doses of MAbs were sufficient to maintain detectable 
serum trough levels until about I day after the last injection. Trough levels, assessed 
by ELISA, varied from 35 ng/ml to 380 l'g/ml during 9 days after transplantation. On 
day 12 postoperatively, levels were all below detection level. Although there was 
significant variation in levels among the individual monkeys, no significant differences 
in MAb levels were observed between the different groups. 
Antibody formation in the rhesus monkey directed to the injected murine MAb was 
also determined by ELISA. None of the monkeys had detectable levels of monkey-anti-
mouse antibodies before the start of experiments (Table 3). However, in all cases these 
antibodies were detectable from the 9th postoperative day onward. Peak titers ranged 
from I in 10' to 1 in 10'. In one case, anti-mouse-antibodies were already detectable 
on the 7th day after operation against both of the MAbs that were injected. This 
monkey (IZV) had received both MDI and 61E71 (group V) and had a relative short 
skin graft survival time of 10.5 days (Table 1). 
A. 3. 7 Serum levels of IFN--y and TNF-01 
Only in an incidental case the presence of IFN--y and TNF-01 could be established 
in serum, preoperatively. Peri- and postoperative fluctuations in serum levels did not 
correlate with any of the afore mentioned clinicopathological events (data not shown). 
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Table 3. Monkey·anti-mouse antibody titers• in rhesus monkeys treated with 
MAbs against IFN--y and TNF-a to prevent skin allograft rejection. 
target of 
group monkey treatment reactivityb d-5 d7 d9 dl4 d28 
III INS MDI MDI 0 0 3 5 5 
2V MDI MDI 0 0 3 4 4 
IV lNG 61E71 61E71 0 0 0 6 
B8 61E71 61E71 0 0 0 5 5 
v IYV combi MDI 0 0 3 5 5 
61E71 0 0 0 3 3 
BB36 combi MDI 0 2 2 6 5 
61E71 0 0 3 4 4 
IZV combi MDI 0 2 2 4 4 
61E71 0 2 2 4 5 
2BK combi MDI 0 0 0 2 4 
61E71 0 0 0 3 4 
•The last ten-fold dilution that still showed a significant higher level (> 2 times SD) of 
anti-mouse IgG antibodies to MDl or 16E71 than the control, was taken as the titer of the 
sample. 
bLevels of monkey-anti-mouse antibody titers were assessed by ELISA to both MD 1 and 61E71 
in all samples. 
A.4 Discussion 
The role of IFN--y and TNF-a in the process of allograft rejection was investigated 
in a rhesus monkey model. Two murine MAbs, MDI" and 61E71" specific for IFN-
'Y and TNF-a respectively, were tested for immuno-suppressive activity in a skin 
lransplantation study. Prophylactic treatment of allogeneic skin graft recipients with MD 1 
(group Ill) or 6!E71 (group IV) alone did not prolong skin graft survival times. 
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Neutralization of just either one of these cytokines, was, apparently, not sufficient to 
suppress the immune response. However, treatment with the combination of MDl and 
61E71 (group V) resulted in a modest but significant prolongation of allograft survival 
times. Compared to MAbs specific for MHC class II positive and CDS+ cells, which 
had MST of 12.4 and 12.9 days"·"• respectively, the immunosuppressive effect of the 
combination of MDI and 6lE7l was equally strong. CD3 and CD4 specific MAbs 
and the combination of MAbs specific for CD3, CD4, CDS and MHC class II antigens 
proved to be more effective and could prolong MST from 14.6 up to 19.3 
days"·"·"•. The fact that the immunosuppressive effect of anti-IFN--y and anti-TNF-a 
was only temporary, might result from the presence of other lymphokines than IFN--y 
and TNF-a that additively take over the upregulation of the immune response". and 
histology revealed that, except in the case of monkey lZV, all grafts in group V were 
infiltrated two to four days later by lymphocytes and histiocytes than the grafts in 
group IV. The evolution of the rejection process, however, was similar in all cases, 
although retarded in the allografts of group V. Immunohistology was confirmative. 
Furthermore, from the observations as summarized in Table 2, we conclude that at the 
time of full blown rejection of an allogeneic skin graft in the rhesus monkey, almost 
all T cells are of the CDS+ phenotype. MD! nor 61E7l, alone or in combination, 
influenced this phenomenon. Striking was that MDI in combination with 61E71 delayed 
the recruitment of lymphocytes and macrophages into the graft. Secondly, the onset of 
MHC class I and II antigen expression was delayed on preexisting donor tissue in 
group V compared to group I and IV. 
In the peripheral blood, however, no effect in any of the groups could be found on 
lymphocyte subset distributions. This might be due to the fact that the injected MAbs 
were primarily directed against local acting lymphokines. On the other hand, the size 
of the grafts were most likely too small to influence subset fluctuations in such a 
manner that they would reflect the local immunological events of the graft. Also the 
serum levels of IFN--y and TNF-01 did not correlate to clinico-pathological events. These 
results suggest that serum levels of IFN--y and TNF-a do not reflect the presence of 
these lymphokines on the site of allograft rejection. 
Neither can the augmented immunosuppressive effect of the combination of MD 1 and 
61E71 be explained on basis of longer bioavailability of these MAbs in circulation 
compared to the groups where the MAbs were given separately. For, in all cases, the 
daily injected doses of MAbs were sufficient to maintain detectable serum levels until 
approximately I day after the last injection. Furthermore, in all treated skin graft 
recipients, similar titers of anti-mouse-antibodies could be detected from 9 days after 
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operation onwards. 
A possible explanation of the effectiveness of MDI and 61E71 might be related to 
interference with the mediatory role of IFN-y and TNF-a on a combination of several 
different pathways. Firstly, the recruitment of lymphohistiocytic cells into the allograft 
was delayed. MDI and 61E71 MAb might have interfered with the induction of 
expression of endothelial adherence molecules such as ICAM-1, ELAM-1" and ENAl" 
and the migration stimulus for lymphocytes and macrophages to cross vascular 
endothelium1'2 • 
Secondly, the combination of MDI and 61E71 impaired the upregulation of MHC 
class I and II antigen expression (Table 2). As a result antigenicity of the grafts might 
be reduced38...m, and enhancement of antigen presentation to T helper lymphocytes and 
the subsequent induction of cell-mediated cytoxicity" might be impaired. 
Thirdly, TNF and IFN-y influence each others production. TNF is primarily 
produced by activated monocytes and macrophages"·" but also by T lymphocytes and 
Natural Killer cellsu. The production of TNF by these cells, however, is dependent on 
the presence of proliferating IFN-y producing T cells". By intervening in these 
interactions anti-IFN-y and anti-TNF-a MAbs might also have prevented the cascade 
of cytokine production and thus preventing amplification of the immune response. 
In conclusion, for the first time in an in vivo transplantation model, a synergistic 
effect of anti-IFN-y MAb (MDI) and anti-TNF-a MAb (61E71) is described, resulting 
in a delayed onset of the immune response towards an allogeneic skin graft. The 
described synergism might be due to interference with the effects of IFN-y and TNF-
a on several separate pathways whose combined action is greater than the sum of their 
separate actions. To gain a better insight in this proces, similar experiments should be 
performed in which administration of the MAb therapy specific for combinations of 
different cytokines is started at different times before and after transplantation. 
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B.l Introduction 
FK-506 is a newly developed drug with impressive immunosuppressive properties. 
There is reluctance to use the drug clinically because of the reported toxicity of FK-506'. 
However, recent results obtained in subhuman primates permit some optimism'. It is likely 
that the future of FK-506 will lie in its cautious use in combination with other 
immunosuppressive agents. 
An obvious candidate to be combined with FK-506 is cyclosporine (CyA), the more so 
as there are indications that both drugs act synergisticallyM. The present experiments were 
performed to investigate the possible synergism and toxicity of low-dose FK-506 and low-
dose CyA using a rat skin transplantation model. 
B.2 Materials and methods 
B.2.1 Animals 
Male rats of the Rt-1 incompatible BN and WAG strains were used respectively as 
donors and recipients. The animals were bred under specific pathogen free conditions and 
weighed about 250 gr. 
B.2.3 Skin transplantation 
Full thickness skin grafts were transplanted to the dorsal thorax according to the method 
described by Bainer'. The compression bandages were removed after 8 days after which the 
grafts were inspected daily. The day on which the graft had necrotized more than 90 % was 
taken as day of rejection. 
B. 2.4 Immunosuppression 
FK-506, kindly supplied by the Fujisawa Pharmaceutical Co., Osaka, Japan, was 
dissolved in olive oil and administered intramuscularly (i.m.) in dosages ofO.l, 0.3 and 0.5 
mg/kg per day. CyA (Sandoz), obtained from a commercial batch, was diluted in olive oil 
and given i.m. at a dose of 5 mg/kg/day. Both drugs were given daily, either alone or 
combined, for 15 days, starting on the day of transplantation. Each group consisted of 5 
animals. 
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B.2.5 Toxicity studies 
Blood samples were taken before and at regular intervals after grafting for blood cell 
countings and determination of glucose, haemoglobin (Hb), SGOT and creatinine levels. 
The animals were weighed regularly. 
B.3 Results and discussion 
The survival times obtained in the different experimental groups are summarized in 
table I. Untreated controls had a mean graft survival time (MST) of 9.6 days. Treatment 
with CyA alone, at a dose of 5mg/kg/day, resulted in a significant prolongation of graft 
survival (MST of 18.0 days). Animals treated with 0.1, 0.3 or 0.5 mg/kg FK-506 showed a 
dose-related prolongation of skin graft survival. The MST's were significantly different from 
the controls and from each other; they amounted to 16.2, 21.6 and 25.8 days, respectively. 
Administration of 0.1 mg FK-506 had a similar effect on graft survival as 5 mg CyA. 
Considering the fact that a skin graft represents a difficult tissue barrier as compared with a 
heart or kidney graft, the survival times obtained with the higher dosages of FK-506 were 
remarkable. 
However, using these dosages a mild toxicity, manifested by a slight and reversable 
increase in SGOT levels, was noted. 
Other parameters remained normal. The combined treatment with CyA and and 0.1 mg 
FK-506led to a MST of 28.2 days; which is significantly longer than the MST of any other 
group, except for the group treated with 0.5 mg FK-506. The prolongation in graft survival 
time obtained in the combined treatment group was longer than the sum of prolongations 
observed in the component groups. In the combination group toxicity studies revealed no 
drug related changes in body weight, blood counts, Hb, glucose , SGOT or creatinine levels. 
The present results are in agreement with earlier studies, indicating that minimally 
therapeutic doses of FK-506 act synergistically with suboptimal doses of CyA'·'. In a dog 
kidney transplantation model it has been demonstrated that this synergism could be best 
exploited if prednisone was added to the immunosuppressive cocktail'. Synergism in 
immunosuppressive activity with FK-506 combined with irradiation in hamster to rat 
xenografting has also been described'. 
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Table 1. Effect of FK-506 and CyA on skin allograft survival in rats 
Treatment Dose Survival time in days Mean +I- SD 
Controls 9, 9, 10, 10, 10 9.6 + 0.5 
CyA 5 mg/kg 17, 18, 18, 18, 19 18 +/- 0.7 
FK-506 0.1 mg/kg 15, 16, 16, 17, 17 16.2 +I- 0.8 
FK-506 0.3 mg/kg 20, 21, 21, 23, 23 21.6 +I- 1.3 
FK-506 0.5 mg/kg 24,25,26,27,27 25.8 +/-1.3 
FK+ CyA 0.1 + 5 mg/kg 26, 28, 28, 29, 30 28.2 +I- 1.5 
Skin transplantation was performed in the WAG to BN rat combination. CyA and Fk-506 were given 
im. daily for 15 days starting on the day of transplantation. The combined treatment group is 
significantly different from all other groups except the group treated with 0.5 mg FK-506. The 
results obtained with 0.1, 0.3 and 0.5 mg FK-506 are significantly different from each other and the 
controls ( P < 0.05). 
These data collectively emphasize the marked potentials of low-dose FK-506 as part of 
triple or quadruple therapy. Especially with regard to difficult organs like the pancreas and 
the small bowel or with regard to composite grafts, FK-506 may become a valuable adjunct 
to the existing immunosuppressive arsenal. 
It may also be useful in highly immunized patients and in xenografting. The redemption 
of these prospects depend on the outcome of the first clinical trials which are currently being 
performed. 
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This 'double-thesis' provides data about the technical, functional and immunological 
aspects of transplantation of the allogeneic (radial side of the) hand investigated in a rhesus 
monkey model. 
Research in this field was prompted by the question from patients and/ or parents as to 
whether the problem of a nonfunctioning or absent hand could be solved by allogeneic 
transplantation of a hand. Whatever the original cause; traumatic, congenital or neoplastic, 
even the most sophisticated prothesis can not restore the lost motor and sensory functions of 
the original hand. 
Nowadays, almost any organ can be transplanted clinically, varying from the kidney'·', 
heart (sometimes in combination with lung)3 , liver4, bone marrow5, pancreas6, intestines 7 and 
skin'. Especially with the advent of Cyclosporine A (CyA) (Chapter l, section B.3.1.4: 
ChLB.3.1.4) reasonable to very good graft and patient survival rates can be obtained'·'. 
Moreover, since the sixties, microsurgical techniques have become available that make it 
possible to suture very small vessels and nerves (ChLA.l). Because of these advancements 
we have investigated in an experimental model whether transplantation could be added to the 
arsenal of modem treatments for hand reconstruction. 
As mentioned previously (ChD, multiple studies have been performed focussing on the 
feasibility of composite tissue allograft (CTA) transplantation under various kinds of 
immunosuppression, but mainly in a rat limb transplantation model9-17 • Rodent models for 
tissue transplantation give leads as to what technical, functional and immunological aspects 
are of importance. In this respect, it could be demonstrated by our group that fluctuations in 
peripheral blood gases as well as glucose and lactate did not predict allograft rejection of the 
CTA (Ch!I A). Furthermore, the flux of peripheral blood cells through the skin of the CTA, 
as could be assessed by laser doppler flowmetry, decreased concomitantly with histological 
and clinical parameters indicating increment of graft rejection. However, these laser doppler 
flow measurements could not predict the initial onset of rejection, before the occurrence of 
clinical signs such as edema, loss of hair and epidermolysis. Presumably, this was due to the 
lack of continuous monitoring using this method. 
For optimal extrapolation to the situation in man, studies in rodents have clear limitations 
from a technical, a functional as well as an immunological point of view. Should 
transplantation of the (total) hand in man ever be performed, then information on these three 
topics will be of ultimate importance. 
Preferably a nonhuman primate should be used for preclinical testing of these aspects of 
CTA-transplantation, because of the obvious anatomical, functional, immunological and 
phylogenetic similarities between monkey and man. 
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Also for these · reasons nonhuman 
primates are known to fulfill the 
requirements for testing the efficacy 
and safety of immunosuppressive 
drugs (such as monoclonal anti-
bodies)18'19. It was therefore our 
objective to study the afore men-
tioned aspects of allogeneic hand 
transplantation in a rhesus monkey 
model. In the experimental model the 
transplant consisted of the radial side 
of the hand enlarged with the radial 
forearm flap (Fig.l, ChiC.l.2).For 
ethical reasons a small independent 
functional unit of the hand was cho-
sen. One of the introductory studies 
indeed proved that the anatomy of the 
transplant of the rhesus monkey was 
practically identical to the situation 
in man (Chii.B). The rhesus monkey 
lives on the ground as well as up in 
the trees. Because of this pattern of 
life the rhesus monkey needs a better 
functioning thumb in comparison to 
arboreal monkeys. The rhesus mon-
key can bring its fingers into oppo-
sition, however not as well as in the 
Figure 1. The transplant model. The dotted line 
marks the radial hand unit. Ventral: A = adductor 
muscle; T = thenar muscle; U.n. = ulnar nerve; 
M.n. = median nerve; f.p.l. = flexor pollicis 
longus; a.p.l. = abductor pollicis longus; r.a. = 
radial artery. Dorsal: e.p.l. = extensor pollicis 
longus; a.p.l. = abductor pollicis longus; s.r.n. 
superficial radial nerve; c.v. =cephalic vein. 
human being. The thumb of a rhesus monkey is shorter in comparison with that in man. 
Important differences were the fact that the long flexor muscle (musculus flexor pollicis 
longus) to the thumb only separated from the other flexor muscles at the level of the wrist. 
Because of this, flexion of the thumb is less independent. Also, the monkey misses the short 
extensor muscle (musculus extensor pollicis brevis) resulting in less stability of the 
metacarpometaphalangeal joint of the thumb during grasp movements. An important 
resemblance between rhesus monkey and man was the fact that the thenar muscles appeared 
to be built up in a similar way. Also the nerves to the thumb followed an almost identical 
course. 
234 ----------------------------------------- Chapter V -----------------------------------------------
Subsequently, a custom-made thermoplastic splint was developed for the protection of the 
transplant following operation (Chi! C). One piece thermoplastic splints proved to be light, 
strong, easy to make, and inexpensive. Furthermore, they provided adequate immobilization 
and protection of the hand and allowed easy removal and reapplication for inspection. 
Complications from 39 splints, applied for 12 to 79 days, were minimal and transient 
(pressure ulcers: three; spontaneous removal of the splint: twice; twisting of the arm within 
the splint: once). They could all be managed by slight remolding of the splint. 
To develop a highly immunosuppressive anti-rejection treatment another introductory 
study was designed (Chi! D). It was anticipated that the allogeneic hand transplant would 
suffer from severe rejection episodes as in two previous hand transplantation studies in the 
baboon where even high doses of Cy A in combination with prednisolone could not prevent 
rejection of the CTA in the majority of the cases20'21 • Nor could an increase in steroid 
treatment reverse all rejection episodes adequately. Monoclonal antibodies (MAbs), 
however, were known to be capable of selective reactivity with target structures that could 
vary from cell-surface markers to distinct molecules (like cytokines) (Chi B.3.1.5). In 
preclinical experiments in the rodent and nonhuman primate as well as in the clinical setting, 
MAbs had proven to be capable of reversing rejection episodes (ChLB.3.1.5). Most 
interestingly, MAbs specific for the panT-cell marker CD3' had been demonstrated to be 
significantly better (kidney allograft rejection reversal rate of 94%) than conventional steroid 
treatment (reversal rate 75%)". Furthermore, anti-CD3 MAbs have also been reported to be 
effective for the reversal of kidney and liver allograft rejection episodes that were 
nonreversible by high-dose steroids and/or anti-lymphocyte globuline"·". It was hoped 
therefore, that by means of a combination of MAbs with immunosuppressive potency an 
effective therapy could be found for the treatment of CTA-rejection episodes. 
In a skin transplantation study in the rhesus monkey, a combination of seven MAbs were 
tested respectively specific for the following cell surface markers: CD3 (pan T-ee!!), CD4 
(helper/inducer T-cell subset), CD8 (cytotoxic/suppressor T-cell subset) and MHC class II 
(antigen presenting cells and activated T-cells)' (Fig.2). A toxicity-effect study in three 
monkeys which received doses ranging from 0.9 to 9 mg/kg revealed that 4.5 mg/kg induced 
maximal effect on lymphocyte subsets while side-effects were minimal and transient (gall 
expectoration once). Promisingly, in this dose, the combination of these MAbs seemed to 
aCD = Cluster of Differentiation, as defined during the Leucocyte Typing Conferences in Paris, 
1982; Boston, 1984; Oxford, 1986; and Vienna, 1989. 
bMHC antigens= Major Histocompatibility Complex antigens (discussed in Chi B.3.1.1) 
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have an additive effect on top of each individual effect of prolongation of skin allograft 
survival times. Mean allograft survival times could be prolonged from 8.3 (SD=0.7) to 19.3 
(SD=l.3) days in a fully ntismatched donor-recipient combination. Immunomodulatory 
effects of each individual MAb seemed to remain present when combined in a cocktail. In 
this respect the following phenomena were observed: coating (formation of a mantle of the 
cell by the injected MAbs), cell elimination (removal of the target cell) and antigen 
modulation (the target at which the injected MAb was aimed is removed from the cell 
surface: the cell is now naked as far as this surface structure is concerned, Chl.B.3.1.5). 
Noteworthy, approximately seven days after operation the appearance of anti-mouse-
antibodies (AMA) neutralized the injected MAbs. This AMA-response is known to limit the 
beneficial use of MAbs. Alternatives to circumvent this major drawback of MAb-treatment 
were discussed in Chi,B.3.1.5. 
In order to obtain maximal information on the immunological events that take place 
during the immune response against the allogeneic (radial side of the) hand, in a last 
introductory study 2 anti-rhesus and 28 anti-human MAbs were tested for 
immunohistochemical staining reactivity on frozen sections of rhesus monkey tissue 
(ChiLE). Out of these MAbs, 23 proved to be suitable for immunohistological studies of the 
following antigens: MHC class I, II-DR, -DQ, and -DP antigens; the leucocyte markers 
CD!, CD2, CD3, CD4, CD4, CDS, CD14, CD25 and CD57; and a proliferation associated 
nuclear antigen. Eventually, a selection of the five most relevant MAbs was used in our later 
studies for the comparison of intravascular and intra-allograft events (Chiii,B,ChN.A) 
following transplantation. 
With the knowledge gained from these introductory studies, four autologous replantations 
of the partial hand were performed" in the rhesus monkey (Ch!I,C). Technical feasibility of 
the model could be demonstrated. By means of a 'sensiometer', electromyography, histology 
and function tests good motor and sensory recovery could also be demonstrated. The 
replanted thumb was again fully integrated in hand function. The contribution of the thenar 
muscle to the overall function of the thumb could, however, not be quantified very well. As a 
consequence of these results, permission was given by the ethical committee of the Primate 
Center TNO to continue the research project and perform the allogeneic transplantations. 
Technical feasibility of allogeneic transplantation of the radial side of the hand could be 
demonstrated (Chili. A). In a consecutive series 14 transplantations were performed between 
a fully mismatched donor-recipient combination. 12 Transplantations were performed 
successfully. Two technical failures occurred due to irreversible vascular occlusion. This 
result supports data from the first and the only two previously published transplantation 
studies in the nonhuman primate, in which the total hand had been transplanted successfully 
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in the baboon20'21 • 
Allograft recipients were divided into four treatment subgroups of three monkeys with 
successfully transplanted allografts per group, following a statistical design according to 
Fisher" (Table 1). This experimental design would enable us to economize on monkeys and 
evaluate the effect of preoperative third party blood transfusions as well as the value of the 
earlier mentioned MAb anti-rejection therapy. Preoperative blood transfusions were added to 
the research protocol for their known favorable effect on graft survival (Chi B.3.1.3). 
Various recent studies in nonhuman primates stressed the inevitability of using continuous 
high doses of CyA (20-48 mg/kg/day) to obtain prolonged survival of CTAs"'·"·". Therefore, 
in the present study, 25 mg/kg/day CyA in combination with a maintenance dose of steroids 
was used, yielding allograft survival times ranging between 21 and 179 days (Table 1). More 
specifically, CTA survival times were short in six monkeys (21-33 days) and long in the 
other six (79-179 days). Based on survival times of fully mismatched skin grafts in the 
rhesus monkey, it can be assumed that without this base line immunosuppression allografts 
would have been rejected within 7 to 10 days" (ChiLD). 
By means of a specific radioimmuno-assay (RIA) it was demonstrated that whole blood 
CyA trough levels were above the minimal required concentration of 400 ng/ml" in 83% of 
all postoperative samples and in 92% of all samples after day five. CyA levels from day 5 to 
start of anti-rejection therapy did not differ significantly between long term and short term 
survivors. Median CyA levels were 861 (SD=272) and 676 (SD=256) ng/ml, respectively. 
Still, ten out of twelve recipients showed rejection of their allograft. 
In general, monitoring of microvascular surgery, as for instance laser doppler flowmetry 
(LDF) and temperature recordings, can be a helpful tool in detecting vascular compromise, 
particularly if monitoring is performed continuously. As far as technical failures are 
concerned, one case could not be predicted as it occurred two days after surgery, the other 
had in retrospect low monitoring values directly after operation. With regard to the 
prediction of the onset of rejection after limb transplantation in the rat also the LDF-
recordings were performed. In this study, falling LDF-values correlated well with the 
progress of rejection. However, a predictive value could not be established (Ch!I A). In the 
rhesus monkey LDF-values appeared to be too variable and could not be assessed frequently 
enough, resulting in the inability to draw any conclusions with regard to the predictive 
parameter for the onset ofrejection (ChULA). 
Third party blood transfusions did not induce a significant difference in the time of onset 
of allograft rejection (Table 1). Blood transfusions in this study neither facilitated reversal of 
graft rejection nor had a significant effect on allograft survival (Chili A&B). 
Table 1. Allogeneic transplantation of the radial side of the hand in the rhesus monkey; Effects of cyclosporine A, prednisone, monoclonal antibodies 
and third party blood transfusions on graft survival and obtained sensory and motor function recovery. 
First sign of 
Rejection Graft survival functional recovery"' Percentage of 
Monkey Protocol reversal times (days) Motor Sensory sensory recovery 
2799 MAbs 79" <79" 34 75 
4023 & + 
trans f. +" 121° 31 41 91 
2988 22" 
,,,,, ..............•••••••••................•••••••••..............•••••••••.............•••••........ 
3992 MAbs 144 <72d 34 80 
3439 + 
+b,e 97" 46 56' 14 
3308 no rejection 179" 42 64 100 
.................................................... 
2596 DAF 30 
21 & 29" 
3310 trans f. no rejection 85" 56 29 84 
.............................................................................. 
IFU DAF 33 
1550 33 
3212 21 
"functional recovery concerns long term survivors only (n=6 monkeys); bsecond rejection episode; cdeath, spontaneously or due to euthanasia; dfirst 
measurement with electromyography; ereversal of rejection was partial: skin on the palmar side of the thumb and thenar was rejected; 'rejection episode at 
day 41. Abbreviations: MAbs: anti-rejection therapy consisted of a ten day course of a combination of seven monoclonal antibodies; transf.: three third 
party blood transfusions were given to the recipient, preoperatively; DAF: anti-rejection therapy consisted of a raise in steroid treatment; +: reversal; ~: no 
reversal. 
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The absence of a protective effect of third party blood transfusions on CTA survival, could 
be due to the usage of high doses of CyA and DAF masking the expected effect. 
Alternatively, the difference in antigenicity of a CTA including skin compared to a kidney or 
heart allograft might have impaired an anticipated transfusion effect". Possibly for the same 
reasons, retrospective analysis did not accord with the recent clinical evidence that heart and 
kidney allograft survival will be impaired by fully mismatched blood transfusions due to the 
induction of sensitization". In this latter study graft survival could only be improved by 
pretransplant blood transfusion from blood donors sharing at least one HLA-DR antigen with 
the transfusion recipients. 
Five out of the ten monkeys that showed rejection of their transplant, were treated with an 
increase in steroids. In none of these cases, could reversal of rejection be obtained (Table 1). 
The other half were treated with the combination of MAbs, described above. In two out of 
five monkeys this treatment reversed their episode of rejection. As a result MAb-anti-
rejection therapy prolonged CTA survival significantly longer than conventional anti-
rejection therapy with steroids (P=0.015, log-rank test) (Chili A&B). Also a second 
rejection episode could be successfully treated, using the same combination of MAbs. Most 
likely this was achievable because in this study, no neutralizing monkey-anti-mouse 
antibodies were formed in any of the monkeys in which CyA and DAF therapy was 
continued during and after reversal of allograft rejection (ChiiLB.3.4). Without CyA and 
DAF, the same MAbs used in a skin transplantation study, did induce an antibody response 
detectable from the 7th day after the first injection onwards (ChiLD). 
In compliance with the skin transplantation study, the injected MAbs generated coating of 
all peripheral blood lymphocytes, cell elimination of mainly CD3+,CD8+ lymphocytes and 
CD3- and CD8-antigen modulation in each of the allograft recipients in which rejection of 
the radial side of the hand could be reversed (Chill B). The first two mentioned effects could 
also be observed within the allograft itself, though of shorter duration'. 
In all long term survivors, sensory as well as motor function recovery occurred (Chili C). 
Longitudinal monitoring showed that initial sensory return occurred after 41,8 and 43,8 days 
respectively (Table 1). The transplanted skin area, supplied by the median nerve, was 
reinnervated for an average of 74% (14-100%) as assessed by the sensiometer. Rejection had 
a negative effect on the sensibility as well as motor function. This could be demonstrated by 
a reduction of the skin area that would respond to sensory testing (provoking a withdrawal 
reflex after application of a small electrical current to the skin) and decrease of the amplitude 
cFor immunohistochemical staining reactivity with a pan-T cell marker a MAb specific for CD2 (and 
not CD3) was used. 
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of the compound motor action potential (CMAP) during electromyography. Reversal of 
rejection, however, established a clear increase of the skin area that was reactive to sensory 
nerve testing. Also increase to pre-rejection values of the amplitude of the CMAP was 
observed. Immunohistochentical staining for viable motor-end plates provided additional 
evidence for thenar muscle re-innervation. Further evidence was retrieved from a terminal 
experiment in one allograft recipient where direct stimulation of the perineurium of the 
median nerve in the forearm produced a clear CMAP at the heterologous thenar muscles. 
These data support the findings of the previous hand transplantation studies in the baboon, 
that host axons can grow into rejection-free but also into severely rejected (but still viable) 
histoincompatible tissue environment and re-innervate donor sensory receptors31 • 
Despite these promising results, complications were noted (Ch1II.D). Long term survivors 
lost weight ranging from 8 to 40% (average 20%) in relation to preoperative weight. Though 
kidney- and liver parameters were elevated in three and four monkeys respectively, no severe 
nephro- and/or hepatotoxicity was observed. Using similar high doses of CyA and steroids in 
man, more severe kidney and liver damage may occui'2 • Seven allograft recipients died 
during the experiment of which one was due to shock after the first injection of MAbs, three 
were due to posttransplantation lymphoproliferative (PTLP)-disorders and three were due to 
opportunistic bacterial infections (Table 1). Furthermore, one monkey that died from sepsis 
also had PTLP-disorder development at autopsy. Remarkably, similar doses of CyA and 
DAF were administered for periods of more than one year in baboons and no such side 
effects were reported"'·". A previous history of kidney donorship or testis radiation did not 
significantly correlate with occurrence of death or PTLP-disorder development. Addition of 
MAbs anti-rejection therapy to baseline immunosuppression did not correlate to incidence of 
death, significantly. However, it remains most likely that the occurrence of side effects is 
increased, directly related to the number and duration of immunosuppressive drugs 
administered33 • 
Though our population is small, an enhanced predisposition is found to PTLP-disorder 
development (P=0.03, one-sided Fisher test) in the monkeys that received MAbs anti-
rejection therapy. The MAbs used, were specifically aimed at lymphocytes, which might 
have precipitated lymphoid lesions, rather than other malignities. Alternatively, virus 
infections, notably Epstein-Barr" and Human T-Leukemia Virus (HTLV) infections", have a 
possible etiological link with the development of lymphoma. Apparently, only two CTA 
recipients, that showed PTLP-disorder development, were seropositive for antibody titers 
against Simian TLV (STLV) (Ch!Il,D). However, all four PTLP-disorders showed presence 
of STLV provirus at the DNA level in malignant tissue (ChiiLE). This implicates a possible 
etiological role of STL V in PTLP-disorder development in combination with additional 
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immunosuppressive therapy. However, the diversity of morphologic and phenotypic PTLP-
disorder characteristics does not indicate a single etiology in the development of these 
disorders. 
Clearly, the limitations of the currently used immunosuppressive treatments indicate that 
further research in this field is required before transplantation of the allogeneic hand in man 
should ever be performed. In this respect the immunosuppressive effect of two new MAbs 
specific for potent immunomodulatory cytokines was investigated in a rhesus monkey skin 
transplantation model (ChiV.A). Prophylactic treatment with an anti-interferon-7 or anti-
tumor necrosis factor-e< specific MAb alone did not prolong skin graft survival times. 
Neutralization of either one of these cytokines, was apparently not sufficient to suppress the 
immune response. However, treatment with the combination of these MAbs resulted in a 
modest but significant prolongation of allograft survival times. Compared to MAbs specific 
for MHC class II positive and CD8+ cells, which had mean skin graft survival time of 12.4 
and 12.9 days" (ChiLD) respectively, the immunosuppressive effect of the combination of 
anti-interferon--y and anti-tumor necrosis factor-a was equally strong. 
Also, a skin transplantation study in the rat was performed to test the newly available drug 
FK-506 (Chi.B.3.1.6 & ChiV.B). Administration for a duration of 15 days of 0.1 mg FK-
506 had a similar effect on skin graft survival as 5 mg CyA. Furthermore, in agreement with 
other experimental data it was found that minimally therapeutic doses of FK-506 act 
synergistically with suboptimal doses of CyA"-". Recently, also in a clinical trial, oral 
administration of FK-506 in low doses was demonstrated to be an effective and safe 
immunosuppressant for liver, kidney and pancreas transplantation". With regard to these 
data, it seems worthwhile to investigate the immunosuppressive potency of FK-506 in an 
allogeneic composite tissue model. Preliminary results on this topic also seem promising"'. 
CONCLUSIONS 
Technical aspects 
Studies with respect to the anatomy of the hand of the rhesus monkey can support the 
assumption that data yielded from hand transplantation experiments in the rhesus monkey 
can be extrapolated to the human situation. 
Technical feasibility of the research model could be demonstrated in the replants. Also 
allogeneic transplantation of the radial side of the hand could be realized technically in a 
rhesus monkey model. Wound healing was uneventful in both replants and transplants. 
Monitoring devices like temperature measuring and laser doppler flowmetry could not 
provide a predictive value for vascular occlusion nor for onset of rejection in this model. 
----------------------------------------- Discussion and summary --------------------------------- 241 
Functional aspects 
The thumb was again fully integrated in hand function following autologous replantation 
of the radial side of the hand. Very good function recovery could be established in these 
monkeys. Also following allogeneic transplantation of the radial side of the hand sensory 
and motor function recovery occurred. Rejection caused a decrease in functional recovery, 
however this increased again if rejection was reversed. 
Evaluation of sensory and motor function recovery could only be performed during a half 
year postoperatively. Nevertheless, sensory recovery reached near normal levels in the non-
rejected allografts when compared to the contralateral side. 
With respect to motor recovery the amplitude of the compound motor action potentials of 
the thenar muscles as well as the distal thenar muscle latency time in non-rejected allografts 
approached the values of the same parameters on the contralateral side. 
Immunohistochemical staining demonstrated vital motor-end plates as evidence for motor 
reinnervation. 
Innnunological aspects 
In skin transplantation studies in the rhesus monkey the immunosuppressive potency was 
tested by a combination of seven monoclonal antibodies (MAbs) specific for the following 
cell surface structures: CD3 (=panT-cell), CD4 (helper/inducer T cell-subset) and CDS 
(cytotoxic/suppressor T-cell subset). In combination these MAbs appeared to possess an 
additive effect on top of their individual effect to prolong allograft survival times. 
Continuous high doses of cyclosporine A and prednisone enabled long term graft survival 
in six out of twelve allograft recipients. The aforementioned MAbs therapy could reverse 
rejection prolonging allograft survival times significantly longer than steroid anti-rejection 
treatment. MAbs therapy induced a vigorous elimination of mainly the CD2 +, CD3 + 
(=pan T-ee!!), and CDS+ (=cytotoxic/suppressor T-cell subset) lymphocyte subsets in the 
peripheral blood as well as in the allograft. 
Despite these and afore mentioned results the currently used immunosuppressive regimen 
also had some major complications: seven rhesus monkeys died during experiment. In four 
of these monkeys a posttransplantation lymphoproliferative (PTLP)-disorder developed and 
in all of these cases the Simian T-Leukemia Virus (STLV)-provirus was detected in the DNA 
of the lymphoproliferative tissue. 
The presence of STL V -provirus in all four PTLP-disorders implicates a possible etiologic 
role of STLV in tumor development, especially when combined with high doses of 
immunosuppressive therapy. It should also be noted that the addition ofMAbs to base-line 
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immunosuppressive therapy correlated (weakly) to PTLP-disorder development. 
In the context of the search for necessary improvements to control rejection and minimize 
side effects, a synergistic effect was found firstly, between MAbs specific for the cytokines 
interferon-gamma and tumor necrosis factor-alpha and secondly, between cyclosporine A and 
the new immunosuppressive drug FK-506. 
Prospects 
Transplantation of the allogeneic hand seems to be closer to reality, since some promising 
results were obtained in technical, functional and immunological aspects. However, as a 
consequence of the fact that using high doses of the best immunosuppressive agents available 
today, still seven monkeys died prematurely, it is therefore necessary to seek a more 
effective and less toxic regimen before transplantation of the (total) hand can be performed in 
man. 
Once such an agent or combination of agents becomes available than most likely the 
indication for functional and esthetic reconstruction by the use of allogeneic tissue will be 
present. 
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Dit 'dubbel-proefschrift' beschrijft onderzoek over de technische, functionele en 
immunologische aspecten van allogene transplantatie van de (radiaireb zijde van de) hand, in 
de rhesusaap. 
Onderzoek op dit gebied werd geinitieerd door de vraag van patienten en/of ouders of het 
probleem van een niet functionerende of afwezige hand eventueel kon worden opgelost door 
allogene transplantatie. Wat de onderliggende oorzaak ook moge zijn, traumatisch, 
aangeboren of oncologisch, zelfs de meest geavanceerde pro these kan het verlies van 
sensibiliteit en motoriek niet vervangen. Tegenwoordig kan klinisch bijna ieder orgaan 
worden getransplanteerd uiteenlopend van nier1'2 , hart (soms in combinatie met de longen)3 , 
lever\ beenmerg5 , alvleesklier6 , ingewanden7 , zelfs huid8 . Met name dankzij de ontdekking 
van Cyclosporine A (CyA) (Chapter I, section B.3.1.4: Chl.B.3.1.4) kunnen redelijke tot 
zeer goede transplantaat- en patientoverlevingstijden worden verkregen 1-7 • Bovendien zijn 
sinds de zestiger jaren microchirurgische technieken ter beschikking gekomen die het 
mogelijk hebben gemaakt zeer kleine vaten en zenuwen te hechten (ChLA.!). Op grond van 
deze ontwikkelingen is experimenteel onderzocht of handtransplantatie met langdurig 
overleven en behoud van functie mogelijk is. 
Talrijke studies zijn verricht die zich concentreerden op de haalbaarheid een combinatie 
van meerdere verschillende weefsels, zoals bot, pezen, zenuwen, vaten en huid (hierna te 
noemen een CTA: 'composite tissue allograft') te transplanteren (Chi). Het betrof dan 
voomamelijk achterpoottransplantaties bij de rat"'. Uit laatstgenoemde experimenten 
kunnen technische, functionele en immunologische aspecten die van belang zijn naar voren 
komen. In dit opzicht kon door onze groep worden aangetoond dat fluctuaties van perifere 
bloedgassen, bloedsuiker- en melkzuurspiegels het moment van afstoting van een CTA niet 
voorspellen (Chi! A). Wei bleek dat de flux (aantal per tijdseenheid) van perifere bloedcellen 
door de huid van een CTA, gemeten met een laserdopplerflow-(LDF)-meter', daalde bij een 
toename van de transplantaatafstoting. Echter, ook deze LDF-metingen hadden geen 
voorspellende waarde ten aanzien van het begin van afstoting, waarschijnlijk door de 
onmogelijkheid om continu te meten. De eerste zichtbare tekenen van afstoting waren steeds 
aafk:omstig van een ander individu van dezelfde species 
baan de kant van de radius, het spaakbeen cq. de kant van de duim 
cDe LDF-meter is een apparaat dat de huiddoorbloeding meet met behulp van een laserstraal op basis 
van bet doppler-effect. 
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oedeemvormingd, haaruitval en 
epidermolysis<. 
V oor extrapolatie naar de situ-
atie bij de mens hebben studies in 
lmaagdieren duidelijk hun beperk-
ingen, zowel vanuit technisch en 
functioneel alsook vanuit immuno-
logisch oogpunt. W anneer ooit tot 
transplantatie van de (totale) hand 
bij de mens wordt overgegaan dan 
zal informatie over de technische 
haalbaarheid, de mate van afsto-
ting en het herstel van functie van 
eminent belang zijn. 
Bij voorkeur dient een nonhu-
mane primaat te worden gebruikt 
voor het preklinisch testen van 
deze aspecten van allogene hand-
transplantati.e vanwege de over-
duidelijke anatomische, functio-
nele, immunologische en fylogene-
tischer overeenkomsten tussen de 
aap en de mens. In verband hier-
mee is de aap een beter proefdier 
dan andere dieren om de werking 
en bijwerking van immunosup-
pressieve middelen en monoclo-
Figuur 1. Het transplantaat. De gestippelde lijn markeert 
de getransplanteerde radiaire zijde van de hand. 
Handpalm: A = adductor spier; T = thenar spier; U.n. 
= ulnaire zenuw; M.n. = mediane zenuw; r.a. = 
radiaire arterie; Pezen: f.p.l. = flexor pollicis longus; 
a.p.l. = abductor pollicis longus. Handrug: s.r.n. = 
superficiale radiaire zenuw; c.v. = cephalica vene; 
Pezen: e.p.l. = extensor pollicis longus; a.p.l. = 
abductor pollicis longus. 
nale antilichamen (MAbs) te testen"·". Op grond van bovengenoemde aspecten van allogene 
handtransplantatie was bet ons doe! dit onderzoek te verrichten in een rhesusaap-
proefdiermodel. «r 
4onderhuidse vloeistofophoping 
0loslating van de opperhuid 
rontwikkeling van de soort gedurende de evolutie 
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In het experimentele model werd gebruik gemaakt van een transplantaat dat bestond uit de 
radiaire zijde van de hand tesamen met de radiaire onderarmslap (Fig. I, ChLC.l.2). Uit 
ethisch oogpunt werd een ldeine, onafhankelijk functionerende eenheid van de hand gekozen. 
Een van de inleidende studies bewees inderdaad dat de anatomie van het transplantaat van de 
rhesusaap zeer te vergelijken was met de situatie bij de mens (ChiLB). De rhesusaap leeft 
gecombineerd op de grond en in de bomen. Door dit leefpatroon heeft de rhesusaap een beter 
functionerende duim nodig dan bijvoorbeeld een slingeraap. De rhesusaap is in staat tot 
oppositie, echter niet zo goed als de mens. De duim van de rhesusaap was in verhouding 
korter dan de duim bij de mens. Belangrijke verschillen waren dat de lange buiger (musculus 
flexor pollicis longus) naar de duim zich pas afsplitste van de andere buigers op het niveau 
van de pols. Ten gevolge hiervan kan de duim minder onafhankelijk buigen. Tevens bleek 
dat bij de rhesusaap de korte strekker (musculus extensor pollicis brevis) ontbreekt, 
waardoor stabilisatie van het metacarpophalangeale gewricht' van de duim minder optreedt 
bij grijpbewegingen. Een belangrijke overeenkomst was dat de duimmuisspieren van de 
rhesusaap in aanleg gelijk waren aan die van de mens. De zenuwen naar de duim hadden een 
vrijwel identiek verloop. 
Vervolgens werd een op maat gemaakte spalk ontwikkeld voor de bescherming van het 
transplantaat na operatie (ChiLC). Spalken van thermoplast uit een stuk bleken Iicht, sterk, 
gemakkelijk te maken en goedkoop te zijn. Bovendien verschaften zij een adequate 
immobilisatie en bescherming van de hand. Ze konden Ievens gemakkelijk verwijderd en 
teruggeplaatst worden bij wondinspectie. De spalken waren geplaatst voor periodes van 12 
tot 79 dagen. De complicaties bij de 39 spalken bleken minimaal (ulcera: driemaal; spontaan 
uittrekken van de spalk: tweemaal; draaien van de arm in de spalk: eenmaal). Ze konden aile 
adequaat worden behandeld door het aanbrengen van Iichte veranderingen aan de spalk. 
Om een sterk immunosuppressieve anti-afstotingsbehandeling te ontwikkelen was een 
andere inleidende studie ontworpen (Ch!I D). Er werd namelijk verwacht dat de allogene 
handtransplantaten episoden van zware afstoting te verduren zouden krijgen. Immers zoals 
bleek uit twee vorige studies van handtransplantatie bij de baviaan konden zelfs zware doses 
CyA in combinatie met steroiden afstoting van het CTA in de meerderheid van de gevallen 
niet voorkomen20'21 • Tevens kon een verhoging van de steroidenbehandeling niet alle 
afstotingsepisoden adequaat omkeren. MAbs echter, kunnen selectief reageren met 
doelwitten die uiteen kunnen !open van celoppervlaktestructuren tot bepaalde moleculen 
&het gewricht tussen de middenhandsbeenderen en de vingerkootjes 
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(zoals cytokinen') (Chi B.3.1.5). In preklinische experimenten bij het knaagdier en de 
nonhumane primaat alsook bij klinische experimenten hebben MAbs bewezen afstotings-
episoden te knnnen omkeren (Chi.B.3.1.5). Interessant genoeg bleken MAbs, specifiek voor 
de 'algemene T-ee! marker' CD3', hiertoe significant beter in staat te zijn (niertransplantaat-
afstotings-omkerings-percentage 94%) dan conventionele behandeling met stero I den 
(afstotings-omkerings-percentage 75% )"". Bovendien is gerapporteerd dat anti-CD3 MAbs 
effectief zijn bij de omkering van nier- en leverafstotingsepisoden die niet meer reageerden 
op hoge doses steroiden en/of anti-lymfocyten globuline"·". Om deze reden werd gehoopt 
dat door middel van een combinatie van meerdere MAbs met immunosuppressieve potentie 
een adequate therapie gevonden kon worden voor de behandeling van CTA-
afstotingsepisoden. 
In een huidtransplantatiestudie bij de rhesusaap werd een combinatie van zeven MAbs 
getest die respectievelijk specifiek waren voor de volgende celoppervlaktestructuren: CD3 
(pan T-ee!), CD4 (helper/inducer T-ee! subset), CDS (cytotoxische/suppressor T-ee! subset) 
en MHC klasse II (antigeen presenterende cellen en geactiveerde T-cellenj (Fig.2). Een 
toxiciteits-effect studie met deze combinatie van MAbs bij drie rhesusapen die doses 
ontvingen varierend van 0.9 tot 9 mg/kg onthulde dat 4.5 mg/kg maximale effecten teweeg 
bracht op de lymfocyten-subsets terwijl de neveneffecten minimaal en van voorbijgaande 
aard bleken te zijn (eenmalig werd gal gebraakt). Veelbelovend bleek dat in deze dosering de 
combinatie van deze MAbs een additief effect bleek te hebben om de transplantaat-overleving 
te verlengen. Gemiddelde huidoverlevingstijden konden worden verlengd van 8.3 (SD=0.7) 
tot 19.3 (SD = 1.3) dagen in een volledig gemismatchte donor-gastheer combinatie. 
Immunomodulatoire effecten van ieder individueel MAb leken aanwezig te blijven bij het 
combineren tot een cocktail. In dit opzicht werden gezien: 'coating' (bedekken van het 
celoppervlak door de ingespoten MAbs), 'cel-eliminatie' (verwijdering van de doelwit-
bimmuno-actieve stoffen die door bepaalde cellen als T-lymfocyten en macrofagen als reactie op 
bepaalde prikkels (o.a. antigenen) worden geproduceerd. 
iCD ::;;: Differentiatie-cluster zoals deze zijn getypeerd gedurende de 'Leucocyt Typerings 
Conferenties' in Parijs, 1982; Boston, 1984; Oxford, 1986; en Wenen, 1989. Deze 'oppervlakte-
antennes' komen voor op allerlei witte bloedcellen Oeucocyten); het gedeelte kleine witte bloedcellen 
met ronde of ovale kern en smalle zoom protoplasma (lymfocyten) is onder te verdelen in: 
lymfocyten die antilicharnen produceren (B-cellen) en lymfocyten die de cellulaire immuniteit 
verzorgen (f-cellen). 
iMHC = 'Major Histocompatibility Complex', bediscussieerd in Chi.B.3.1.1. 
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cellen) en 'antigeen-modulatie' (het doelwit waartegen de ingespoten MAbs gericht waren is 
van het celoppervlak verwijderd: de eel is 'naakt' voor wat betreft deze oppervlakte-
structuur) (Chi.B.3.1.5). Opgemerkt dient te worden dat ongeveer zeven tot negen dagen na 
eerste toediening de verschijning van anti-muis-antilichamen (AMA) de ingespoten MAbs 
(die van muizen-origine waren) neutraliseerden. Van de AMA-respons is bekend dat deze het 
werkzame effect van MAbs teniet doet. Altematieven om deze beperking van het gebruik van 
MAbs te voorkomen zijn besproken in Chi B.3.1.5. 
Om maximale informatie te verkrijgen over de immunologische gebeurtenissen die plaats 
vinden gedurende de immuunrespons tegen de allogene (radiaire zijde van de) hand, werden 
in een laatste inleidende studie twee anti-rhesus en 28 anti-mens MAbs getest op hun 
immunohistochemische ldeuringsactiviteit op diepgevroren coupes van rhesusaapweefsel 
(ChiLE). Van deze MAbs bleken 23 stuks geschikt te zijn voor de immunohistochemische 
studie van de volgende antigenen: MHC klasse I, II-DR, -DQ, en -DP antigenen; de 
leucocyt-markers CD!, CD2, CD3, CD4, CDS, CD14, CD25 en CD57; en een kem-anti-
geen geassocieerd met celdeling. Uiteindelijk is in onze latere studies een selectie van de vijf 
meest relevante MAbs gebruikt voor de vergelijking van post-transplantatie-gebeurtenissen 
binnen de bloedbaan en die buiten de bloedbaan in het transplantaat zelf (QillL.!l & 
ChiV.A). 
Met de kennis verkregen uit deze vijf inleidende studies, werden bij de rhesusaap vier 
autologe replantaties van de radiaire zijde van de hand verricht (ChiLC). De technische 
haalbaarheid van het proefdiermodel kon worden aangetoond. Door middel van een 
"sensiorneter"\ electromyografie, histologie en functietesten kon eveneens een goed 
motorisch en sensibel herstel worden aangetoond. De duim was weer volledig geintegreerd 
in de handfunctie na replantatie, het aandeel van de duimmuisspieren in de totale 
samengestelde beweging van de duim kon echter niet goed gequantificeerd worden. Naar 
aanleiding van deze gegevens werd het door de ethische commissie van het Primaten 
Centrum TNO toegestaan te continueren met allogene transplantaties. 
Eveneens kon de technische haalbaarheid van transplantatie van de radiaire zijde van de 
hand in de allogene proefopzet worden aangetoond (ChULA). In een opeenvolgende serie 
werden 14 transplantaties verricht tussen volledig gemismatchte donoren en ontvangers; 
hiervan waren 12 succesvol. Twee technische mislukkingen waren te wijten aan vaat-
afsluiting in de direct postoperatieve fase. Dit resultaat ondersteunt data van de eerste en 
enige twee voorafgaande transplantatiestudies bij de nonhumane primaat, waarbij de totale 
kApparaat waarmee een zeer Iichte stroomstoot gegeven werd op de huid. Bij gevoelsherstel van het 
huidgebied volgde een terugtrek reactie van de arm. 
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hand succesvol kon worden getransplanteerd bij de baviaan"'·". 
De transplantaat-ontvangers werden verdeeld in vier behandelingsgroepen, ieder bestaande 
uit drie apen met een succesvol getransplanteerde radiaire zijde van de hand per groep (fabel 
1). Deze factoriele 'proefopzet van Fisher'" stelde ons in staat economisch verantwoord met 
het aantal benodigde apen om te gaan en maakte simultane evaluatie mogelijk van zowel het 
effect van preoperatieve derde partij bloedtransfusies' als de waarde van de eerder genoemde 
MAbs anti-afstotingstherapie. Preoperatieve bloedtransfusies werden toegevoegd aan het 
onderzoeksprotocol omdat bekend is dat zij een gunstig effect op de transplantaatoverleving 
kunnen hebben (ChLB.3.1.3). 
Meerdere recente studies bij de nonhumane primaat hebben de noodzaak benadrukt om 
continu hoge doseringen van Cy A te gebruiken (20-48 mg/kg/ dag) om verlengde overleving 
van CTA's te verkrijgen"·"·". Zodoende werd in de huidige studie 25 mg/kg/dag CyA 
gebruikt in combinatie met een onderhoudsdosering stero I den. Dit leverde transplantaat-
overlevingstijden op die uiteen1iepen van 21 tot 179 dagen (fabel 1). De CTA-overle-
vingstijden waren kort bij zes apen (21-33 dagen) en lang bij de overige zes (79-179). 
Gebaseerd op de overlevingstijden van volledig gemismatchte huidtransplantaten bij de 
rhesusaap kan worden aangenomen dat wnder basis-immunosuppressie de allotransplantaten 
binnen 7 tot 10 dagen zouden zijn afgestoten" (ChiLD). 
Door midde1 van een specifieke radioimmuno-assay (RIA) werd aangetoond dat de 
volbloed-dalspiegels van CyA boven de minimaal vereiste concentratie van 400 ng/ml 
waren" in 83% van aile postoperatieve monsters en in 92% van aile monsters na dag 5. 
Cy A-dalspiegels tussen dag 5 en de dag van het begin van afstotingsbehandeling verschilden 
niet statistisch significant tussen lange en korte transplantaatoverlevers. Mediaan CyA-
dalspiegels waren respectievelijk 861 (SD=272) en 676 (SD=256) ng/ml. Desalniettemin 
vertoonden lien uit twaalf rhesusapen afstoting van hun transplantaat. 
In het algemeen is het monitoren na microvasculaire operaties door bijvoorbeeld 
laserdopplerflow-(LDF)-metingen en temperatuurregistratie, een zinnige methode om 
vasculaire problemen vroegtijdig te detecteren, met name als de monitoring continu word! 
verricht. Wat betreft de twee technische mislukkingen kon in een geval vaatafsluiting niet 
worden voorspeld, aangezien deze pas twee dagen na operatie optrad. In het tweede geval 
bleek, achteraf bezien, dat de meetwaarden direct na operatie reeds laag waren. 
1hiervan is sprake indien bet bloed afk:omstig is van bloeddonoren waarvan het MHC volledig 
verschilt van het MHC van zowel de transplantaatdonor als van dat van de 
transplantaat/bloedontvanger. 
Tabell. Allogene transplantatie van de radiaire zijde van de hand bij de rhesusaap; Effecten van cyclosporine A, prednison, monoclonale antilichamen 
en preoperatieve derde--partijmbloedtransfusies op transplantaatoverleving en verkregen sensibel en motorisch herstel. 
transplantaat Eerste teken van 
Rejectie omkering van overlevingstijd functioneel herstel"- Percentage 
Aap Protocol afstoting (dagen) motorisch sensibel sensibel herstel 
2799 MAbs 79" <79" 34 75 
4023 & + 
trans f. +' 121" 31 41 91 
2988 22" 
....................................................................................................... 
3992 MAbs 144 <72d 34 80 
3439 + 
+'" 97" 46 56' 14 
3308 geen afstoting 179" 42 64 100 
...................................................... 
2596 DAF 30 
2! & 29" 
3310 trans f. geen afstoting 85" 56 29 84 
............ 
IFU DAF 33 
1550 33 
3212 21 
"functioneel herstel betreft aileen de lange overlevers (n=6 a pen); btweede afstotingsperiode; ~dood, spontaan of ten gevolge van euthanasie; deerste meting 
met electromyograaf; eafstoting werd slechts gedeeltelijk omgekeerd: de huid aan de palmaire zijde van duim en thenar werd afgestoten; rafstotingscrisies op 
dag 41. Afkortingen: MAbs: anti-rejectie therapie bestaat uit een 10-daagse kuur met de combinatie van 7 MAbs; transf.: drie derde-partij-bloedtransfusies 
werden preoperatief gegeven aan de ontvanger; DAF: anti-rejectie therapy bestond uit een verhoging van de prednison doses; +: omkering; -: geen 
omk:ering van afstoting. 
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Ten aanzien van het voorspellen van begin van afstoting werden bij de allogene 
extremiteitstransplantaties bij de rat o.a. LFD-metingen gebruikt. In deze studie correleerde 
de daling van de LDF-waarden goed met het optreden van afstoting, echter een predictieve 
waarde kon niet worden vastgesteld (Ch!I A). In de rhesusaap bleken de LDF-metingen te 
variabel en kon niet vaak genoeg gemeten worden, zodat geen conclusies konden worden 
getrokken uit dit onderzoek betreffende de voorspellende waarde voor begin van afstoting 
(Ch!II. A). 
Derde-partij-bloedtransfusies induceerden geen significant verschil in het moment van 
begin van transplantaatafstoting (Tabel 1). Bloedtransfusies bleken noch omkering van 
afstoting te vergemakkelijken, noch hadden ze een significant effect op de transplantaat-
overlevingstijden in deze studie (Chlll,A&B). De afwezigheid van een beschermend effect 
van derde-partij-bloedtransfusies op de CTA-overleving kan te wijten zijn aan het gebruik 
van hoge doses CyA en steroiden die het verwachte effect zouden hebben gemaskeerd. 
Anderzijds kan het verschil in antigeniteit• van een CTA met huid vergeleken met een nier-
of harttransplantaat het bloedtransfusie-effect teniet hebben gedaan". Mogelijk vanwege 
dezelfde redenen bleek retrospectieve analyse niet overeen te komen met he! recent 
beschreven klinische bewijs dat nier- en harttransplantaatoverleving verslechterd zullen 
worden door volledig gemismatchte bloedtransfusies ten gevolge van sensitisatie"'. In deze 
klinische studie bleek transplantaatoverleving alleen te worden verbeterd door pre-
transplantatiebloedtransfusies die kwamen van donoren die ten minste een HLA-DR antigeen 
deelden met de bloedtransfusie-ontvangers. 
De helft van de tien rhesusapen die een afstotingsreactie van hun transplantaat lieten zien, 
werd behandeld met een verhoging van de steroidendoses. In geen van deze gevallen kon 
omkering van de afstoting worden bewerkstelligd (Tabel 1). De andere helft werd behandeld 
met de hierboven beschreven combinatie van MAbs. Bij !wee van de vijf apen werd met deze 
behandeling de rejectie-episode omgekeerd (Ch!II.B.3.4). Door de MAbs-anti-afstotings-
therapie werd de CTA-overlevingstijd significant sterker verlengd dan het geval was met de 
conventionele anti-afstotingsbehandeling door steroiden (P=0.015, log-rank test) 
(Chili A&B). Een tweede episode van transplantaatafstoting kon eveneens succesvol worden 
behandeld, gebruikmakend van dezelfde combinatie van MAbs. Zeer waarschijnlijk was dit 
mogelijk vanwege het feit dat, in deze studie, geen neutraliserende aap-anti-muis-
antilichamen waren gevormd in die a pen waarbij de Cy A en stero i dentherapie was 
gecontinueerd tijdens en na de omkering van de transplantaatafstoting. Zonder CyA en 
mhet vermogen als antigeen (stof die bet organisme aanzet tot de produktie van antilicharnen) te 
werken 
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steroiden induceerden dezelfde MAbs in een huidtransplantatiestudie wei degelijk een 
antilichaamrespons. Deze was detecteerbaar vanaf de zevende dag na de eerste injectie met 
MAbs (ChiLD). 
De ingespoten MAbs bewerkstelligden coating van aile perifere bloedcellen, cel-eliminatie 
van hoofdzakelijk CD3+ en CDS+ lymfocyten en modulatie van CD3- en CD8-antigenen 
bij ieder van de CTA-ontvangers waarbij afstoting kon worden omgekeerd. Dit was ook het 
gevai in de eerder verrichte huidtransplantatiestudie (Chill,B). De eerste twee genoemde 
effecten konden met immunohistochemische kleuringen eveneens worden geobserveerd in de 
ailotransplantaten zelf, zij het dat ze korter duurden". 
Bij aile lange transplantaat overlevers trad zowel herstel van gevoel ais spierfunctie op 
(Chill, C). Longitudinaal onderzoek toonde aan dat tekenen van eerste herstel van gevoel en 
spierfunctie respectievelijk na 41,8 en 43,8 dagen optraden (Tabel 1). Het getransplanteerde 
huidgebied, verzorgd door de nervus medianus was gemiddeld voor 74% (14-100%) 
gereinnerveerd, gemeten met behulp van de sensiometer. Afstoting had een negatief effect op 
zowel sensibiliteit ais motoriek. Dit kon worden aangetoond door een verkleining van het 
gebied dat reageerde op sensibiliteitsonderzoek en een verlaging van de amplitude van het 
samengesteld ('compound') motor-actie potentiaal (CMAP) van de duimmuisspieren tijdens 
electromyografie. Omkering van afstoting echter, liet een duidelijk herstel zien van het 
huidgebied dat reageerde op sensibiliteitsonderzoek. De waarden van de amplitudes van de 
CMAP van de duimmuis spieren waren eveneens reversibel. Immunohistochemische kleu-
ring van vitale motor-eindplaatjes leverde additioneel bewijs voor re'innervatie van de 
duimmuisspieren. Extra ondersteuning hiervoor was afkomstig uit een terminaal experiment 
bij een ailotransplantaat-ontvanger waarbij directe stimulatie op het perineurium van de 
nervus medianus" in de onderarm een duidelijk CMAP produceerde afkomstig van de 
ailogene duimmuisspieren. Deze data geven aan dat gastheer-axonen sensibiliteitsreceptoren 
van de donor kunnen reinnerveren31 • 
Ondanks deze veelbelovende resultaten traden ook complicaties op (Chili D). Lange 
overlevers daalden 8 tot 40% (gemiddeld 20%) in gewicht ten opzichte van voor de operatie. 
Alhoewel nier- en leverwaarden verhoogd waren in respectievelijk drie en vier gevallen, trad 
4 Voor een immunohistochemische kleuringsreactie met de algemene T -eel marker werd een MAb 
gebruikt specifiek voor CD2 (en niet CD3). 
'de in bet midden van de pols gelegen zenuw die !evens de belangrijkste zenuw was bij het tot stand 
komen van sensibel en motorisch herstel van bet transplantaat. 
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geen ernstige nier- en/oflevertoxiciteit op. Indien vergelijkbare doses CyA en steroiden bij 
de mens worden gebruikt, dan kunnen weldegelijk ernstiger schade aan de nier en lever 
worden verwacht". Zeven allotransplantaat-ontvangers overleden tijdens experiment (Tabel 
1). Een ten gevolge van shock na de eerste injectie van MAbs, drie ten gevolge van 
posttransplantatie lymfoproliferatieve (PTLP)-afwijkingen en drie ten gevolge van 
opportunistische bacteriele infecties. Een van de apen die overleed aan een bacteriele infectie 
bleek bij autopsie ook een PTLP-afwijking te hebben ontwikkeld. Opmerkelijk is dat bij 
bavianen vergelijkbare doses van CyA en steroiden gedurende perioden Ianger dan een jaar 
zijn gegeven en dat geen van dit soort neveneffecten optrad20.21 • De voorgeschiedenis, zoals 
nierdonorschap of testisbestraling bleek niet te correleren met het optreden van dood of 
PTLP-afwijkingen. Toevoeging van MAbs-anti-afstotingstherapie aan de basis-
immunosuppressie correleerde niet significant met het optreden van dood. Echter, het blijft 
zeer waarschijnlijk dat in directe samenhang met het aantal immunosuppressieve 
medicamenten en de duur van toediening, het optreden van neveneffecten wordt verhoogd32 • 
Alhoewel onze populatie klein is, werd een verhoogde predispositie gevonden tussen de 
apen die MAbs-anti-afstotings therapie hadden ontvangen en ontwikkeling vertoonden van 
PTLP-afwijkingen (P=0.03, eenzijdige Fisher-test). De gebruikte MAbs waren specifiek 
gericht op lymfocyten, wat eerder het ontstaan van lymfoide dan andersoortige maligne 
afwijkingen in de hand kan hebben gewerkt. Als alternatief moet worden opgemerkt dat 
virusinfecties, met name Epstein-Barr- 33 en Humaan T-Leukemie Virus (HTLV) -infecties, 
een mogelijk oorzakelijk verband hebben met de ontwikkeling van lymfoma's. 
Ogenschijnlijk waren slechts twee van de vier aj>en die PTLP-afwijking vertoonden 
seropostief voor antilichamen tegen Simiaan-TLV (STLV)' (Chili D). Echter, aile vier 
gevallen die PTLP-afwijkingen hadden ontwikkeld bleken de aanwezigheid van STLV-
provirus op DNA-niveau in het lymfoproliferatieve weefsel te hebben (Chill,EJ'. Dit 
impliceert een mogelijke rol van STL V bij de ontwikkeling van maligne afwijkingen in 
combinatie met additionele immunosuppressie. De diversiteit van de morfologische en 
fenotypische PTLP-karakteristieken' duidt niet op een eenduidige oorzaak achter de 
Psimia = aap 
qin aile gevallen bleek dus in het erfeiijk materiaal van de lyrnfoide tumor die van apen-origine was, 
erfelijk rnateriaal van het virus te zijn ingebouwd. 
'de vorm en structuur (morfologie) van de tumor werd bepaald met algemene lichtmicroscopie op 
standaard gekleurde coupes; de verschijningsvorm (fenotype) van de tumor werd bepaald met 
immunohistochemische kleuringen. 
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ontwikkeling van deze afwijkingen. 
Het lijkt duidelijk dat de beperkingen van de huidig gebruikte immunosuppressieve 
behandeling aangeven dat verder onderzoek op dit gebied geindiceerd is voordat bij de mens 
de allogene hand getransplanteerd kan worden. Met dit idee werd het immunosuppressieve 
effect van twee nieuwe MAbs specifiek voor potente immunomodulatoire cytokines 
onderzocht in een huidentransplantatiestudie bij de rhesusaap (ChN.A). Profylactische 
behandeling met aileen een anti-interferon-gamma of anti-tumor necrosis factor-alpha 
specifiek MAb, verlengde de huidoverlevingstijden niet. Neutralisatie van slechts een van 
beide lymfokines was blijkbaar niet afdoende om de immuunrespons te onderdrukken. 
Echter, behandeling met de combinatie van deze twee MAbs resulteerde in een bescheiden 
maar significante verlenging van de allotransplantaat-overlevingstijden. Vergeleken met 
MAbs, specifiek voor MHC klasse II en CD8-positieve cellen die respectievelijk een 
gemiddelde huidoverlevingstijd bewerkstelligden van 12.4 en 12.9 dagen" (Chi! D), was dit 
immunosuppressieve effect van de combinatie van anti-interferon-gamma en anti-tumor-
necrosis factor-alpha even sterk. 
Eveneens werd een huidtransplantatiestudie bij de rat verricht om het nieuwe medicijn 
FK-506 te testen (Chi.B.3.1.6 & ChiV.B). Toediening van 0.1 mg FK-506 voor de duur van 
15 dagen had een gelijkwaardig effect op de huidtransplantaatoverleving als toediening van 5 
mg CyA voor dezelfde duur. Bovendien werd in overeenkomst met andere experimentele 
data geconstateerd dat minimale therapeutische doseringen van FK-506 synergistisch 
reageerden met suboptimale doseringen CyA"·". Kortgeleden bleek oak uit een klinisch 
onderzoek dat orale toediening van FK-506 in !age doseringen resulteerde in een effectieve 
en veilige immunosuppressie bij lever-, nier- en alvleesldier-transplantatie38 • Naar aanleiding 
van deze gegevens Jijkt het zinvol de immunosuppressieve potentie van FK-506 te 
onderzoeken in een allogeen samengesteld-weefsel transplantatiemodel. Voorlopige 
resultaten op dit gebied lijken veelbelovend". 
Conclusies 
Techuische aspecten 
Studies naar de anatomie van de hand van de rhesusaap kunnen ondersteunen dat 
bevindingen uit handtransplantatie-experimenten bij de rhesusaap geextrapoleerd kunnen 
worden naar de situatie bij de mens. 
Technische haalbaarheid van het onderzoeksmodel kon aangetoond worden in de 
replantaties. Eveneens kon allogene transplantatie van de radiaire zijde van de hand technisch 
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gerealiseerd worden in het rhesusaapmodel. 
De wondgenezing was ongestoord in zowel replantatie als transplantatie. 
Postoperatieve bewakingssystemen zoals temperatuurmeting en laserdopplerflowmetrie 
hebben geen voorspellende waarde gehad voor vaatafsluiting noch voor begin van afstoting, 
doordat ze onder andere niet continu konden worden toegepast. 
Functionele aspecten 
De duim was weer volledig gereintegreerd in de handfunctie na autologe replantatie. Er 
tract een zeer goed sensibel en motorisch functioneel herstel op. Sensibel en motorisch herstel 
kon eveneens worden aangetoond na allogene transplantatie van de radiaire zijde van de 
hand. Afstoting bewerkstelligde een daling in functioneel herstel, welke weer grotendeels 
herstelde na omkering van dit proces. 
Evaluatie van sensibel en motorisch functieherstel kon slechts tot een half jaar 
postoperatief plaatsvinden. Desondanks bereikte het sensibele functieherstel in de niet 
afgestoten transplantaten waarden die de contralaterale zijde benaderden. 
Ten aanzien van het motorisch herstel kan vermeld worden dat de waarden van zowel de 
amplitude van de samengestelde motor actiepotentialen van de thenarspieren, als de 
latentietijd van de distale thenar spier, gemeten door electromyografie, in de niet afgestoten 
transplantaten elksar eveneens tegemoet kwamen. 
Immunohistochemische k:leuring liet vitale motor-eindplaatjes zien als bewijs voor 
motorische reiinervatie. 
Innnunologische aspecten 
In huidtransplantatiestudies bij de rhesusaap werd de immunosuppressieve potentie getest 
van een combinatie van zeven monoclonale antilichamen (MAbs) specifiek voor de volgende 
cel-oppervlaktestructuren: CD3 (pan T-ee!), CD4 (helper/inducer T eel-subset), CDS 
(cytotoxische/suppressor T-ee! subset). Tesamen bleken deze MAbs een additief effect te 
hebben bovenop hun individuele effect om de transplantaatoverleving te verlengen. 
Kontinue hoge doseringen van cyclosporine A en prednison bewerkstelligden lange 
termijn overleving bij zes van de twaalf transplantaatontvangers. De hierboven genoemde 
MAbs-therapie kon afstoting omkeren en de transp!antaatoverlevingstijden significant sterker 
verlengen dan anti-afstotingstherapie met steroiden. MAbs-therapie induceerde een sterke 
eliminatie van voornamelijk CD2+, CD3+ (=pan T-ee!), en CDS+ (=cytotixische/ 
suppressor T-ee! subset) lymfocyten. Eliminatie van deze witte bloedcelsubsets werd zowel 
gezien in het perifere bloed (mbv een immunofluorescentie-techniek) als in het 
allotransplantaat zelf (mbv immunohistochemische k:leuringen). 
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Ondanks deze en bovengenoemde resultaten bracht het huidig gebruikte 
immunosuppressieve regime een aanta.l ernstige complicaties met zich mee: zeven rhesusapen 
overleden tijdens het experiment. In vier van deze gevallen traden posttransplantatie 
lymfoproliferatieve (PTLP)-afwijkingen op en in aile deze gevallen werd het STL V -provirus 
aangetoond in het DNA van deze afwijkingen. Het is dus zeer goed mogelijk dat STL V in 
combinatie met hooggedoseerde immunosuppressieve therapie een rol speelt bij het ontstaan 
van PTLP-afwijkingen. Het dient vervolgens opgemerkt te worden dat ook het toevoegen 
van de MAbs aan de basis-immunosuppressieve therapie (zwak) correleerde met bet ontstaan 
van lymfoproliferatieve afwijkingen. 
In het kader van de speurtocht naar immunosuppressiva om afstoting beter onder controle 
te houden en neveneffecten te minimaliseren werd een synergistisch effect gevonden tussen 
enerzijds MAbs specifiek voor de cytokines interferon-/' en tumor-necrosis-factor-a en 
anderzijds tussen cyclosporine A en het nieuwe immunosuppressieve middel FK-506. 
Toekomstverwachtingen 
Allogene transplantatie van de allogene hand lijkt gezien de veelbelovende resultaten op 
technisch, functioneel en immunologisch gebied dichter bij de realiteit zijn komen te staan. 
Echter, het feit dat met de hoge doseringen van de beste immunosuppressieve middelen 
hedentendage beschikbaar nog steeds zeven van de twaalf rhesusapen voortijdig overlijden, 
maakt het, naar onze mening, noodzakelijk te zoeken naar een effectiever minder toxisch 
immunosuppressieve therapie voordat (totale) handtransplantatie bij de mens verricht kan 
worden uitgevoerd. 
Indien eenmaal een dergelijk middel of combinatie van middelen beschikbaar is gekomen, 
dan zal zeer wei mogelijk sprake zijn van een indicatiegebied voor functionele en esthetische 
reconstructie met gebruikmaking van allogene weefsels. 
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